 
Official Title:  A Phase II, Multicenter, Randomized, Active Treatment -Controlled 
Study of the Efficacy and Safety of the Ranibizumab Port Delivery 
System for Sustained Delivery of Ranibizumab in Patients With 
Subfoveal Neovascular Age- Related Macular Degeneration  
Study ID: [REMOVED] 
Document  Date : Protocol  Version 8: 07-February -2018  
 
 
 
PROTOCOL AMENDMENT APPROVAL  
 
CONFIDENTIAL  
The information contained in this document, especially any unpublished data, is the property of 
Genentech, Inc. (or under its control) and therefore is provided to you in confidence as an 
investigator, potential investigator, or consultant, for review by [CONTACT_10825], your staff, and an applicable 
Ethics Committee or Institutional Review Board.  It is understood that this information will not be 
disclosed to others without written authorization from Genentech except to the extent necessary 
to obtain informed consent from persons to whom the drug may be administered.  
 
Ranibizumab Port Delivery System—Genentech, Inc.  
Proto col GX28228, Version 8 PROTOCOL  
TITLE:  A PHASE II, MULTICEN TER, RANDOMIZED, ACT IVE 
TREATMENT −CONTROLLED STUDY OF THE EFFICACY AND 
SAFETY OF THE RANIBI ZUMAB PORT DELIVERY SYSTEM FOR 
SUSTAINED DELIVERY O F RANIBIZUMAB IN PATIE NTS WITH 
SUBFOVEAL NEOVASCULAR AGE -RELATED MACULAR 
DEGENERATION  
PROTOCOL NUMBER:  GX28228  
VERSION NUMBER:  [ADDRESS_667222] NUMBER:  Not applicable  
IND NUMBER:  113,[ADDRESS_667223]:  Ranibizumab Port Delivery System for Sustained 
Delivery of Ranibizumab (RO4893594)   
MEDICAL MONITOR:  , M.D.  
SPONSOR: Genentech, Inc.  
DATE FINAL:  Version 1:  02 January 2015  
DATE S AMENDED:  Version 2 :  03 Apr il 2015  
Version 3:  13 July 2015  
Version 4:   08 December 2015  
Version 5:   18 February 2016  
Version 6:  [ADDRESS_667224] 2016  
Version 7:  04 May 2017 
Version 8:  See electronic date stamp below. 
 
07-Feb-2018 05:07:28
Title
Approver's Name
[CONTACT_26862] (UTC)

 
Ranibizumab Port Delivery System —Genentech, Inc.  
2/Protocol GX28228, Version 8 PROTOCOL AMENDMENT, VERSION 8: 
RATIONALE  
Protocol GX28228, Version [ADDRESS_667225] the extension of 
study duration for patients in the intravitreal ranibizumab control arm.  C hanges to the 
protocol, along with a rationale for each change, are summarized below.  
• Study duration for patients in the intravitreal ranibizumab control arm  has been 
extended by [CONTACT_3450] 4 months to align with the other treatment arms and to 
allow for continued monthly evaluation and study treatment until the Sponsor 
decides, based on the primary analysis results, to either terminate the study and 
discontinue study treatment, or offer patients entry into the Ranibizumab Port 
Delivery System  (RPDS ) Extension Study .  Primary analysis data is expected to be 
available approximately [ADDRESS_667226] patient random ly 
assigned in the study.  The study duration extension for this control arm aligns the 
duration of patient participation for all study treatment arms  at approximately 
13−38 months  ,dependent on the date of the patient's  randomization to the study  
(Sections  3.1 and [IP_ADDRESS], Figure 2, and Table 3). 
• "RPDS Exten ded Use Life Study " has been replaced with "RPDS Extension Study " 
(Sections 3.1, 3.2, 4.4.2, and [IP_ADDRESS], and Appendix 1) . 
• The Secondary Medical Monitor information has been updated (Section 5.4.1). 
 
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative changes to the original protocol.
 
Ranibizumab Port Delivery System—Genentech, Inc. 
3/Protocol GX28228, Version 8 TABLE OF CONTENTS 
PROTOCOL AMENDMENT AC CEPTANCE FORM .......................................... 11  
PROTOCOL SYN OPSIS .................................................................................... 12  
1. BACKGROUND  .......................................................................................... 23  
1.1  Background on Age-Related Macular 
Degenerat ion ......................................................................... 23  
1.1.1 Pathophysiology of  Age-Related Macular 
Degenerati on ......................................................................... 23 
1.1.2 Treatment for Age-Related Macular 
Degenerati on ......................................................................... 24 
1.2  Background on Ranibizumab ................................................. 24  
1.3  Background on the Ranibizumab Port Delivery S ystem ..................................................................... 25
 
1.4  Study Rationale and Benefit-Risk Assessment ...................... 30  
2. STUDY OBJECTIVES ................................................................................. 31  
2.1  Efficacy Obje ctives ................................................................ 31  
2.2  Safety Obje ctives  ................................................................... 32  
2.3  Pharmacokinetic Objectiv es .................................................. 32  
2.4  Exploratory Ob jectives  ........................................................... 32  
3. STUDY DES IGN ......................................................................................... 33  
3.1  Description of Study  .............................................................. 33  
3.1.1 Refill/Re-Treatm ent Criter ia ................................................... [ADDRESS_667227] udy .......................................................................... 42  
3.4  Rationale for Study Desi gn .................................................... 42  
3.4.1 Rationale for Ranibizu mab Dose Sele ction ........................... 42 
3.4.2 Rationale for Pharmacokinetic Evaluation 
Schedule ................................................................................ 43 
3.4.3 Rationale for Pati ent Populati on ............................................ 43 
3.4.4 Rationale for Control Gr oup ................................................... 43 
Ranibizumab Port Delivery System—Genentech, Inc. 
4/Protocol GX28228, Version 8 3.5  Outcome Meas ures ............................................................... 43  
3.5.1 Primary Efficacy Outcome Meas ure ...................................... 43 
3.5.2 Secondary Efficacy Outcome Meas ures ................................ 44 
3.5.3 Safety Outcom e Measures  .................................................... 44 
3.5.4 Pharmacokinetic Ou tcome Measur es .................................... 44 
3.5.5 Exploratory Outc ome Measur es ............................................ 44 
4. MATERIALS AND METHODS .................................................................... 45  
4.1  Patients .................................................................................. 45  
4.1.1 Inclusion Criteria  .................................................................... 46 
4.1.2 Exclusion Criteria  ................................................................... 49 
4.2  Method of Treatment A ssignment and Masking .................... 52  
4.2.1 Randomization and Masking  ................................................. 52 
4.2.2 Unmasking Procedure ........................................................... 53 
4.3  Study Treat ment .................................................................... 53  
4.3.1 Formulation, Pack aging, and Handl ing .................................. 53 
[IP_ADDRESS] Ranibizumab Port  Delivery S ystem ....................................... 53 
[IP_ADDRESS] Formulation of Rani bizumab Used to Fill/Refill 
the Implant ............................................................................. 53 
[IP_ADDRESS] Formulation of Ranibizumab Used in ITV 
Injection Cont rol Arm ............................................................. 54 
[IP_ADDRESS] Formulation of O pen-Label Ranibi zumab .............................. 54 
4.3.2 Dosage, Administra tion, and Comp liance .............................. 54 
[IP_ADDRESS] Impl ant ................................................................................... 54 
[IP_ADDRESS] Dos age .................................................................................. 54 
[IP_ADDRESS] Administ ration ........................................................................ 56 
[IP_ADDRESS] St orage .................................................................................. [ADDRESS_667228] Quality A ssessments ................................................ 58  
4.4.1 Ranibizumab in Contents Retrieval from Implant ................... 58 
[IP_ADDRESS] Explanted Impl ants with Cont ents ......................................... 58 
[IP_ADDRESS] Ancillar y Devices ................................................................... 59 
4.4.2 Continued Acce ss to RPDS  ................................................... 59 
4.5 Concomitant Therapy ............................................................ 59 
4.5.1 Permitted Therapy ................................................................. 59 
Ranibizumab Port Delivery System—Genentech, Inc. 
5/Protocol GX28228, Version 8 4.5.2 Prohibited Therapy ................................................................ 60 
4.6 Study Asse ssments ............................................................... 61 
4.6.1 Medical History, Concomitant Medication, and 
Demographic Data ................................................................. 61 
4.6.2 Vital Signs .............................................................................. 61 
4.6.3 Physical Exam inations ........................................................... 61 
4.6.4 Ocular A ssessments .............................................................. 62 
4.6.5 Ocular Imaging ...................................................................... 63 
4.6.6 Laboratory A ssessments ....................................................... 64 
4.6.7 Patient-Repor ted Outcom e .................................................... 66 
4.6.8 Video Capturing of Im plant Insertion, Refill, and 
Explantation Procedures ........................................................ 66 
4.6.9 Exploratory Substudies  .......................................................... 66 
4.6.10 Timing of Study  Assessment s ............................................... 66 
[IP_ADDRESS] Screening and Pr etreatment Assessments ............................ 66 
[IP_ADDRESS] Assessments dur ing Treatm ent ............................................. 68 
[IP_ADDRESS] Assessments at Early Study Treatment 
Discontinuati on ...................................................................... 68 
[IP_ADDRESS] Assessments at Early Study Discontinuation ......................... 69 
[IP_ADDRESS] Assessment at Study Comple tion .......................................... 69 
[IP_ADDRESS] Follow-Up Assessment s ........................................................ 70 
[IP_ADDRESS] Assessments at Unscheduled Visits ...................................... 70 
4.6.11 Refill Needle Sa mple Collection ............................................ 70 
4.6.12 Samples for [COMPANY_002] Clinical Repo sitory.................................. 70 
[IP_ADDRESS] Overview of the Ro che Clinical Re pository ............................ 70 
[IP_ADDRESS] Approval by [CONTACT_27859] .................................................................. 70 
[IP_ADDRESS] Sample Collecti on .................................................................. 71 
[IP_ADDRESS] Confiden tiality ........................................................................ 71 
[IP_ADDRESS] Consent to Partici pate in the [COMPANY_002] Clinical 
Repositor y ............................................................................. 72 
[IP_ADDRESS] Withdrawal from the Ro che Clinical Repository ..................... 72 
[IP_ADDRESS] Monitoring and Oversight ....................................................... 73 
4.7  Patient, Treatment, Study, and Site 
Discontinua tion ...................................................................... 73  
Ranibizumab Port Delivery System—Genentech, Inc. 
6/Protocol GX28228, Version [ADDRESS_667229] an ............................................................................ 75  
5.1.1 Management of Specif ic Adverse Events .............................. 78 
[IP_ADDRESS] Dosing Interruption/ Study Treatment or Study 
Discontinuation Criteria.......................................................... 78 
[IP_ADDRESS] Rescue Treatment with Open-Label Ranibizumab 
For Implant Pa tients .............................................................. 80 
[IP_ADDRESS] Management of Pati ents Who Meet Lack of 
Clinical Efficacy Criteria  ......................................................... 80 
[IP_ADDRESS] Recommended Manag ement of Cases of 
Vitreous Hemo rrhage ............................................................ 82 
[IP_ADDRESS] Implant Clogging Assessment  ............................................... 83 
5.2  Safety Parameters and Defini tions ........................................ 83  
5.2.1 Adverse Events ..................................................................... 83 
5.2.2 Serious Adverse Event s (Immediately Reportable 
to the Sponsor) ...................................................................... [ADDRESS_667230] (Immediately 
Reportable to the Sponsor) .................................................... [ADDRESS_667231] ing Adverse Events ............................ 88 
[IP_ADDRESS] Diagnosis versus  Signs and Sy mptoms................................. 89 
[IP_ADDRESS] Adverse Events That  Are Secondary to Other 
Events .................................................................................... 89 
[IP_ADDRESS] Persistent or Recu rrent Adverse Events ................................ 89 
[IP_ADDRESS] Abnormal Labor atory Valu es ................................................. 90 
[IP_ADDRESS] Abnormal Vital Sign Valu es ................................................... 91 
Ranibizumab Port Delivery System—Genentech, Inc. 
7/Protocol GX28228, Version 8 [IP_ADDRESS] Abnormal Liver Function Te sts .............................................. 91 
[IP_ADDRESS] Deat hs ................................................................................... 91 
[IP_ADDRESS] Preexisting Medical Conditions .............................................. 92 
[IP_ADDRESS] Worsening of Neovascular Age-Related Macular 
Degeneration in Study Eye .................................................... 92 
[IP_ADDRESS] Hospi[INVESTIGATOR_267466] .......................... 92 
[IP_ADDRESS] Adverse Events Asso ciated with an Overdose or 
Error in Drug Admi nistrati on .................................................. 92 
[IP_ADDRESS] Patient-Report ed Outcome Da ta ........................................... [ADDRESS_667232] ...................................................... 94 
[IP_ADDRESS] Events That Occur Pr ior to Initiation of Study 
Drug (Day 1) .......................................................................... 94 
[IP_ADDRESS] Events That Occur After Study Drug Init iation ....................... 94 
5.4.3 Reporting Requirem ents for Pregnanc ies .............................. 95 
[IP_ADDRESS] Pregnancies in Fe male Pati ents ............................................ 95 
[IP_ADDRESS] Pregnancies in Female Part ners of Male Pa tients ................. 95 
[IP_ADDRESS] Abor tions ............................................................................... 96 
[IP_ADDRESS] Congenital Anomal ies/Birth De fects ...................................... 96 
5.4.4 Reporting Requirement s for Medical Device 
Complaints ............................................................................. 96 
[IP_ADDRESS] Device Defects or Deficiencies that Could Have 
Led to Medical O ccurrence .................................................... [ADDRESS_667233]-Study Adve rse Event s ................................................... 97  
5.7  Expedited Reporting to Health Authorities, Investigators, Institut ional Review Boards, and 
Ethics Commi ttees ................................................................. 98
 
6. STATISTICAL CONSIDERATIONS AND ANALYSIS  PLAN ....................... 98  
6.1  Determination of Sample Si ze ............................................... 98  
Ranibizumab Port Delivery System—Genentech, Inc. 
8/Protocol GX28228, Version [ADDRESS_667234] of Study ............................................ 99 
6.3 Summaries of Treatment Group Comparabi lity ..................... 99 
6.4 Efficacy Analyses .................................................................. 99 
6.4.1 Primary Effica cy Analysis  ...................................................... 99 
6.4.2 Secondary Efficacy Analysis ................................................ 100 
6.5  Safety Anal yses ................................................................... 101 
6.5.1 Adverse Events ................................................................... 101 
6.5.2 Deat hs ................................................................................. 102 
6.5.3 Laboratory Tests .................................................................. 102 
6.5.4 Vital Signs ............................................................................ 102 
6.5.5 Ocular A ssessments ............................................................ 102 
6.6  Pharmacokinetic Analyses ................................................... 102  
6.7  Patient-Reported Outcome Analyse s .................................. 102  
6.8  Exploratory A nalyses ........................................................... 103  
6.8.1 Time to Event Analysis with Data after Month 9 .................. 103 
6.8.2 Analysis of Time to Subsequent Re fills ............................... 103 
6.9  Flexible Interim Analysis  ...................................................... 103  
7. DATA COLLECTION A ND MANAGEME NT ............................................. 103  
7.1  Data Quality A ssurance ....................................................... 103  
7.2  Electronic Case Report Forms ............................................. 104  
7.3  Patient-Reported Outcome Data  ......................................... 104  
7.4  Source Data Documentation ................................................ 104  
7.5  Use of Computeriz ed System s ............................................ 105  
7.6  Retention of Records ........................................................... 105  
8. ETHICAL CONSID ERATIONS .................................................................. 105  
8.1  Compliance with Laws and Regulations  .............................. 105  
8.2  Informed Cons ent ................................................................ 105  
8.3  Institutional Review Boar d or Ethics Co mmittee .................. 107  
8.4  Confidentia lity ...................................................................... 107 
8.5  Financial Discl osure ............................................................ 108  
Ranibizumab Port Delivery System—Genentech, Inc. 
9/Protocol GX28228, Version [ADDRESS_667235] OF TABLES 
Table 1  Components of the Ranibizum ab Port Delivery System with 
Corresponding Te rminology ........................................................ 27  
Table 2  Dosing Guidelines Pr ior to Scre ening ......................................... 36  
Table 3  Ranibizumab Dosing and Safe ty Assessment  Schema .............. 37  
Table 4  Definition of Terms Pertaining to  AMD Inclusion Criteria ............ 47  
Table 5  Imaging Requirements at Pre-Screening, Run-In, and 
Screening .................................................................................... 49  
Table 6  Dose Interruption/Study Treatme nt or Study Discontinuation 
Criteria ........................................................................................ [ADDRESS_667236] OF FIGURES 
Figure 1   RPDS Com ponents ..................................................................... 26  
Figure 2   Study Schema ............................................................................. 34  
 
Ranibizumab Port Delivery System—Genentech, Inc. 
10/Protocol GX28228, Version [ADDRESS_667237] OF APPENDICES 
Appendix 1  Schedule of Assessments for Implant Arms: Screening, 
Randomization, Day 1, Month 1 through Month 9, Month X, 
Safety Visits, and Final/Early  Termination Vi sits ....................... 112  
Appendix 2  Schedule of Assessments fo r ITV arm: Screening, 
Randomization/Day 1, Month 1 through Month 9, Month X, 
and Final/Early Termination Visits ............................................. 125  
Appendix 3  Pre-Screening Visits (i f Applicab le) ........................................... 132  
Appendix 4  Run-In Visit (if Applicable ) ......................................................... [ADDRESS_667238] Corrected Vi sual Acuity Testing .............. 143  
Appendix 12  Grading Scales ......................................................................... 144  
Appendix 13  Fundus Autofluor escence ......................................................... 146  
Appendix 14  Color Fundus P hotographs ....................................................... 147  
Appendix 15  Fluorescein Angi ography .......................................................... 148  
Appendix 16  Spectral Domain Optical Coherence Tom ography .................... 149  
Appendix 17  External and Implant  Photographs  ............................................ 150  
Appendix 18  Optical Coherence Tomography  Angiography (at Selected 
Sites) ......................................................................................... 151  
Appendix 19  Macular Degeneration Treat ment Satisfaction Questionnaire ... 152  
Appendix 20  Central Laboratory Sample  Collection and Shippi[INVESTIGATOR_007] ................. 182  
Appendix 21  Ranibizumab Port Delivery System: Device Clinical 
Investigation Plan ...................................................................... 184  
Ranibizumab Port Delivery System —Genentech, Inc.
11/Protocol GX28228 , Version 8PROTOCOL A MENDMENT A CCEPTA NCE FORM
TITLE: A PHA SE II ,MULTICENTER, RA NDOMI ZED, 
ACTIVE TRE ATMENT CONTROLLED STUDY OF
THE EFFICA CY AND SAFETY OFTHE 
RANIBIZUMA B PORT DEL IVERY SYSTEM FOR
SUSTA INED DELIVER Y OF RA NIBIZUMAB IN 
PATIENTS WITH SUBFOV EAL NEOVA SCULA R 
AGE-RELA TED MA CULA R DEGE NERA TION
PROTOCOL NUMBER: GX28228
VERSION NUMBER: [ADDRESS_667239] NUMBER: Not applicable
IND NUMBER: 113,[ADDRESS_667240]: Ranibizumab Port Delivery System for Sustained 
Delivery of Ranibizumab (RO4893594)
MEDICA L MONITOR: , M.D.
SPONSOR: Genentech, Inc.
I agree to conduct the study in accordance with the current protocol.
Principal Investigator’s Name  (print)
Principal Investigator’s Signature [CONTACT_33505].  Please return a copy of 
this form to your local study monitor. 

Ranibizumab Port Delivery System —Genentech, Inc.
12/Protocol GX28228 , Version 8PROTOCOL SYNOPSIS
TITLE: A PHA SE II, MULTICENTE R, RANDOM IZED, A CTIV E 
TREA TMENT CONTROLLED STUDY OF THE EFFICA CY A ND 
SAFETY OF THE RA NIBIZUM AB PORT DELIVERY SYSTEM FOR 
SUST AINED DELIVERY O F RA NIBIZUM AB IN PA TIENTS WITH 
SUBFOVEA L NEOVA SCULA R AGE-RELA TED M ACULAR 
DEGENERA TION
PROTOCOL NUM BER: GX28228
VERSION NUMBER: [ADDRESS_667241] NUMBER: Not applicable
IND NUMBER: 113,[ADDRESS_667242]: Ranibizumab Port Deliver y System for Sustained Delivery of 
Ranibizumab (RO4893594)
PHASE: II
INDIC ATION: Subfoveal neovascular age -related macular degeneration
SPONSOR: Genentech, Inc.
Objectives
Efficacy Objectives
The primary  efficacy  objective for this study is as follows:
To evaluate the relative efficacy of 10 -mg/mL, 40 -mg/mL, and 100- mg/mL formulations of 
ranibizumab, delivered via the Implant, as measu red by [CONTACT_29623] a patient first requires
Implant refill according to protocol -defined refill criteria
The secondary efficacy objectives for this study are as follows:
To eval uate and compare the relative efficacy of 10 -mg/mL, 40 -mg/mL, and 100 -mg/mL 
formulations of ranibizumab, delivered v ia the Implant, tothat of 10-mg/mL (0.5 -mg dose) 
monthly ITV ranibizumab injections, as measured by [CONTACT_514845] 9
To evaluate the efficacy  of 10 -mg/mL, 40 -mg/mL, and 100 -mg/mL formulations of 
ranibizumab, delivered via the Implant, with that of 10 -mg/mL (0.5 -mg dose) monthly ITV 
ranibizumab injections over time, as measured by [CONTACT_514846] r 
time
To evaluate the efficacy of 10 -mg/mL, 40 -mg/mL, and 100 -mg/mL formulations of 
ranibizumab, delivered via the Implant, with that of 10- mg/mL (0.5 -mg dose) monthly ITV 
ranibizumab injections over time, as measured by [CONTACT_514847] 
(CFT , defined as the retinal thickness in the center of the fovea )from baseline over time
To evaluate the functionality of the Implant by [CONTACT_514848] 10 % of patients in the Implant arms at Mont h 9
Ranibizumab Port Delivery System —Genentech, Inc.
13/Protocol GX28228 , Version 8Safety Objectives
The safety  objectives for this study are as follows:
To evaluate the safety of ranibizumab delivered via the Implant, compared with that of 
monthly ITV injection, as measured by [CONTACT_514849] -ocular adverse events and serious 
adverse events
To evaluate the safety of the Ranibizumab Port Delivery System (RPDS ), as measured by 
“Prespecified RPDS -associated adverse event s”
To evaluate the proportion of patients with positive serum antibodies to ranibizumab
Pharmacokinetic Objectives
The pharmacokinetic (PK) objectives for this study are as follows:
To characterize the serum pharmacokinetics of ranibizumab in patients after the initial fill 
and subsequent refills in the Implant treatment arms
Exploratory Objectives
The exploratory objectiv es for this study are as follows:
To evaluate the development of macular atrophy in all three Implant treatment arms relative 
to one another and to the monthly ITV arm
To examine the impact of ranibizumab treatment on patient -reported treatment satisfactio n 
as assessed by [CONTACT_514850] (MacTSQ) 
at Months 1, 6, 9, and the final or early termination visit for patients who speak English or 
Spanish
To explore time to subsequent Implant refills according to protoco l-defined refill criteria
To describe the number of times patients meet protocol -specified refill criteria
To evaluate the proportion of patients in each Implant arm who first meet the protocol -
defined refill criteria prior to and at Months 4, 5, and 6
To evaluate the proportion of patients with an improvement of 15letters in BCVA from 
baseline 
To evaluate the proportion of patients with a loss of  15letters in BCVA from baseline over 
time
To explore the utility of BCVA measured under low luminance as a predictor of treatment 
benefit over time
To evaluate the changes in total lesion area, area of CNV lesion, and CNV leakage over 
time, as assessed by [CONTACT_228628]
To explore the serum ranibizumab concentration data with a PK model in an attempt to infer 
the concentration time pattern in the vitreous or aqueous humor and, if possible, derive 
information on the rate of ranibizumab release from the Implant
To characterize ranibizumab aqueous humor concentration over time (optional)
To charac terize ranibizumab vitreous or aqueous humor concentration after Implant 
explantation (if applicable)
To evaluate the potential association of circulating biomarkers with disease characteristics 
and response to ranibizumab (optional)
To evaluate the relati onship of genetic variants (such as AMD risk alleles; poly morphisms 
within the complement pathway; and poly morphisms within the VEGF -A genetic locus) with 
the disease characteristics and/or response to treatment with ranibizumab (optional)
To evaluate the potential association of vitreous or aqueous humor biom arkers with disease 
characteristics and/or response to ranibizumab 
To evaluate the proportion of patients meeting lack of clinical efficacy  criteria
To evaluate the proportion of patients requiring ex plantation
To evaluate the changes in CNV perfusion over time as assessed by [CONTACT_514851] (at 
selected sites that have OCT angiography equipment )
Ranibizumab Port Delivery System —Genentech, Inc.
14/Protocol GX28228 , Version 8Study Design
Description of Study
Study GX28228 is a Phase II, multicenter, dose -ranging, randomized, active treatment (monthly 
ITV injection) -controlled study to evaluate the efficacy, safety, and pharmacokinetics of 
ranibizumab delivered through the Implant using three ranibizumab formulation arms (10 mg/mL, 
40 mg/mL, and 100 mg/mL) compared with the con trol arm (0.5 -mg monthly ITV injections of 
10-mg/mL form ulation) in patients with subfoveal neovascular age -related macular degeneration 
(nAMD).  The study will also evaluate the safety of the RPDS combination product.  The study 
will include pre -screening , screening, and randomization visits followed by a treatment period.  
Treatment and safet y assessment schedules are set.
Number of Patients
Approximately 220 patients at up to 60sites in the [LOCATION_002] will be randomized in a 
3:3:3:2 ratio to four tre atment arms (60 per each of three Implant treatment arms and 40 to th e 
ITV injection arm) within an approximate 24 -monthperiod of time .
Target Population
Patients with subfoveal neovascularization secondar y to age-related macular degeneration 
(AMD )diagnosed within 9months and treated with ITV anti -VEGF agents will be enrolled in 
thestudy .
Inclusion Criteria
Patients must meet the following criteria for study entry:
General Inclusion Criteria
Age 50 years
Willingness and ability to provide signe d informed consent and Health Insurance Portability 
and Accountability Act (HIPPA) authorization
Willingness and ability to undertake all scheduled visits and assessments
For sexually active women of childbearing potential, agreement to the use of an appropriate 
form of contraception (or abstinence) for the duration of the study.  A woman is considered 
not to be of childbearing potential if she is postmenopausal or has undergone hy sterectom y 
and/or bilateral oophorectomy .  
For women who are not postmenopau sal (12 months of non -therapy -induced 
amenorrhea) or surgically sterile (absence of ovaries and/or uterus):  agreement to 
remain abstinent or use single or combined contraceptive methods that result in a 
failure rate of 1% per year during the treatmen t period and for at least [ADDRESS_667243] dose of study treatment
Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the 
patient.  Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, or 
postovulation methods) and withdrawal are not acceptable methods of contraception.
Sexually active men are recommended to use a barrier contraceptive method (condom), 
even if they have been surgically sterilized, for the duration of the treatment period and for 
at least [ADDRESS_667244] dose of study treatment.
Ocular Inclusion Criteria (Study Eye)
Newly diagnosed with nAMD within 9months prior to screening visit
Patient must have received at least 2 prior anti -VEGF injections (including ranibizumab, 
bevacizumab, or aflibercept).  However, the most recent anti -VEGF injection must have 
been ranibizumab and must have occurred at least 7 days prior to the screening visit.
Demonstrated response to prior ITV anti -VEGF treatment, as evidenced by [CONTACT_716]:
Decrease i n CFT of 50 m since commencing ITV anti -VEGF treatment
OR
Stable or improved BCVA since commencing ITV anti -VEGF treatment
BCVA using ETDRS charts of 20/20 -20/200 Snellen equivalent 
Ranibizumab Port Delivery System —Genentech, Inc.
15/Protocol GX28228 , Version 8All subtypes of nAMD choroidal neovascularization (CNV) lesions are permissible 
(i.e., classic CNV, occult CNV, or with some classic CNV component, or retinal 
angiomatous proliferation lesions). 
Active primary  CNV lesions at the time of diagnosis of nAMD must be subfoveal or 
juxtafoveal with a subfoveal component related to the CNV activity (such as subretinal 
hemorrhage, subretinal fluid, or retinal pi[INVESTIGATOR_1836] [RPE] detachment)
Ocular Inclusion Criteria for Pre -Screening (Study Eye) ( If Applicable)
Treatment naïve nAMD patients
BCVA using ETDRS charts of 20/2 0to 20/200 Snellen equivalent
All subtypes of nAMD choroidal neovascularization (CNV) lesions are permissible 
(i.e., classic CNV, occult CNV, or with some classic CNV component, or retinal 
angiomatous proliferation lesions). 
Active primary  CNV lesions must be subfoveal or juxtafoveal with a subfoveal 
component related to the CNV activity (such as subretinal hemorrhage, subretinal fluid, 
or RPE detachment)
Ocular Inclusion Cr iteria for Run -In (Study Eye) (If Applicable)
Previous treatment with a single anti -VEG F ITV injection or no more than eight anti-VEGF 
ITV injections ,with aflibercept or bevacizumab being the most recent injection 
BCVA using ETDRS charts of 20/2 0to 20/200 Snellen equivalent
All subtypes of nAMD CNV lesions are permissible (i.e., classic CNV, occult CNV, or with 
some classic CNV component or retinal angiomatous proliferation lesions) 
Active primary  CNV lesions at the time of diagnosis of nAMD must be subfoveal or 
juxtafoveal with a subfoveal component related to the CNV activity (such as subretinal 
hemorrhage, subretinal fluid, or RPE detachment)
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
Prior Ocular Treatment
Treatment with ITV anti -VEGF agents other than ranibizumab within 1 month prior to the 
randomization visit in either eye
History of vitrectom y surgery, submacular surger y, or other surgical intervention for AMD in 
the study eye
Prior treatment with Visudyne®, external -beam  radiation therapy, or transpupi[INVESTIGATOR_5778] y 
thermotherapy in the study eye
Previous treatment with ITV corticosteroid injection or device implantation in the study eye
Previous focal laser photocoagulation used for AMD treatment in the study eye
Prior participation in a clinical trial involving anti -angiogenic drugs, other than ranibizumab, 
in either eye within 2 months prior to therandomization visit
Treatment with Visudyne®in the fellow eye  7 days preceding screening visit
CNV Lesion Characte ristics
Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of 
the hemorrhage is either 50% of the total area of the lesion or 1 disc area (2.54 mm2) in 
size at screening
Subfoveal fibrosis or atrophy in the study  eye
CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or 
pathologic m yopia
Concurrent Ocular Conditions
BCVA using ETDRS charts lower than 20/200 Snellen equivalent in the fellow eye
Retinal pi[INVESTIGATOR_514806] —Genentech, Inc.
16/Protocol GX28228 , Version 8Any concurrent intraocular condition in the study eye (e.g., cataract, glaucoma, or diabetic 
retinopathy) that, in the opi[INVESTIGATOR_871], would either require surgical intervention 
during the study to prevent or tre at visual loss that might result from that condition or affect 
interpretation of study results
Active intraocular inflammation (grade trace or above) in the study eye
History of vitreous hemorrhage in the study eye within 3 months prior to the randomizatio n 
visit
History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study 
eye
History of idiopathic or autoimmune -associated uveitis in either eye
Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either e ye
Aphakia or absence of the posterior capsule in the study eye
Previous violation of the posterior capsule break in the study eye is also excluded 
unless it occurred as a result of yttrium aluminium garnet laser posterior capsulotomy  
in association with p rior, posterior chamber intraocular lens implantation.
Spherical equivalent of the refractive error in the study eye demonstrating more than 
8diopters of m yopia
For patients who have undergone prior refractive or cataract surger y in the study eye, the 
preoperative refractive error in the study eye does not exceed 8 diopters of m yopia
Intraocular surger y (including cataract surgery) in the study eye within 3 months preceding 
the randomization visit
Uncontrolled ocular hypertension or glaucoma in the study eye (defined as intraocular 
pressure [IOP] 25 mmHg or a Cup to Disc ratio 0.8, despi[INVESTIGATOR_40792] -
glaucoma medication) and any such condition for which the investigator feels may requ ire a 
glaucoma filtering surgery while in the study
History of glaucoma -filtering surgery in the study eye, tube shunts , or microinvasive 
glaucoma surgery in the study eye
History of corneal transplant in the study eye
Concurrent Sy stemic Conditions
Uncontrolled blood pressure ( defined as systolic  155mmHg and/or diastolic 95mmHg , 
based on the average of 3 readings taken with the patient in a resting state [i.e., supi[INVESTIGATOR_514807] , but consistent across readings] over a period of up to 15 minutes at sc reening )
If the average of 3 readings exceeds these values, patient’s blood pressure mustto be 
controlled by [CONTACT_66310].  The patient can become eligible for 
rescreening if medication is taken continuously for at least 30 day s prior to th e 
randomization visit.
Uncontrolled atrial fibrillation within 3 months of informed consent
History of stroke within the last 3 months prior to informed consent
History of myocardial infarction within the last 3 months prior to informed consent
History of other disease, metabolic dysfunction, phy sical examination finding, or clinical 
laborator y finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that contraindicates 
the use of ranibizumab or placement of the Implant, that might affect interpretati on of the 
results of the study or renders the patient at high risk of treatment complications
Current treatment for any active systemic infection
Use of any s ystem ic anti -VEGF agents
Use of oral corticosteroids (prednisone 10mg/day or equivalent)
Ranibizumab Port Delivery System —Genentech, Inc.
17/Protocol GX28228 , Version 8Use of anticoagulants, antiplatelets (other than aspi[INVESTIGATOR_248]), or medications known to exert 
similar effects at the time of study entr y for a pre -existing condition .  Oral anticoagulants
include vitamin K antagonists (e.g. warfarin), direct factor Xa inhibitors (e.g .,rivaroxaban, 
api[INVESTIGATOR_3822], edoxaban, fondaparinux) and direct thrombin inhibitors (e.g. ,dabigatran). 
Antiplatelet therapi[INVESTIGATOR_178723], prasugrel, dipyridamole, ticagrelor and ticlodipi[INVESTIGATOR_050] .
Bleeding disorders, including platelet disorders, acquir ed or hereditar y coagulations 
disorders, and acquired or hereditar y vascular disorders.
Active malignanc y within 12 months of randomization except for appropriately treated
carcinoma in situ of the cervix, non- melanom a skin carcinoma, and prostate cancer w ith a 
Gleason score of 6 and a stable prostate -specific antigen for 12months.
History of allergy to fluorescein, not amenable to treatment
Inability to obtain fundus photographs, fluorescein angiograms, fundus autofluorescence, or 
spectral domain op tical coherence tomography (SD- OCT) images of sufficient quality to be 
analyzed and graded by [CONTACT_73475] 
Inability to comply with study or follow -up procedures
Previous participation in any non -ocular (systemic) disease studies of investigational drugs 
within 1 month preceding the informed consent (excluding vitamins and minerals)
Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half -lives of the 
Randomization visit 
Intolerance or hypersensitivity to topi[INVESTIGATOR_12866], mydriatic medications, any of the 
excipi[INVESTIGATOR_514808], fluorescein, or components of the Implant
Requirement for continuous use of any medications or treatments indicated in t he 
“Prohibited Therapy” section .
Women who are pregnant or lac tating or intending to become pregnant during the study
Women who are of childbearing potential, including those who have had tubal ligation, must 
have a negative serum pregnanc y test result within 21 day s prior to Day 1.  A woman is 
considered not to be of childbearing potential if she is postmenopausal or has undergone 
hysterectom y and/or bilateral oophorectom y.
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the 
study population will be representative of all eligible patients
Length of Study
The estimated study duration is 38months.
Patients randomized to the Implant treatment arms will have the Implant (pre -filled with 
ranibizumab) surgically inserted in the study eye at their Day [ADDRESS_667245] approximately 13 38months
dependent on the date of their randomization to the study.
Patients randomized to the ITV injection treatment arm (control) will be treated monthly with ITV 
injections of ranibizumab until the Sponsor decides, based on the primary analysis results, to 
either terminate the study and discontinue study treatment, or offer patients entry into the 
RPDS Extension Study.   The duration of the ir participation in the study is expected to last 
approximately 1338months dependent on the date of their randomization to the study.   
End of Study
The end of the study is defined as the date when the last patient, last study visit occurs.
Ranibizumab Port Delivery System —Genentech, Inc.
18/Protocol GX28228 , Version 8Outcome Measures
Efficacy Outcome Measures
The primary  efficacy  outcome measure for this study is the time until a patient first requires the 
Implant refill according to protocol -defined refill criteria.
The secondary efficacy  outcome measures for this study are as follows:
Change in BCVA from baseline at Month 9
Average change in BCVA from baseline over time
Change in BCVA from baseline over time
Change in CFT over time, as assessed on SD -OCT by [CONTACT_305828]
Occurrence of im plant clogging
Safety Out come Measures
The safety  outcome measures for this study are as follows:
Incidence of adverse event s of Special Interest:  Adverse events associated with 
ranibizumab, the Implant, implant -associated proce dures, and/or ancillary devices
Incidence of “Prespe cified RPDS -associated adverse event s” 
Incidence of ocular and non -ocular adverse event s and serious adverse events
Incidence of positive serum antibodies to ranibizumab
Pharmacokinetic Outcome Measures
The PK outcome measures related to ranibizumab serum concentration -time data following the 
Implant insertion and refills are as follows:
Observed maximum serum concentrations (C max) and selected post dose serum 
concentrations after Implant insertion and all subsequent refills 
Additional estimated PK p arameter values including AUC, t max, and t 1/2after Implant 
insertion and all subsequent refills
Observed serum concentrations (C t) over time from monthly serum sampling when no refills 
are administered
Observed trough serum concentrations (C trough) prior to refills
In addition, optional anterior chamber (aqueous humor) will be collected to as sess ocular drug 
concentration.
Exploratory Outcome Measures
The exploratory outcome measures for this study are as follows:
Treatment emergent macular atrophy in all treatment arms
The MacTSQ score at randomization and at Months 1, 6, 9, and the final or early 
termination visit for patients who speak English or Spanish
Time to subsequent Implant refills according to protocol -defined refill criteria
Number of times a p atient meets protocol -specified refill criteria
Proportion of patients in each Implant arm who first meet the protocol -defined refill criteria 
prior to and at Months 4, 5,and 6
Proportion of patients with an improvement of BCVA from baseline of 15 letter s over time
Proportion of patients losing 15 letters in BCVA from baseline over time
Change in BCVA from baseline over time measured under low luminance conditions
Ranibizumab Port Delivery System —Genentech, Inc.
19/Protocol GX28228 , Version 8Changes from screening in total lesion area, area of CNV lesion, and CNV leakage over 
time, as assessed by [CONTACT_228628]  
Proportion of patients meeting lack of clinical efficacy criteria 
Proportion of patients requiring explantation
Changes in CNV perfusion over time, as assessed by [CONTACT_514852], vitreous samples from the Refill Needle (if applicable), optional aqueous humor 
samples, and optional serum and plasma samples may be collected to assess the relationship 
between biomarkers and the disease characteristics and/or response to tr eatment with 
ranibizumab.  Optional whole blood samples will be collected for DNA extraction (genetic 
analysis) to assess the relationship between genetic variants and the disease characteristics 
and/or response to treatment with ranibizumab.
In addition, vitreous or aqueous humor samples before Implant explantation, and optional 
aqueous humor samples prior to or immediately following one or more refills and at the Day [ADDRESS_667246] (Investigational Drug)
The Implant initially filled and then refilled as per protocol specified refill criteria, with either 
10-mg/mL, 40 -mg/mL, or 100 -mg/mL ranibizumab formulations .
Non-Investigational Medicinal Products
Comparator
Ranibizumab 0.5 -mg monthly intravitreal (ITV) injections of 10 -mg/mL form ulation
Statistical Methods
Detailed specifications of the statistical methods will be described in the statistical analysis plan 
(SAP).
Primary A nalysis
The primary  endpoint for this analysis will be time to first meeting refill criteria .  The primary  
analyses will be based on data as of [ADDRESS_667247] patient’s entry into the study .  For 
patients without any refills prior to o r on the cut -off date of 9 months after LPI , the time of refill 
will be censored. The censoring date will be defined as the date of a patient’s last visit before 
the cut -off date of [ADDRESS_667248] at a 
one-sided significance level of 15%.  The stratification factors to be included are baseline BCVA 
score ( 65letters vs. 66letters ) and number of anti -VEGF ITV injections ( 3 vs. 4).
Implant with 100 mg/mL versus Implant with 10 mg/mL
Implant with 100 mg/mL versus Implant with 40 mg/mL
Implant with 40 mg/mL versus Implant with 10 mg/mL
Inaddition, the HR for each pair -wise comparison of the treatment arms will be estimated using 
a Cox proportional hazards regression model stratified by [CONTACT_514853] (65letters vs.
66letters ) and number of prior anti -VEGF ITV injections ( 3 vs. 4)with main effects for 
treatment.  Estimated HRs for each pair -wise comparison will be presented with the 
corresponding 80% CIs .  
Ranibizumab Port Delivery System —Genentech, Inc.
20/Protocol GX28228 , Version 8Kaplan Meier plots will be provided showing TTFR by [CONTACT_514854].  Median time to first 
meeting refill criteria will be calculated for each treatment arm with the Kaplan Meier method, 
and the corresponding 80% confidence intervals will also be reported.
Moreover, for each treatment group, percentage of patients not meeting the protocol -
defined first refill criteria by [CONTACT_514855] 4, 5, 6, 7, 8, and 9, derived from Kaplan -Meier 
estimates will be provided.
Determination of Sample Size
This study is explorator y in nature and designed to estimate the time to first refill (TTFR) for 
each of the RPDS treatment arms (10 mg/mL, 40 mg /mL, and 100 mg/mL) enrolling 60 patients 
in each of the RPDS treatment arms.  The sample size of approximately 220 randomized 
patients will be adequate to evaluate the primary  objective of the study.  PK/PD modeling and 
simulation was performed to inform key assumptions used in sample size calculation.  Given the 
simulation results, the HR for comparing the 100 -mg/mL arm  with the 10 -mg/mL arm  was 
estimated to be 0.[ADDRESS_667249] 125 events from all three 
Implant groups is expected at the primary analysis time (ap proximately 85 events in the 
10-mg/mL group and a higher dose group).  W ith [ADDRESS_667250] approximately 
80% power to detect an HR 0.[ADDRESS_667251] at a 
one-sided significance level of 15%.  No multiplicity adjustment is planned for this Phase II 
study.
Forty patients in the ITV arm are considered sufficient to compare each device arm versus the 
ITV arm in change in BCVA from baseline through Month 9 (assuming an estimated 
SD10letters, a two -sided 80% CI will extend approximately 2.62 letters from the observed 
mean). 
Ranibizumab Port Delivery System —Genentech, Inc.
21/Protocol GX28228 , Version 8LIST OF A BBREVI ATIONS AND DEFINITIONS OF TERMS
Abbreviation Definition
ADE adverse device effect
AE adverse event
AESI adverse event of special interest
AMD age-related macular degeneration
ANCOVA analysis of covariance
AREDS Age-Related Eye Disease Study
ATE arterial thromboembolic event
AUC area under the concentration –time curve
BCVA best corrected visual acuity
BLQ below the lower limit of quantification
CFT central foveal thickness
Cmax maximum serum concentration
CNV choroidal neovascularization
Ctrough steady -state serum concentration at the end of a
dosing interval
EC Ethics Committee
eCRF electronic Case Report Form
EDC electronic data capture
ETDRS Early Treatment Diabetic Retinopathy Study
FA fluorescein angiogram
FAF fundus autofluorescence
FDA (U.S.) Food and Drug Administration
FSV4 ForSight VISION 4, Inc.
HA health authority
HCl hydrochloride
HIPAA Health Insurance Portability and Accountability Act
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonisation
IFU instruction for use
IMC Internal Monitoring Committee
IMP investigational medicinal product
IND Investigational New Drug ( Application)
IOP intraocular pressure
IRB Institutional Review Board
Ranibizumab Port Delivery System —Genentech, Inc.
22/Protocol GX28228 , Version 8Abbreviation Definition
ITV intravitreal
IxRS interactive voice/ Web response system
LPI [INVESTIGATOR_514809]-related macular degeneration
PK pharmacokinetic
PRO patient -reported outcome
OCT optical coherence tomography
RCE release control element
RCR [COMPANY_002] Clinical Repository
RPDS Ranibizumab Port Deliver y System
RPE retinal pi[INVESTIGATOR_514810]-OCT spectral domain optical coherence tomography
SOC standard of care
t1/[ADDRESS_667252] upper limit of normal
VA visual acuity
VEGF vascular endothelial growth factor
Ranibizumab Port Delivery System —Genentech, Inc.
23/Protocol GX28228 , Version 81. BACKGROUND
1.1 BACKGROUND ON AGE -RELA TED MA CULA R DEGENERA TION
Age-related macular degeneration (AMD) is one of the major causes of legal blindness 
in elderly persons in the developed world (Bressler et al. 2011 ).  Late stage AMD 
includes two morphological subtypes: neovascular AMD and geographic atrophy.  The 
prevalence of neovascular AMD increases exponentially with age ,with prevalence 
estimates in the U nited States in 2011 ranging from 0.5% among those 65 to 69 years of 
age to 14.6% among those 90 years of age or greater (Rudnic kaet al. 2012 ).In the 
next 40 years, the global population aged 60 years and older is projected to increase 
dramatically translating into an increase in the prevalence of neovascular AMD from
23million in 2010 to 80 million by 2050 ( Smith 2010 ).  The precise causes of AMD 
remain unk nown, although numerous risk factors have been identified, including genetic 
(e.g., complement factor H polymorphisms), demographic (e.g., ethnicity), nutritional 
(e.g., lack of antioxidant vitamins, dietary fats ,or fish), lifestyle (e.g., smoking), medical 
(e.g., cardiovascular risk factors), environmental (e.g., sun exposure), and ocular factors 
(Chakravarthy et al.2010 ).
1.1.1 Pathophy siology  of Age-Related Macular Degeneration
AMD is categorized into two subtypes, dry and neovascular , based on clinical 
examination, ocular imaging, and pathologic findings.  In dry AMD, which represents 
approximately 80% 90% of AMD cases, damage occurs at the level of the retinal 
pi[INVESTIGATOR_1836] (RPE) and Bruch’s membrane, the base ment membrane between 
the RPE and the underlying choriocapi[INVESTIGATOR_167583].  The most notable early change in dry AMD 
is the accumulation of drusen within the macula and posterior pole of the retina.  Drusen 
are focal deposits of extracellular debris located betwee n the basal lamina of the RPE 
and the inner collagenous layer of Bruch’s membrane. Drusen compositional studies 
have revealed carbohydrates, zinc, nearly [ADDRESS_667253] single component of drusen is lipid, thought to be 
derived from a large lipoprotein of intra -ocular origin ( Spaide and Curcio 2010 ). Early 
dry AMD may not produce symptoms for many years.  However, as drusen continue to 
accumulate, the patient’s central vision can become impaired, sometimes significantly.  
At its most extreme, dry AMD results in widespread loss of the RPE, a condition called 
geographic atrophy that can cause severe central vision loss and legal blindness.
In approximately 10% of dry AMD cases, a conversion to neovascular AMD (nAMD)
occurs over time.  Although nAMD is comparatively rare, prior to the development of 
anti-VEGF therapy, it accounted for the majority of severe vision loss from AMD.  nAMD
is typi[INVESTIGATOR_514811] (CNV) 
beneath the macula.  Abnormal capi[INVESTIGATOR_514812]’s membrane damage.  The new vessels are abnormally 
permeable, and result in accumulation of exudative fluid and hemorrhage beneath the 
RPE and/or neurosensory retina.  This fluid and hemorrhage can cause acute and, 
Ranibizumab Port Delivery System —Genentech, Inc.
24/Protocol GX28228 , Version 8historically, permanent loss of central vision.  At the end stage, fibrous metaplasia can 
occur, resulting in a chronic subretinal scar (disciform scar ; Jager et al. 2008 ).
The stimuli that result in the development of CNV remain unclear.  However, there is 
significant experimental and clinical evidence implicating vascular endothelia l growth 
factor (VEGF) -A in the pathogenesis of nAMD, as discussed in the Ranibizumab Port 
Delivery System (RPDS )Investigator’s Brochure (IB).
1.1.[ADDRESS_667254] and are being investigated.  The Age -Related Eye Disease Study 
(AREDS), conducted by [CONTACT_242183], demonstrated that the rate of 
progression of dr y AMD could be decreased by a specific vitamin and mineral 
supplement ( AREDS Research Group 2001 ). 
The treatment of nAMD was significantly impacted by [CONTACT_178754] -VEGF 
therapy. Prior to the availability of anti -VEGF therapy, vision loss could be slowed but 
not reversed. Ranibizumab, a recombinant, humanized monoclonal antibody fragment 
(Fab), which binds to all known isoforms of VEGF -A, was approved by [CONTACT_941] U .S.Food
and Dr ug Administrati on (FDA) for use in neovascular AMD, in June 2006. In November 
2011, a second anti -VEGF therapy, aflibercept ,was approved for nAMD in the United 
States, with a similar safety and efficacy profile to ranibizumab .  Both ranibizumab and 
aflibercept therapi[INVESTIGATOR_514813] (ITV) injections and physician 
monitoring.
1.2 BACKGROUND ON RANIBIZUMA B
Ranibizumab is a recombinant humanized immunoglobulin ( Ig) G1 kappa isotype 
monoclonal Fab developed by [CONTACT_8229], Inc. as a therapeutic agent for treating ocular 
vascular diseases by [CONTACT_514856].   Itbinds to and inhibits the biologic activity of human 
VEGF -A.  Ranibizumab is produced by [CONTACT_514857].  Ranibizumab is not 
glycosylated and has a molecular mass of approximately 48,000 Daltons.
Monthly ITV injection of 0.5 mg ofranibizumab wasapproved for treatment of nAMD by 
[CONTACT_8956] 30June 2006 . Current U .S
.prescribing inf ormation also provides 
information on results that may be expected following less frequent than monthly dosing 
(after 3 to 4 monthly injections ).  
See the RPDS Investigator Brochure (IB) for details on relevant nonclinical and clinical
ranibizumab informa tion.
Ranibizumab Port Delivery System —Genentech, Inc.
25/Protocol GX28228 , Version 81.3 BACKGROUND ON THE RA NIBIZUMA B PORT 
DELIVERY SYSTEM
The RPDS is a drug delivery technology that allows physicians to use ranibizumab with 
a sustained drug delivery profile without altering its chemistry and consists of the port 
delive ry implant (referred to as the I mplant), ancillary devices (I nsertion Tool, Initial Fill 
Needle, R efill Needle , and Explant Tool), and ranibizumab (see Figure 1).
TheImplant is an intra-ocular refillable device that is surgically placed through the pars 
plana (simil ar to other surgically implanted ophthalmic devices such as Retisert [Bausch 
and Lomb , FDA approved in 2005]) to allow for a sustained delivery of ranibizumab into 
the vitreous. After insertion of the Implant , the proximal end of the Implant is
subconjunc tival but external to the sclera, with the body of the Implant extending into the
vitreous.  The I mplant is designed to be used in conjunction with ranibizumab to 
precisely control the rate and duration of drug delivery a nd is refillable through the 
Implant septum in situ.  
The following are the intended uses of the RPDS components:
Implant: The Implant is intended to be inserted through the pars plana of the eye to 
deliver ranibizumab in a controlled manner into the vitreous humor. The physician 
will initially fill the reservoir with the drug and will refill it in accordance with the 
instructions for use.  Contraindication:  the RPDS is contraindicated for use with 
medications other than ranibizumab .
Insertion Tool:  The Insertion To ol is a component designed to a) hold the Implant 
during sterilization and insertion, b) assist with filling of the Implant before insertion, 
and c) enable insertion of the Implant through a pars plana sclerotomy.
Initial Fill N eedle: The Initial F ill Needle is a custom 33G Luer -Lock needle 
designed to perform the initial fill of the Implant while the Implant is held in the 
Insertion Tool.
Refill needles: The Refill Needle is a custom Luer -Lock needle designed to 
simultaneously exchange (in situ) any rema ining old drug produc t in the Implant
reservoir with new drug product.
Explant Tool:The Explant Tool is a component designed to enable the removal of 
the Implant from the posterior segment of the eye after resection of the conjunctiva 
and removal of any scar tissue.
For additional RPDS details (e.g., fill, insertion, refill, and explantation of the Implant ), 
consult the RPDS instructions for use (IFU) document and theRPDS IB.
Ranibizumab Port Delivery System —Genentech, Inc.
27/Protocol GX28228 , Version 8The Implant has been investigated in a prospective, Phase I, open -label study in patient s 
with nAMD, conducted by [CONTACT_178757], ForSight VISION 4, Inc. (FSV4) ,at a 
single site in Latvia.  The study investigated the safety, tolerability ,and duration of 
ranibizumab exposure delivered withthe Implant .  This Phase I Implant was composed 
of biocompatible materials (polymethyl methacrylate, silicone, 316L stainless steel, 
seeTable 1 ).  For further Phase I study details, see Section1.4and the RPDS IB.
Table 1Components of the Ranibizumab Port Deliver y System w ith 
Corresponding Terminology
TerminologyRanibizumab Port Deliver y System 
Components
Ranibizumab port delivery sy stem Ranibizumab, Implant , and ancillar y devices
Implant Port delivery Implant
Phase I Implant Port delivery Implant with stainless s teel RCE 
used in Phase I FSV4 (FH-1.2)study
Phase II Implant Port delivery Implant with Titanium RCE to be 
used in this Phase II study
Ancillary d evices Insertion Tool, Initial Fill Needle, R efill Needles, 
and Explant Tool
RCE release control element.
Thefollowing RPDS components are manufactured by  
; see Figure 1):  Initial Fill Needle.
Thefollowing RPDS components are manufactured by  
; see Figure 1):  Implant , Insertion Tool, Refill Needle s, and 
Explant Tool .
While the size and shape of the Implant is unchanged between the Pha se I and II 
studies, material changes were made to improve functionali ty and reliability of the 
Phase II Implant .  These changes include the use of polysulfone for the Implant body 
and encapsulation of the subconjunctival Implant retention features with si licone.  
Changes to the release control element ( RCE )porosity and tortuosity were mad e 
between the Phase I and Phase II Implant designs to enable the use of higher 
concentrations of ranibizumab during Phase II.  A change in material of the RCE from 
stainless steel to titanium was also implemented to take advantage of the superior 
physical and chemical properties of titanium .
Phase I RPDS Study
The safety, tolerability, and duration of ranibizumab exposure delivered through the 
Implant were investigated in a Phase I prospective, open -label study in a nAMD patient 
population by [CONTACT_178758]4 at a single site in Latvia.  Patient enr ollment was initiated in 
August 2010, and the study assessed the safety of the RPDS in 20 eyes through the 
collection and anal ysis of adverse event s and complications, including procedure -related 

Ranibizumab Port Delivery System —Genentech, Inc.
28/Protocol GX28228 , Version 8adverse events , device- related adverse events , ranibizumab -related adverse events , 
and all general health and patient -reported adverse events . 
All [ADDRESS_667255] to follow -up 
after 12 months.  The remaining 13 patien ts continued in the safety -monitoring phase; 
one patient was subsequently lost to follow up after [ADDRESS_667256] been reported in this study as of 26February 2015 :  
87during the 12 -month treatment phase and 8during the additional 2 -year safety 
monitoring phase.  Of the 87adverse events during the 12- month treatment phase, 
76were considered related (possibly, probably, or definitely) to the Implant i nsertion
procedure, the refill procedure, the Implant removal procedure, or drug treatment.  
These 87reported adverse events occurred in 20 out of 20 (100%) enrolled patients.
Among the [ADDRESS_667257] frequent adverse events were 
conjunctival hyperemia (59%), vitreous hemorrhage (7%), hyphema (7%), VA decrease 
(5%), eye dryness (4%), and conjunctival edema ( 3%).  Conjunctival hyperemia 
occurred in 19 of 20 patients (95% ), for a total of 45 events. The majority of these events 
(44/45, 98%) were considered mild and one was considered moderate. The average 
duration of these events was [ADDRESS_667258] frequent adverse events related to the Implant 
insertion procedure were conjunctival hyperemia (55% of the patients ), vitreous 
hemorrhage (25%), hyphema (15%), and VA decrease (15%).  Single adverse events 
were reported as related to the Implant insertion procedure:  endophthalmitis (5% of the 
patients )and traumatic cataract (5%). A single adverse event of retinal pi[INVESTIGATOR_514814] (5%) was reported as possibly related to the Implant placement. The number of 
adverse events related to the Implant insertion procedure in the first 10 patients (Patient 
Group 1) was greater ( 63% versus 19% ) than that observed in the second 10 patients 
(Patient Group 2), suggesting that refinements in surgical instrumentation, training, and
surgical experience that occurred during the trial may have in part mitigated the risk of 
the device placement procedure in Patient Group 2.
Ranibizumab Port Delivery System —Genentech, Inc.
29/Protocol GX28228 , Version 8A total of [ADDRESS_667259] frequently 
reported adverse events considered to be related to Implant refill on a per -procedure 
basis by [CONTACT_514858] (33%), eye dryness (2%), vitreous 
haze (2%), increased lacrimation (1%), and ocular discomfort (1%). The adverse event 
rate per Implant refill procedure was 38%.  These adverse events were mild in severity 
and the average duration to resolution was seven days.
Six patients underwent planned removal of the Implant at the 12 -month visit as 
scheduled in the protocol .  All of these patients were in Group 1. Of these 6 patients, 
4patients experienced 5 adverse events related to the Implant removal procedure
:  two
incidents of conjunctival hyperemia ( 33%) and single incidences of hyphema (17%), VA 
decrease (17%), and conjunctival hemorrhage (17%).   All adverse events related to the 
implant removal procedure resolved within 7 days.
There were sixreported serious adverse events during the treatment phase of the study.  
Four study -related serious adverse events were reported: twoincidents of decreased 
VA consequent to adverse events of vitreous hemorrhage, one incident of 
endophthalmitis, and one incident of decreased VA consequent to the incident of 
endophthalmitis.  Two non -study -related serious adverse events were reported: gastric 
adenocarcinoma and rotavirus infection.  The twoincidents of vitreous hemorrhage were 
likely caused by [CONTACT_447] -operative bleeding and were determined to be related to the 
Implant insertion procedure.  The single incident of endophthalmitis was observ ed at the 
2-week post -Implant insertion visit and was considered possibly related to the Implant 
insertion procedure.  Th e duration of this event was 14 days.
Of the 76 study -related adverse events, 7 were ongoing at the time of study exit.  These 
ongoing events were vitreous haze (3), and single incidents of vitreous hemorrhage, VA 
decrease, foreign body sensation in the eye, and retinal pi[INVESTIGATOR_514815].   
Thirteen patients entered the 24 -month safety -monitoring phase (one patient was lost to 
follow- up after the 12 -month follow -up); out of [ADDRESS_667260] to follow -up after 21 months.  There were a total 
of eight reported adverse events during the safety -monitoring phase of the study.   Four 
advers e events were considered related (possibly, probably, or definitely) to the Implant 
insertion procedure, the refill procedure, or drug treatment.  These related adverse 
events were cataract progression ( 3) and a single incident of mild ocular discomfort.  
Two additional incidents of cataract progression, one incident of blurred vision, and one 
incident of leg edema were not considered study -related by [CONTACT_093].  No serious 
adverse events were reported during the safety -monitoring phase .
Ranibizumab Port Delivery System —Genentech, Inc.
30/Protocol GX28228 , Version 8There were no patient deaths during the 12 -month treatment phase (the status of the 
2patients lost to follow -up during the 24 -month extended follow -up phase was not able 
to be confirmed), no adverse events led to patient withdrawal or dose reduction, and no 
adverse events represented a previously unsuspected important adverse effect of the 
device (implantation procedure or Implant).  
Refer to the RPDS IB for further details.
1.4 STUDY RA TIONA LE A ND BENEFIT -RISK A SSESSMENT
As a result of the chronic, progressive nature of nAMD,frequent ranibizumab ITV 
injections continue for extended periods for many patients .  Pi[INVESTIGATOR_514816] ( Studies FVF2598g and FVF2587g ) demonstrated significant and 
well-maintained visual acuity (VA) outcome s with monthly 0.5 mg ITV injections for 
2years.  Trials that investigated less freq uent than monthly dosing (Study FVF3192g 
and Lalwani et al. 2009 ) showed that visual outcomes were not as well maintained with 
more intermittent dosing schedules.  A recent trial that compared monthly to PRN 
ranibizumab ITV administration (Study FVF4579g) showed comparable effi cacy and 
maintenance of visual and anatomic improvements for [ADDRESS_667261] a significant burden on patients and their 
caregivers ,as well as treating physicians and the health care system. Sustained release 
of ranibizumab from the Implant is an alternate dosing method that may res ult in less 
frequent need of re -treatment than monthly dosing with ITV injections.   This decrease in 
treatment burden could possibly reduce the risk of ITV injection related adverse events , 
increase compliance, and reduce the burden to patients, their caregivers ,and the 
healthcare system , while maintaining optimum visual outcomes.
The safety, tolerability, and duration of ranibizumab exposure delivered through the 
Implant were investigated in a Phase I prospective, open -label study in a nAMD patient 
population by [CONTACT_178758]4 at a single site in Latvia.  Patient enrollment was initiated in August 
2010 and the study was completed i n July 2013. The study assessed the safety of the 
RPDS in 20 eyes through the collection and analysis of adverse events and 
complications, including procedure -related adverse events , device -related adverse 
events , ranibizumab- related adverse events and all general health and patient -reported 
adverse events . Secondary endpoints of VAand optical coherence tomography (OCT )
change were also collected.
All 20 patients completed the 12-month treatment phase of the Phase I study. At 
month 12, 6 patients underwent per -protocol planned Implant removal and exited the 
study after completion of the 13-month visit.  Complete 13 -mont h data are available for 
Ranibizumab Port Delivery System —Genentech, Inc.
31/Protocol GX28228 , Version 8these [ADDRESS_667262] from the available study data is
generally consistent with the known safety profile of ranibizumab as administered by [CONTACT_514859] (ranibizumab USPI) and similar surgical procedures involving intraocular 
implants ( Vitrasert USPI, 2013; Retisert USPI, 2013; Dunn et al. 2004; Gedde et al. 2012 ; 
Buys 2013) . Procedure- related adverse events for the 20 Impla nt placements were not 
unexpected.  In 96 Implant refill procedures, the refill procedure -related adverse events
were comparable to adverse events related to ITVinjections (see Section 5.1for further 
details).
The i mprovement in best corrected visual acuity ( BCVA) appeared comparable to 
monthly injections with sustained reduction in macular thickness and area of CNV 
leakage. The Phase Istudy provided evidence of the safety and tolerability of the 
combination product and suppor ts the evaluation of RPDS in a Phase II study. It is 
expected that in the Phase II study the drug efficacy of the Implant treatment arms will 
be similar to the control ITV monthly injection treatment arm.
2. STUDY OBJECTIVES
2.1 EFFICA CY OBJECTIVES
The primary efficacy objective for this study is as follows:
To evaluate the relative efficacy of 10-mg/mL, 40 -mg/m L, and 100- mg/mL 
formulations of ranibizumab, delivered via the Implant ,as measu red by [CONTACT_29623] a 
patient first requires Implant refill accord ing to protocol -defined refill criteria
The secondary efficacy objectives for this study are as follows:
To evaluate and compare the relative efficacy of 10-mg/mL, 40 -mg/mL, and 
100-mg/mL formulations of ranibizumab, delivered v ia the Implant, tothat of 
10-mg/mL (0.5 -mg dose) monthly ITV ranibizumab injections, as measured by [CONTACT_514860] 9
To evaluate the efficacy of 10-mg/mL, 40 -mg/mL, and 100 -mg/mL formulations of 
ranibizumab, delivered via the Implant, with that of 10 -mg/mL (0.5 -mg dose ) monthly 
ITV ranibizumab injection s over time, as measured by [CONTACT_514861] —Genentech, Inc.
32/Protocol GX28228 , Version 8To evaluate the efficacy of 10-mg/mL, 40 -mg/mL, and 100 -mg/mL formulations of 
ranibizumab, delivered via the Implant, with that of 10 -mg/mL (0.5 -mg dose) monthly 
ITV ranibizumab injections over time, as measured by [CONTACT_514862] (CFT , defined as the retinal thickness in the center of the fovea ) from 
baseline over time
To evaluate the functionality of the Implant by [CONTACT_514863] t there is no evidence of 
Implant clogging in more than 10% of patients in the Implant arms at Month 9
2.2 SAFETY OBJECTIVES
The safety objectives for this study are as follows:
To evaluate the safety of ranibizumab delivered via the Implant , compared with that 
of monthly ITV injection, as measured by o cular and non- ocular adverse events and 
serious adverse events
To evaluate the s afety of the RPDS ,as measured by “Prespecified 
RPDS -associated adverse events ” (see Section 6.5.1 )
To evaluate the proportion of patients with positive serum antibodies to ranibizumab
2.3 PHA RMA COKINETIC OBJE CTIVES
The pharmacokinetic (PK) objectives for this study are as follows:
To characterize the serum pharmacokinetic sof ranibizumab in patients after the 
initial fill and subsequent refills i n the Implant treatment arms
2.4 EXPLORA TORY OBJECTIV ES
The exploratory objectives for this study are as follows:
To evaluate the development of macular atrophy in all three Implant treatment arms 
relative to one another and to the monthly ITV arm
To examine the impact of ranibizumab treatment on patient -reported treatment 
satisfaction as assessed by [CONTACT_514864] ( MacTSQ) at Months 1, 6, 9, and the final or early termination visit for 
patients who speak English or Spanish (see Appendix 19)
To explore time to subsequent Implant refills according to protocol -defined refill 
criteria
To describe the number of times patients meet protocol -specified refill criteria
To evaluate the proportion of patients in each Implant arm who first meet the 
protocol -defined refill criteria prior to and at Months 4, 5, and 6
To evaluate the proportion of patients with an improvement of 15letter s in BCVA 
from baseline 
To evaluate the proportion of patients with a loss of 15 letters in BCVA from 
baseline over time
To explore the utility of BCVA measured under low luminance as a predictor of 
treatment benefit over time
Ranibizumab Port Delivery System —Genentech, Inc.
33/Protocol GX28228 , Version 8To evaluate the changes in total lesion area , area of CNV lesion, andCNV leakage
over time, as assessed by [CONTACT_228628]
To explore the serum r anibizumab concentration data with a PK model in an attempt 
to infer the concentration time pattern in the vitreous or aqueous humor and, if 
possible, derive information on the rate of ranibizumab release from the Implant
To characterize ranibizumab aqueous humor concentration over time (optional)
To characterize ranibizumab vitreous or aqueous humor concentration after Implant 
explantation (if applicable)
To evaluate the potential association of circulating biomarkers with disease 
characteristics and response to ranibizumab (optional)
To evaluate the relationship of genetic variants (such as AMD risk alleles; 
polymorphisms within the complement pathway; and polymorphisms within the 
VEGF -A genetic locus) with the disease characteristics and/or response to 
treatment with ranibizumab (optional)
To evaluate the potential association of vitreous or aqueous humor biomarkers with 
disease characteristics and response to ranibizumab
To evaluate the proportion of patients meeting lack of clinical e fficacy criteria
(see Section [IP_ADDRESS])
To evaluate the proportion of patients requiring explantation
To evaluate the changes in CNV perfusion over time as assessed by [CONTACT_514865] (at select edsites that have OCT angiography equipment )
See the Device Clinical Investigation Plan ( Appendix 21) for addi tional details of 
RPDS -specific data analyses to be conducted using the data generated during this study.
3. STUDY DESIGN
3.1 DESCRIPTION OF STUDY
Study GX28228 is a Phase II, multicenter, dose- ranging, randomized , active treatment 
(monthly ITV injection) control led study to evaluate the efficacy, safety, and 
pharmacokinetics of ranibizumab delivered through the Implant using three r anibizumab 
formulation arms (10 mg/mL, 40 mg/mL, and 100 mg/mL) compared with the control arm 
(0.5-mg monthly ITV injections of 10 -mg/mL formulation) in patients with n AMD.  The 
study will also evaluate the safety of the RPDS combination product .  Approximately 
220patients at up to 60 sites inthe [LOCATION_002] will be randomized in a3:3:3:2 ratio to 
four treatment arms within an approximate 24-month period of time (see Figure 2).
Ranibizumab Port Delivery System —Genentech, Inc.
34/Protocol GX28228 , Version 8Figure 2Study Schema
D1Day 1; ITVintravitreal; LPIlastpatient in; M1Month 1; M9Month 9; PAprimary
analysis; PRNas needed (as per therefill criteria );RBZ PDranibizumab port deliver y; 
RBZranibizum ab; SOC standard of care ; ranibizumab filled Implant inserted (Day  1).
Patients randomized to the Implant treatment arms will have the Implant (pre-filled with 
ranibizumab) surgically inserted in the study eye at their Day 1 visit, after which they will 
be evaluated monthly for the need for an Implant refill, based upon protocol -specified 
refill criteria (see Section 3.1.1 ),for the remainder ofthe study treatment duration
(see Section 3.2).  Patients randomized to the ITV injection treatment arm (control) will 
be treated monthly with ITV injections of ranibizumab, starting at their Day 1 visit and 
continuing for the remainder of the study treatment duration (see Section 3.2).  The 
monthly ITVtreatment arm patients will also be evaluated monthly according to the 
protocol -specified refill criteria (see Section 3.1.1 ),but will be treated monthly regardless 
of whether they meet the refill criteria.  Study vi sits will be conducted every 307days 
relative to the Day [ADDRESS_667263] -implant 
insertion safety data by [CONTACT_514866] ( IMC).In the case of such a 
pause, dosing will continue as per the protocol for patients who have already received 
study drug (e .g.,patients who have performed Day 1 visit), while pat ients who have not 
yet received study drug will stay in Pre-Screening, Run -In, Screening, or Randomization
period (as applicable) and receive monthly open -label ITV ranibizumab treatment until 
enrollment and implant insertion surgeries are restarted.  In ad dition, in the case of a
pause, patients who have been randomized but have not yet received the study drug 
must repeat the Randomization assessments after enrollment and implant insertion 
surgeries have recommenced and before receiving the study drug.  Pat ients who exceed 
nine total anti -VEGF doses before receiving the study drug will no longer be eligible for
the study .  
The study will include screening and randomization visits followed by a treatment period .  
Baseline measurements will be taken at therandomization visit.  On the day of patient

Ranibizumab Port Delivery System —Genentech, Inc.
35/Protocol GX28228 , Version 8randomization, BCVA will be measured based upon the Early Treatment Diabetic 
Retinopathy Study (ETDRS )chart assessment at a starting test distance of 4 meters .
Thepatients will then be randomized to a treatment arm using a stratified randomization :  
BCVA score (65letters vs. 66letters )and number of prior anti-VEGF ITVinjections 
(3 vs. 4). Patient smust satisfy all eligibility criteria at both the screening and the 
randomization visits, including receipt of all screening visit images by a central reading 
center.  Historical OCT images taken at the time of diagnosis of nAMD will also be 
evaluat ed by [CONTACT_514867] ’seligibility .  If fluorescein 
angiograms were taken at the time of diagnosis of nAMD, they must be submitted to the 
reading center as well . If available, h istorical fluorescein angiograms willbe evaluated 
by [CONTACT_171120], but are not required to det ermine patient’s eligibility at the 
screening visit .  As part of the screening process, thecentral reading center will evaluate 
the patient’s FA, FP, and SD -OCT images taken both at the time of diagnosis of nAMD 
and at the screening visit to provide an objective, masked assessment of patient 
eligibility regarding lesion CNV , lesion classification, total lesion size, area of CNV lesion, 
and CNV leakage (see the Reading Center manual for details).  Macular atrophy will 
also be evaluated at screening , using fundus autofluorescence (FAF) and SD -OCT 
measurements (see the reading center manual for further details) .After all eligibility 
requirements are confirmed, patient swill be randomized through an interactive 
voice/ Web response system (IxRS) in a 3:3:3:2 ratio so that approximately 60patients 
will receive the Implant filled with 10- mg/mL ranibizumab formulation, 60patients will 
receive the Implant filled with 40- mg/mL ranibizumab formulation, 60patients will receive 
the Implant filled with 100- mg/mL ranibizumab formulation, and 40patients will receive 
mont hly ITV injections of 10 -mg/mL ranibizumab formulation (50 L for the 0.5 -mg dose; 
seeFigure 2). 
There are 4 patient eligibility scenarios based on pr ior anti -VEGF treatment history:
1.Newly diagnosed nAMD patients who are treatment naïve .These patients will 
undergo pre- screening if they satisfy el igibility criteria and sign informed consent
(Table 2).  During the pre -screening, patients will receive two ranibizumab ITV 
treatments to determine if they demonstrate response to ranibizumab treatment as 
outlined per the eligibility criteria (see Section 4.1.1 ). 
2.Patients diagnosed with nAMD in the study  eye within [ADDRESS_667264] been treated with a singl e anti -VEGF ITV injection .These 
patients may receive one “run -in” ITVranibizumab treatment prior to screening if 
they satisfy eli gibility criteria and sign the informed consent form ( seeTable 2). 
3.Patients diagnosed with nAMD in the study  eye within [ADDRESS_667265] recent dose being aflibercept or bevacizumab .  
These patients may receive one “run -in” ITVranibizumab treatment prior to 
screening if they satisfy eli gibility criteria and sign the informed consent form 
(seeTable 2 ). 
Ranibizumab Port Delivery System —Genentech, Inc.
36/Protocol GX28228 , Version 84.Patients diagnosed with nAMD in the study  eye within 9months prior to 
screening who have been treated with no more than nine anti-VEGF ITV 
injections and with the most recent dose being ranibizumab.  These patients
can proceed directly to screening (see Table 2 ). 
Table 2Dosing Guidelines Prior to Screening
Historical anti -VEGF use in the 
study eye within the last 
9months prior to screeningOpen -label ranibizumab
dose(s) required prior to 
screening Comments
Anti-VEGF treatment na ive 2 The Sponsor will provide 
2ranibizumab doses prior to 
screeninga
Single previous anti -VEGF 
dose1 The Sponsor will provide 
1ranibizumab dose prior to 
screeninga
28prior anti-VEGF dose AND 
most recent dose was 
aflibercept or bevacizumab1 The Sponsor will provide 
1ranibizumab dose prior to 
screeninga
29prior anti-VEGF dose AND 
most recent dose was 
ranibizumab0 Patients can proceed directly 
to screening
VEGF vascular endothelial growth factor.
aIn the case of a pause of patient enrollment, additional ITV ranibizumab doses will be provided 
before receiving study drug ,until enrollment and implant insertion surgeries recommence .  
Patients who exceed 9total anti-VEGF doses before receiving the study drug will be excluded 
from the study.
A patient’s screening visit should occur no sooner than 7 days following administration of 
the lastITV ranibizumab treatment inthe study eye.  All patients will be enrolled in the 
study on the day of their randomizat ion visit and receive their Day 1 study treatment after 
conclusion of the Randomization visit .  If necessary, the Day 1 study treatment may be 
scheduled at a later da te.  
Randomization visit cannot occur earlier than 2 8days andno later than 37 days after the 
patient’s last ITV ranibizumab treatment.  
Day 1 study treatment visit cannot occur earlier than 28 days after and no later than 
37days after the patient’s la st ITV ranibizumab treatment ,unless a patient randomized 
to the Implant arm needs more time to interrupt aspi[INVESTIGATOR_514817] 7days before 
Day 1 (see Section [IP_ADDRESS]).   For these patient s, Day [ADDRESS_667266] occur 
no later than 45 days after the patient’s last ITV ranibizumab treatment.
Patients who are randomized to the Implant treatment arms will have scheduled safety 
visit assessments on Day 2 ( 0), Day 7 ( 2days ), and Day 14 (2days ) after their 
Day1 visit.  Starting at the Mon th 1 visit, the patients in the Implant treatment arms will 
be ass
essed monthly for the need for Implant refill with ranibizumab according to the
Ranibizumab Port Delivery System —Genentech, Inc.
37/Protocol GX28228 , Version 8protocol -specified refill criteria (see Section 3.1.1 ).  Their Implant will be refilled only if 
they meet re -treatment criteria.   The safety visits will be scheduled 7 ( 2) days after 
each refill (see Appendix 1).  After the Day 1 visit treatment, patients randomized to the
monthly ITV injection treatment arm will also beassessed monthly using the same 
re-treatment criteria as those for the Implant treatment arms (see Section 3.1.1 ) but will 
receive monthly ranibizumab injection treatment regardless of whether they meet the 
criteria (see Appendix 2andTable 3 ).
Table 3Ranibizumab Dosing and Safety  Assessment Schema
VisitDay Month
Month 
XbFinal/
ET 
visit1a2 7 14 1 2 3 4 5 6 7 8 9
Implant 
insertion/refillcxRefill Implant if refill criteria are met NA
Safety 
assessment 
visitsdx x x
7 Day s after each Implant refillNA
ITV injectionex x x x x X x x x x x NA
ETend of treatment; ITVintravitreal; NAnot applicable .
aThe Day 1 treatment in all treatment arms ( Implant and ITV injection) will occur on such date 
so that no fewer than [ADDRESS_667267] elapsed from patient’s last 
study eye ranibizumab ITV treatment.
bMonth X visits : After completion of the Month 9 visit, the study patients in the Imp lant arms 
will continue monthly evaluation for refill according to the Month X schedule of assessments 
(see Appendix 1) until the Sponsor decides, based on the primary  analysis results, to either 
terminate the study and discontinue study treatment or offer patients entry into the RPDS 
Extension Study . The ITV arm patients will continue to be treated monthly according to the 
Month X schedule of assessment s(see Appendix 2) until the Sponsor decides, based on the 
primary analysis results, to either terminate the study and discontinue study treatment ,or 
offer patients entry into the RPDS Extension Study .
cStarting at the Month 1 visit, Implant treatment arms will receive a refill with ranibizumab only 
if protocol refill criteria are met (see Section 3.1.1 ).
dThere will be safety assessment visits on Days 2, 7, and 14 after the Implant insertion and 
then 7 days after each Implant refill.  These safety assessment visits are not applicable to the 
ITV injections treatment arm .
eITV injection arm patients will b e treated monthly regardless of meeting the re -treatment 
criteria.
Starting at the Day 1 visit (ITV treatment arm) or starting at the Month 1 visit ( Implant
arms), all patients will be contact[CONTACT_178766] 3 ( 1) days after each ITV 
injection or Implant refill to elicit reports of decrease in vision, eye pain, unusual redness, 
or any other new ocular symptoms in the study eye. Patients in the Implant treatment 
arms will also be asked to verify whether they have taken the pres cribed, 
self-administ ered, post -injection antimicrobial treatments .  The ITV arm patients’ 
self-administered antimicrobial treatments will be prescribed at the investigator’s 
discretion.
Ranibizumab Port Delivery System —Genentech, Inc.
38/Protocol GX28228 , Version 8Only one eye will be selected as the study eye during the screening period . If both eyes 
are eligible, the investigator will determine ,during the screening, which eye will be 
selected for study treatment (study eye).  
Should a non- study (fellow) eye require treatment for nAMD after randomization, 
treatment with ranibizumab is n ot recommended within 7days of the study eye 
scheduled visit.  For patients in the Implant arm s, if t he fellow eye will be treated 
7days after study eye treatment, ranibizumab should be administered after serum 
PK sample collection.  
The drug for the fe llow eye during the study will be open
-label ranibizumab and will 
be supplied by [CONTACT_8229] (see Section [IP_ADDRESS] for the drug formulation for the 
non-study eye).If a change in therapy is clinically indicated for the fellow eye per 
investigator judgment, the change must be discussed and agreed by [CONTACT_514868].   
All study patients will have scheduled monthly visits during the study .  After the Day [ADDRESS_667268] to be re lative to the 
Day 1 (first study treatment) visit date until the patient completes the study .
Each potential study patient can be randomized into the study only once.
Please see Section [IP_ADDRESS] for the criteria to be used for dose interruption and 
treatment/study discontinuation.  Missed ranibizumab doses will not be replaced.
The ITV treatment arm p atients who are discontinued from study treatment prematurely 
will be asked to undergo the scheduled monthly assessments until Last Patient In (LPI)
Month9 visit ,after which they will be scheduled 30 ( 7) days later for their final study 
visit.  The patients who are discontinu ing study treatment from the Implant treatment 
arms will be scheduled, within 7 days after the treatment discontinuation decision is 
made ,for Implant explantation followed by [CONTACT_514869] 1 and 7 (2) days 
post-explantation. After wards ,they will be followed in the study, attending their monthly 
scheduled visits, until LPI[CONTACT_43380] 9 visit, after which they will be schedule d for the early 
termination visit (see Appendix 1).  As per investigator judgement, these patients may 
start an approved anti -VEGF for their AMD once the need for Implant explantation is 
confirmed and ,preferably ,after explantation is completed . All explanted Implant s with 
their remaining content will be returned to the designee of the Sponsor for storage and 
potential future exploratory analysis (see Section 4.4). A vitreous or aqueous humor
sample will be collected at the start of explantation for patients undergoing an 
explantation procedure (see Appendix 19).
Ranibizumab Port Delivery System —Genentech, Inc.
39/Protocol GX28228 , Version 8Patients who withdraw from the study prior to scheduled study completion will be asked 
to return for an early termination evaluation 30 ( 7) days following their last study 
treatment for monitoring of adverse events and early termination visit assessments if 
they are in the ITV treatment arm . The p atients who are discontinu ingthe study from the 
Implant treatment a rms will be scheduled for Implant explantation within 7 days of the 
treatment discontinuation decision ,followed by [CONTACT_514870] 1, 7 (2),30(7),and 60 
(7)days post -explantation after which they will be scheduled for the early termination 
visit 30 (7)days later. As per investigator judgment, these patients may start an 
approved anti-VEGF treatment for their AMD once the need for Implant explantation is 
confirmed and, preferably, after explantation is completed .All explanted Implant s with 
remaining content will be retur ned to the designee of the Sponsor for storage and 
potential future exploratory analysis (see Section 4.4).A vitreous or aqueous humor
sample will be collected at the start of explantation for patients undergoing an 
explantation procedure (see Appendix 19).
Patients in the ITV injection arm will be evaluated monthly and will receive monthly 
study treatments (Day 1, Month 1 through Month Xvisit, see Appendix 2)until the 
Sponsor decides, based on the primary analysis results, to either terminate the study 
and discontinue study treatment ,or offer patients entry into the RPDS Extension 
Study.   Their participation (excluding screening period) in the study will last
approximately 1338months dependent on the date of their randomization to the study .  
The patients in the I mplant arms will be evaluated monthly for the I mplant refill 
(see Appendix 1) until the Sponsor decides, based on the primary analysis results , to 
either terminate the study and discontinue study treatment ,oroffer patients entry into 
the RPDS Extension Study . If a patient requires refills outside of the protocol -defined
visits window , the Medical Monitor must be contact[CONTACT_19379].  Study 
participation for patients in the Implant arms (excluding screening period) is expected to 
last approximately 13 38months dependent on the date of their randomization to the 
study.
Study invest igators will be qualified ophthalmologists ,trained in the management of 
retinal diseases and ocular surgery and will be certified by a Sponsor -selected vendor to 
perform initial Implant fill, insertion, refill, and explantation.  The surgical procedures 
involved in the use of the investigational devices are also detailed in the IFU document.  
Itis strongly preferred that a site has one investigator who evaluates and treats all 
patients with a backup investigator selected.  The site may opt to have two sep arate 
investigators but to maintain consistency in the evaluation and treatment of patients, it is 
strongly suggested that the same physician conduct the evaluation and treatment of a 
patient throughout the trial.
Study patients and all study site personnel will be masked to the Implant treatment arms’ 
ranibizumab formulation assignment (10 mg/mL vs. 40 mg/mL vs. 100 mg/mL) until the 
study’s conclusion (see Section [IP_ADDRESS] for more details on formulation assignment for 
Ranibizumab Port Delivery System —Genentech, Inc.
40/Protocol GX28228 , Version 8patients who meet lack of clin ical efficacy criteria ).  The Sponsor’s personnel directly 
involv ed in the study conduct (except prespecified IMC members ) will be masked to the 
Implant treatment arms’ ranibizumab formulation assignment (10 mg/mL vs. 40 mg/mL 
vs. 100 mg/mL) until the time of primary analyses (see S ection [IP_ADDRESS] for more details
on formulation assignment for patients who meet lack of clinical efficacy criteria ).  The
IMC will closely monitor patient safety throughout the study (see Section 3.1.4 ).
Clinical pharmacology and PK scientists may be unmasked early for the purposes of 
interpret ingemerging safety and efficacy data; those staff will not be part of the study 
team or have any interactions with sites or investigators.
In addition, the VA examiner will only conduct refraction and VA assessments and will be 
masked to patient study eye assignment andpatient treatment assignment .  The VA 
examiner will have no access to patient VA scores from previous visits, and will be only 
aware of the patient’s refraction data from previous visits .  The VA examiner may 
perform no other direct patient -care tasks .  Patients will be asked not to discuss their 
study eye assignment (right vs. left) with the VA examiner.  
3.1.1 Refill/Re -Treatment Criteria
Starting at the Month 1 visit, all randomized patients will be assessed monthly for the 
refill/ re-treatment .  The patients randomized to the ITV injection arm will be treated 
monthly, regardless of whether they meet re -treatment criteria.  The patients randomized 
to the Implant treatment arms will have their Implant refilled only if anyof the following 
criteria is met , as automatically determined by [CONTACT_514871] :  
Increase in CFT of [ADDRESS_667269] 2 available measurements , due to nAMD disease activity 
OR
Increase in CF T of 100  mfrom the lowest CFT measurement on study, dueto 
nAMD disease activity 
OR
Decrease of [ADDRESS_667270] twoavailable measurements , due to nAMD disease activity 
OR
Decrease of [ADDRESS_667271] recorded BCVA on study ,due to nAMD disease 
activity 
OR
Presence of new macular hemorrhage , due to nAMD disease activity
Ranibizumab Port Delivery System —Genentech, Inc.
41/Protocol GX28228 , Version 8Note: To assess the need for refill at 1 month a fter initial fill, please utilize the following 
criteria:
Decrease of 10 letters in BCVA at the current visit compared with the baseline 
BCVA, due to nAMD disease activity
OR
Increase in CFT of 100  m at the current visit compared with the baseline CFT , 
due to nAMD disease activity
OR
Presence of new macular hemorrhage, due to nAMD disease activity
Patients assigned to the Implant treatment arms will be scheduled for a safety evaluation 
visit 7 (2)days after each refill.
Theschedule sof study assessments areprovided in Appendix 1and Appendix 2. 
3.1.2 Pharmacokinetic Evaluation
The objective of the PK analysis is to characterize the Implant sustained -delivery 
performance by [CONTACT_514872] s 
(see Appendix 1for details ) of 10 -mg/mL, 40 -mg/mL, and 100 -mg/mL formulations of 
ranibizumab delivered via the Implant.  PK parameters of interest will be estimated after 
implant and at subsequent refills using noncompartmental analysis (NCA) and/or a 
population PK model as appropriate; parameters will include area under the 
concentration time curve ( AUC), maximum serum concentration (Cmax) observed , time to 
maximum concentration (tmax), steady -state serum concentration at the end of a dosing 
interval (Ctrough[predose]), and terminal half-life(t1/2).  
The population PK model couples the in-vitro release parameters of the Implant with the 
population pharmacokinetics of ranibizumab in AMD patients to describe the 
pharmacokinetics of ranibizumab i n AMD patients receiving these Implant s. Inter-patient 
variability will be assessed. Coefficient of variation (%CV) of serum concentration at 
each PK sampling time point will be reported.   The observed serum pharmacokinetics
will be compared to the expected PK profiles as predicted by a population PK model .
3.1.3 Planned Total Sample Size
The study will randomize approximately 220patient s, 60 per each of three Implant
treatment arm sand 40 to 
the ITV injection arm (up to 60sites). For further details 
seeSection 6.1.
Ranibizumab Port Delivery System —Genentech, Inc.
42/Protocol GX28228 , Version 83.1.4 Internal Monitoring Committee
Ongoing review of s tudy data ( including adverse events of special interest [AESIs ], 
serious adverse events , adverse device effects [ ADEs ], and laboratory abnormalities ) 
will be performe d by [CONTACT_27904] .The IMC roles and responsibilities will be outlined in the 
IMC Agreement .
3.[ADDRESS_667272] study visit occurs.
3.4 RATIONA LE FOR STUDY DESIGN
3.4.1 Rationale for Ranibizumab Dose Selection
Delivery of ranibizumab via the Implant was chosen to investigate an alternate dosing 
method.  Sustained release of ranibizumab from the Implant is an alternate dosing 
method that may result in less -frequent need of re- treatment than monthly dosing with 
ITV injections . Ithas the potential to reduce the number of patient visits, as well as the 
burden on patients, caregivers, and healthcare providers.  In addition, increased 
treatment compliance and optimum visual outcomes may result from the sustained 
delivery of ranibizum abthrough the Implant .
The three ranibizumab formulations administered via the Implant will be evaluated 
monthly to determine the efficacy and safety of each formulation.  Based on the fill 
volume of 20L of the Implant , the maximum amount of ranibizumab with which the 
Implant can be initially filled and subsequently refilled is approximately 0.2 mg for the 
10-mg/mL formulation, 0.8 mg for the 40 -mg/mL formulation, and 2 mg of ranibizumab 
for 100 -mg/mL formulation.  The selection of the proposed Phase II doses was 
determined by [CONTACT_71411].  The selected doses are anticipated to maintain 
ranibizumab vitreous trough concentrations either below (10 -mg/mL), at (40 -mg/mL), or 
above (100 -mg/mL) the vitreous drug levels estimated to be correlated with efficacy 
(12g/mL), as assessed from pi[INVESTIGATOR_514818] 0.[ADDRESS_667273] antially on efficacy, as a result of potentially frequent refills for lower doses 
according to the “as needed ” protocol defined refill criteria, then the treatment arms are 
expected to differentiate on the basis of time to first meeting refill criteria and number of 
Ranibizumab Port Delivery System —Genentech, Inc.
43/Protocol GX28228 , Version 8refills over the course of the study.  In addition, all doses were selected taking into 
account prior clinical experience to ensure patient safety.
3.4.[ADDRESS_667274] been well 
characterized, however the PK profile for sustained delivery is expected to be markedly 
different.  In order to characterize the PK profile and the in vivo sustained delivery of 
ranibizumab via the Implant , serum PK samples will be collected from patients in the 
Implant treatment arms at multiple timepoints (see Appendix 1) before and after refills.  
The sampling timepoints are expected to be sufficient to estimate key PK parameters of 
interest (see Section 3.1.2 ) following initial insertion of the ranibizumab -filled Implant and 
subsequent refills, and to demonstrate sustained exposure to ranibizumab.  An optional 
aqueous humor 
sample (collected prior to or immediately following Implant refills) ,and a 
vitreous or aqueous humor sample (collected at the start of explantation for patients 
undergoing an explantation procedure), will also be collected to further characterize 
Implant kinetics and relate serum to vitreous ranibizumab concentrations.  For additional 
detai lson ITV ranibizumab pharmacokinetics ,refer to the RPDS IB.  
3.4.3 Rationale for Patient Population
Ranibizumab has been shown to be effective in preventing or reducing vision loss in 
patients with nAMD; therefore , this patient population was selected to be t he first in 
which the RPDS would be evaluated. The goal is to demonstrate a treatment approach 
that maintains the efficacy seen with monthly IT Vinjections while reducing the number of 
ITVinjections and monitoring visits . Other indications ( diabetic macular edema, retinal 
vein occlusion) may also benefit but would be considered for investigat ionfollowing the
Phase II study results in nAMD.
3.4.4 Rationale for Control Group
Ranibizumab is an approved treatment for nAMD in the European Union, [LOCATION_002] ,
and many other countries worldwide.  The monthly dosing of 0.5 mg (10- mg/mL) of ITV 
ranibizumab is the approved posology in the [LOCATION_002] and was selected as the 
appropriate control group based on discussions with both the FDA and European 
Medicines Ag ency .  Therefore, patients in the control arm in the randomized phase of 
thestudy will be treated with monthly IT Vinjections of 0.5-mg dose of ranibizumab.
3.[ADDRESS_667275]
requires theImplant refill according to protocol -defined refill criteria. 
Ranibizumab Port Delivery System —Genentech, Inc.
44/Protocol GX28228 , Version 83.5.2 Secondary  Efficacy Outcome Measures
The secondary efficacy outcome measures are as follows :
Change in BCVA from baseline at Month 9
Average change in BCVA from baseline over time
Change in BCVA from baseline over time
Change from baseline in CFT over time, as assessed on SD-OCT by [CONTACT_64295] l 
reading center
Occurrence of Implant clogging (see Section [IP_ADDRESS] for details)
3.5.3 Safety  Outcome Measures
The safety outcome measures are as follows:
Incidence of adverse events of special i nterest (see Section 5.2.3 for details) :  
Adverse events associated with ranibizumab, the Implant, implant -associated 
procedures, and/or ancillary devices (see Table
1)
Incidence of “ prespecified RPDS -associated adverse events ” (see Section 6.5.1 for 
details)
Incidence of ocular and non -ocular adverse events andserious adverse events
Incidence of positive serum antibodies to ranibizumab
3.5.4 Pharmacokinetic Outcome Measures
The PK outcome measures related to ranibizumab serum concentration -time data 
following the Implant insertion and refills (see Appendix 1fordetails) :
Observed C maxand selected post -dose serum concentrations after Implant insertion
and all subsequent refills 
Additional estimated PK parameter values including AUC, tmax, and t1/2after Implant 
insertion and all subsequent refills
Observed serum concentrations (C t) over time from monthly serum sampling when 
no refills are administered
Observed C troughprior to refills
In addition, o ptional anterior chamber (aqueous humor) will be collected to assess ocular 
drug concentration.  
3.5.5 Exploratory  Outcome Measures
The exploratory outcome measures are as follows:
Treatment emergent macular atrophy in all treatment arms
The MacTSQ score at randomization and at Months 1, 6, 9,and the final or early 
termination visit for patients who speak English or S panish (see Appendix 19)
Time to subsequent Implant refills according to protocol -defined refill criteria
Ranibizumab Port Delivery System —Genentech, Inc.
45/Protocol GX28228 , Version 8Number of times a patient meets protocol -specified refill criteria
Proportion of patients in each Implant arm who first meet the protocol -defined refill 
criteria prior to and at Months 4, 5, and 6
Proportion of patients with an improvement of BCVA from baseline of 15 letters 
over time
Proportion of patients losing 15 letters in BCVA from baseline over time
Change in BCVA from baseline over time measured under low luminance conditions
Changes from screening in total lesion area, area of CNV lesion, and CNV leakage 
over time, as assessed by [CONTACT_228628]
Proportion of patients meeting lack of clinical e fficacy criteria (see Section 5.1.1. 3)
Proportion of patients requiring explantation
Changes in CNV perfusion over time, as assessed by [CONTACT_514873], vitreous samples from the Refill Needle (if applicable) , optional aqueous 
humor samples, and op tional serum and plasma samples may be collected to assess 
the relationship between biomarkers andthe disease characteristics a nd/or response to 
treatment with ranibizumab.   Optional whole blood samples will be collected for DNA 
extraction (genetic analysis) to assess the relationship between genetic variants andthe 
disease characteristics and/or response to treatment with ranibizumab (see 
Section 4.6.12).
In addition, vitreous or aqueous humor samples beforeImplant explantation, and 
optional aqueous humor samples prior to or immediately following one or more refills 
and at the Day [ADDRESS_667276] refill will be collected to characterize ranibizumab 
vitreous and aqueous humor concentration.
4. MATERI ALS AND METHOD S
4.1 PATIENTS
Patients with subfoveal neovascularization secondary to AMD diagnosed within 
9months and treated with ITV anti -VEGF agents will be enrolled in the study.  W ritten 
informed consent will be obtained before initiation of any study -related procedures.  A 
patient’s screening visit should occur no sooner than [ADDRESS_667277] study treatment (Day 1) may occur at the conclusion of the randomization visit 
for the ITV treatment arm; the Implant arm patients may have these two visits separa ted 
due to the systemic medication wash out period (see note below) and the surgery room 
availability.  Randomization visit and Day1 study treatment visit must occur on a date 
such that no less than [ADDRESS_667278] elapsed from the
patient’s last stud y eye ITV ranibizumab treatment .
Ranibizumab Port Delivery System —Genentech, Inc.
46/Protocol GX28228 , Version 8There are 4 patient eligibility scenarios based on prior anti -VEGF treatment history.
1.Newly diagnosed nAMD patients who are treatment naïve .These patients will 
undergo pre- screening if they satisfy eligi bility criteria and sign informed consent
(Table 2). During the pre -screening, patients will receive two ranibizumab ITV 
treatments to determine if they demonstrate response to ranibizumab treatment as 
outlined per the eligibility criteria (see Section 4.1.1).  
2.Patients diagnosed with nAMD in the study  eye within 9months prior to 
screening who have been treated with a single anti -VEGF ITV injection . These 
patients may receive one run -inITV ranibizumab treatment prior to screening if they 
satisfy eligibility criteria and sign the informed consent form (see Table 2 ).
3.Patients diagnosed with nAMD in the study  eye within 9months prior to 
screening who have been t reated with no more than eight anti-VEGF ITV 
injections and with the most recent dose bei ng aflibercept or bevacizumab .  
These patients may receive one run-in ITV ranibizumab treatment prior to screening 
if they satisfy eligibility criteria and sign the informed consent form (see Table 2).
4.Patients diagnosed with nAMD in the study  eye within [ADDRESS_667279] recent dose being ranibizumab .  These patients
can proceed directly to screening (see Table 2 ).
4.1.[ADDRESS_667280] meet the following criteria for study entry:  
General Inclusion Criteria
Age 50 years
Willingness and ability to provide signed informed consent and Health Insurance 
Portability and Accountability Act (HIPAA) authorization
Willingness and ability to undertake all scheduled visits and assessments
For sexually active women of childbearing potential, agreement to the use 
ofanappropriate form of contraception (or abstinence) for the duration of the study.  
Awoman is considered not to be of c hildbearing potential if she is postmenopausal 
or has undergone hysterectomy and/or bilateral oophorectomy.  
For women who are not postmenopausal ( 12months of non -therapy -induced 
amenorrhea) or surgically sterile (absence of ovaries and/or uterus):  
agreement to remain abstinent or use single or combined contraceptive 
methods t hat result in a failure rate of 1% per year during the treatm ent period 
and for at least [ADDRESS_667281] dose of study treatment
Abstinence is only acceptable if it is in line with the preferred and usual lifestyle 
of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulation methods) and withdrawal are not acceptable methods of 
contraception.
Ranibizumab Port Delivery System —Genentech, Inc.
47/Protocol GX28228 , Version 8Sexually active men are recommended to use a barrier contraceptive method 
(condom), even if they have been surgically sterilized, for the duration of the 
treatment period and for at least [ADDRESS_667282] dose of study treatment.
Ocular Inclusion Criteria (Study  Eye)
Newly diagnosed with nAMD within 9months prior to screening visit
Patient must have received at least 2 prior anti-VEGF injections (including 
ranibizumab, bevacizumab, or aflibercept).  However, t hemost recent anti-VEGF 
injection must have been ranibizumab and must have occur red at least 7 days prior 
to the screening visit. 
Demonstrated response to prior ITV anti-VEGF treatment ,as evidenced by [CONTACT_14504]:
Decrease in CFT of 50 m since commencing I TVanti-VEGF treatment
OR
Stable o r improved BCVA since commencing I TVanti-VEGF treatment
BCVA using ETDRS charts of 20/20 20/200 Snellen equivalent 
All subtypes of nAMD CNV lesions are permissible (i.e., classic CNV, occult CNV, or 
with some classic CNV component ,or retinal angio matous proliferation lesions ). 
Active primary CNV lesions at the time of diagnosis of nAMD must be subfoveal 
or juxtafoveal with a subfoveal component ( as defined in Table 4 ) related to the 
CNV activity (such as subretinal hemorrhage , subretinal fluid, or RPE 
detachment)
Note: Refer to Table 5 for further details on imaging requirements.
Table 4Definition of Terms Pertaining to A MD Inclusion Criteria
Term Definition
Primary Newly diagnosed within 9months of screening visit 
Subfoveal Including the center of the fovea within the boundaries of the CNV
Juxtafoveal Confined to an area up to 199 m from the geometric center of the fovea
Total area of
lesionA contiguous area of abnormal tissue in the macula that encompasses 
angiographically documented CNV with possible additional components of 
subretinal hemorrhage, blocked fluorescence not from hemorrhage, 
serous detachment of the retinal pi[INVESTIGATOR_1836], and subretinal fibrosis
AMD Clinical and/or angiographic signs consistent with AMD (e.g., drusen, 
retinalpi[INVESTIGATOR_514819], CNV) with no other likely etiologic 
explanations for the degenerative changes
AMD age-related macular degeneration; CNV choroidal neovascularization.
Ranibizumab Port Delivery System —Genentech, Inc.
48/Protocol GX28228 , Version 8Ocular Inclusion Criteria for Pre -Screening (Study Eye) ( If Applicable)
Treatment naïve nAMD patients
BCVA using ETDRS charts of 20/20 to 20/200 Snellen equivalent
All subtypes of nAMD CNV lesions are permissible (i.e., classic CNV, occult CNV, or 
with some classic CNV component, or retinal angiomatous proliferation lesions). 
Active primary CNV lesions must be subfoveal or juxtafoveal with a subfoveal 
component (as defined in Table 4 ) related to the CNV activity (such as 
subretinal hemorrhage, subretinal fluid, or RPE detachment)
Note: Refer to Table 5 for further details on imaging requirements .  
Ocular Inclusion Criteria for Run -In (Study Ey e) (If Applicable)
Previous treatment with a single anti -VEGF ITV injection or no more than eight
anti-VEGF ITV injections ,with aflibercept or bevacizumab being the most recent 
injection 
BCVA using ETDRS charts of 20/20 to 20/200 Snellen equivalent
All subtypes of nAMD CNV lesions are permis sible (i.e., classic CNV, occult CNV, or 
with some classic CNV component or retinal angiomatous proliferation lesions) 
Active primary CNV lesions at the time of diagnosis of nAMD must be subfoveal 
or juxtafoveal with a subfoveal component (as defined in Table 4) related to the 
CNV activity (such as subretinal hemorrhage, subretinal fluid, or RPE 
detachment)
Note: Refer to Table 5 for further details on imaging requirements.
Ranibizumab Port Delivery System —Genentech, Inc.
49/Protocol GX28228 , Version 8Table 5 Imaging Requirements at Pre- Screening, Run -In, and Screening
Visit Applies toRequired Ocular 
Imaging at the 
Study VisitRequired 
Historical 
OCTaImaging 
Evaluation
Pre-s creening Treatment -naive patients FA, SD -OCTbNAbInvestigator (locally)
Run-in Patients previously 
treated with anti -VEGFcNA Yes Investigator (locally)
Screening All patients FA, FP, FAF, SD -
OCT, lens photoYes Central reading 
centerd
aHistorical OCT taken at the time of diagnosis of nAMD is required to determine patient’s 
eligibility, and must be submitted to the reading center at the screening visit only.  If fluorescein 
angiograms were taken at the time of diagnosis of nAMD, they must be submitted to the 
reading center as well .If available, h istorical fluorescein angiograms will be evaluated by [CONTACT_514874], but are not required to determine patient’s eligibility.  Refer to the Reading 
Center Manuals for details. 
bFluorescein angiograms and SD -OCT will be required for entr y to Pre -Screening, and must be 
taken following the instructions on the Reading Center Manual; these images will be used as 
historical images for patient’s eligibility at the screening visit.
cSee Table 2for details.
dThe central reading center will evaluate fundus photography, fluorescein angiograms, and SD -
OCT for determination of a patient’s eligibility.  Historical OCT taken at the time of diagnosis of 
nAMD is also required to determine patient’s eligibility at the screening visit.
4.1.2 Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
Prior Ocular Treatment
Treatment with ITV anti -VEGF agents other than ranibizumab within 1month prior to 
the randomization visitin either eye
History of vitrectomy surgery, submacular surgery, or other surgical intervention for 
AMD in the study ey e
Prior treatment with Visudyne®, external- beam radiation therapy, or transpupi[INVESTIGATOR_514820]
Previous treatment with ITVcorticosteroid injection or device implantation in the 
study eye
Previous focal laser photocoagulation used for AMD treatment in the study eye
Prior participation in a clinical trial involving anti -angiogenic drugs, other than 
ranibizumab, ineither eyewithin 2 months prior to the randomization visit
Treatment with Visudyne®in the fellow eye 7 days preceding screening visit
Ranibizumab Port Delivery System —Genentech, Inc.
50/Protocol GX28228 , Version 8CNV Lesion Characteristics
Subretinal hemorrhage in the study eye that involves the center of the fovea, if the 
size of the hemorrhage is either 50% of the total area of the lesion or 1 disc area 
(2.54 mm2) in size at screening
Subfove al fibrosis or atrophy in the study eye
CNV in either eye due to other causes, such as ocular histoplasmosi s, trauma, or 
pathologic myopia
Note: Historical OCT taken at the time of diagnosis of nAMD will also be required to 
determine patient’s eligibilit y at the screening visit.  If fluorescein angiograms were taken 
at the time of diagnosis of nAMD, they must be submitted to the reading center as well . 
If available, h istorical fluorescein angiograms will be evaluated by [CONTACT_171120], but
are not required to determine patient’s eligibility. If historical OCT images are not 
available or are not of sufficient quality to be evaluated by [CONTACT_66322], patients
would not be eligible for enrol lment in the study.
Concurrent Ocular Condition s
BCVA using ETDRS charts lower than 20/200 Snellen equivalent in the fellow eye
Retinal pi[INVESTIGATOR_514821]
Any concurrent intraocular condition in the study eye (e.g., cataract, glaucoma, or 
diabetic retinopathy) that, in the opi[INVESTIGATOR_871], would either:   require 
surgical intervention during the study to prevent or treat visual loss that might res ult 
from that condition or affect interpretation of study results
Active intraocular inflammation (grade trace or above) in the study eye
History of vitreous hemorrhage in the study eye within 3months prior to the
randomization visit
History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the 
study eye
History of idiopathic or autoimmune -associated uveitis in either eye
Activ einfectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
Aphakia or absen ce of the posterior capsule in the study eye
Previous violation of the posterior capsule break in the study eye is also 
excluded unless it occurred as a result of yttrium aluminium garnet laser 
posterior capsulotomy in association with prior, posterior cha mber intraocular 
lens implantation .
Spherical equivalent of the refractive error in the stud y eye demonstrating more than 
8diopters of myopia
For patients who have undergone prior refractive or cataract surgery in the study 
eye, the preoperative refractiv e error in the study eye does not exceed 8 diopters of 
myopia
Ranibizumab Port Delivery System —Genentech, Inc.
51/Protocol GX28228 , Version 8Intraocular surgery (including cataract surgery) in the study eye within 3 months 
preceding therandomization visit
Uncontrolled ocular hypertension or glaucoma in the study eye (defined as 
intraocular pressure [IOP]25mmHg or a Cup to Disc ratio 0.8, despi[INVESTIGATOR_514822] -glaucoma medication) and any such condition for which the investigator 
feels may require a glaucoma filtering surgery while in the study
History of glaucoma- filtering surgery , tube shunts , ormicroinvasive glaucoma 
surgery in the study eye
History of corneal transplant in the study eye
Concurrent Sy stemic Conditions
Uncontrolled blood pressure (defined as systolic 155mmHg and/or diastolic 
95mmHg , based on the average of 3 readings taken with the patient in a resting 
state [i.e., supi[INVESTIGATOR_103169], but consistent across readings] over a period of up to 
15minutes at screening )
If the average of 3 readings exceeds these values, patient’s blood pressure 
must be co ntrolled by [CONTACT_66310] .  The patient can become 
eligible for rescreening if medication is taken continuously for at least 30 days 
prior to the randomization visit.
Uncontrolled atrial fibrillation within 3 months of informed consent
Histor y of stroke within the last 3 months prior to informed consent
History of myocardial infarction within the last 3 months prior to informed consent
History of other disease, metabolic dysfunction, physical examination finding, or 
clinical laboratory finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that 
contraindicates the use of ranibizumab or placement of the Implant , that might affect 
interpretation of the results of the study or re nders the patient at high risk of 
treatment complications
Current treatment for anyactive systemic infection
Use of any systemic anti -VEGF agents
Use of oral corticosteroids (prednisone 10mg/day or equivalent)  
Use of anticoagulants, antiplatelets (other than aspi[INVESTIGATOR_248] ),ormedications known to 
exert similar effects at the time of study entry for a pre -existing condition .  Oral
anticoagulants include vitamin K antagonists (e.g. ,warfarin), direct factor Xa 
inhibitors (e.g. ,rivaroxaban, api[INVESTIGATOR_3822], edoxaban, fondaparinux) and direct thrombin 
inhibitors (e.g. ,dabigatran). Antiplatelet therapi[INVESTIGATOR_178723], prasugrel, 
dipyridamole, ticagrelor and ticlodipi[INVESTIGATOR_050] (see Section 4.5.2 ).
Bleeding disorders , including platelet disorders, acquired or hereditary coagulations 
disorders, and acquired or hereditary vas cular disorders.
Ranibizumab Port Delivery System —Genentech, Inc.
52/Protocol GX28228 , Version 8Active malignancy w ithin 12 months of randomization except for appropriately 
treated carcinoma in situ of the cervix, non -melanoma skin carcinoma, and prostate 
cancer with a Gleason score of 6and a st able prostate- specific antigen
for 12months.
History of allergy to fluorescein, not amenable to treatment
Inability to obtain fundus photographs, fluorescein angiograms , fundus 
autofluo rescence, or SD -OCT images of sufficient quality to be analyzed and graded 
by [CONTACT_73475] 
Inability to comply with study or follow -up procedures
Previous participation in any non-ocular (systemic) disease studies of investigational 
drugs within 1 month preceding the informed consent (excluding vitamins and 
minerals)
Use of antimitotic or ant imetabolite therapy within 30 days or 5 elimination half -lives 
of the randomization visit
Intolerance or hypersensitivity to topi[INVESTIGATOR_12866], mydriatic medications, any of 
the excipi[INVESTIGATOR_514808], fluorescein, or components of the Implant
Requirement for continuous use of any medications or treatments indicated in the 
“Prohibited Therapy” section (see Section 4.5.2 )
Women who are pregnant or lactating or intending to become pregnant during the 
study
Women who are of childbearing potential, including those who have had tubal 
ligation, must have a negative serum pregnancy test result within 21 days prior to 
Day 1 .  Awoman is considered not to be of childbearing potential if she is 
postmenopausal or has undergone hysterectomy and/or bilateral oophorectomy .
No additional exclusions may be applied by [CONTACT_093], in order to ensure that 
the study population will be representative of all eligible patients .
4.2 METHOD OF TREA TMENT ASSIGNMENT A ND MASKING
4.2.1 Randomization and Masking
Patients will be randomized through an IxRS in a 3:3:3:2 ratio so that approximately 
60patients will receive the Implant with 10 -mg/mL ranibizumab formulation, 60 patients 
will receive the Implant with 40 -mg/mL ranibizumab formulation, 60 patients will receive 
the Implant with 100- mg/mL ranibizumab formulation, and 40 patients will receive 
monthly ITV injections of 10- mg/mL ranibizumab formulation. On the day of patient 
randomization visit, BCVA will be measured based upon the ETDRS chart assessment 
at a starting test distance of 4 meters, and randomization will be stratified by [CONTACT_514875] ( 65 letters vs. 66 letters) and number of prior anti -VEGF injections ( 3 vs 4).
Study patients and all study site personnel will be masked to the Implant treatme nt arms ’ 
ranibizumab formulation assignment (10 mg/mL vs. 40 mg/mL vs. 100 mg/mL) until the 
study’s conclusion (see Section [IP_ADDRESS] for more details on formulation assignment for 
patients who meet lack of clinical efficacy criteria ).  The Sponsor’s personn el directly 
Ranibizumab Port Delivery System —Genentech, Inc.
53/Protocol GX28228 , Version 8involved in the study conduct (except prespecified IMCmembers ) will also be masked to 
the Implant treatment arms’ ranibizumab formulation assignment (10 mg/mL vs. 
40mg/mL vs. 100 mg/mL) until unblinding of treatment code after database lock
(seeSection [IP_ADDRESS] for more details on formulation assignment for patients who meet 
lack of clinical efficacy criteria ).  Inaddition, the VA examiner will conduct only refraction , 
BCVA assessment, BCVA assessment under low luminance conditions, and will be 
masked to patient study eye assignment and patient treatment assignment .  The VA 
examiner will have no access to the BCVA scores of a patient’s previous visits, and will 
beonly aware of thepatient’s refraction data from previous visits.  The VA examin er may 
provide no other direct patient care.  Patients will be asked not to discuss their study eye 
assignment with the VA examiner.
Patients and study site personnel will not be masked with regard to patient assignment 
to the ITV arm or an Implant arm bec ause of the difficulties of maintaining masking 
following the surgical procedure , the additional safety visits applicable only to the Implant 
arms, and Implant visualization upon ophthalmic examination.
4.2.2 Unmasking Procedure
Treatment assignment should be unmasked for a patient in an Implant treatment arm in 
the event of a life -threatening medical emergency (if the investigator considers this 
necessary for treatment of the patient ) that requires immediate unmasking or in the 
event of an unexpected serious adverse events judged by [CONTACT_514876] , for FDA safety reporting.  In such cases, unmasking will be 
implemented following standard procedure s.
4.3 STUDY TRE ATMENT 
4.3.1 Formulation, Packaging, and Handling
[IP_ADDRESS] Ranibizumab Port Delivery System
For the list of the components of the RPDS, see Table 1 .  For detailed information on the 
RPDS components, initial Implant fill, insertion, refill ,as well as the explantation 
procedure consult the RPDS IFU and RPD S IB documents. 
Note:  Unless otherwise directed by [CONTACT_1034], only ranibizum ab willbe injected into 
the Implant .
[IP_ADDRESS] Formulation of Ranibizumab Used to Fill/Refill the Implant
Ranibizumab 10 mg/mL, 40 mg/mL , and 100 mg/mL
Ranibizumab is formulated as a st erile solution aseptically filled in a sterile 3 -mL 
stoppered glas s vial.  Each vial contains 0.5 mL of the 10 -mg/mL, 40-mg/mL, or 
100-mg/mL formulations of ranibizumab aqueous humor solution (pH 5.5) with 10 mM 
histidine hydrochloride ( HCI), 10% ,-treha lose dihydrate, and 0.01% polysorbate 20, 
pH 5.5.  Each vial contains no preservative and is suitable for single use only.  Vial
content should not be frozen or shaken and should be protected from direct light. 
Ranibizumab Port Delivery System —Genentech, Inc.
54/Protocol GX28228 , Version 8Ranibizumab vials must be refrigerated at 2 C to 8 C (36 F to 46 F) upon receipt until 
used. All vials will be labeled as required by [CONTACT_178776] . 
[IP_ADDRESS] Formulation of Ranibizumab Used in ITV Injection Control Arm 
Ranibizumab 10 mg/mL
Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 2 -mL 
stoppered glass vial.  Each vial contains 0.3 mL of the 10 -mg/mL formulation of 
ranibizumab aqueous humor solution (pH 5.5) with 10 mM histidine HCI, 
10% ,-trehalose dihydrate, and 0.01% polysorbate 20, pH 5.5.  The vial contains no 
preservative and is suitable for single use only.  Vial contents should not be frozen or 
shaken and should be protected from direct light. Ranibizumab vials must be 
refrigerated at 2 C to 8 C (36 F to 46 F) upon receipt until used .  Each vial will be 
labeled as required by [CONTACT_178776].
For further details, see the RPDS IB.
[IP_ADDRESS] Formulation of Open -Label Ranibizumab
Ranibizumab 10 mg/mL
Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 2 -mL 
stoppered glass vial.  Each vial contains 0. 3mL of the 10 -mg/mL formulation of 
ranibizumab aqueous humor solution (pH 5.5) with 10 mM histidine HCI, 
10% ,-trehalose dihydrate, and 0.01% polysorbate 20, pH 5.5.  The vial contains no 
preservative and is suitable for single use only.  Vial contents should not be frozen or 
shaken and should be protected from direct light. Ranibizumab vials must be 
refrigerated at 2C to 8 C (36 F to 46 F) upon receipt until used .  
4.3.2 Dosage, A dministration, and Compliance
[IP_ADDRESS] Implant
Please see the RPDS IFU document for a detailed description of the Implant initial fill, 
insertion, refill, and explantation procedures.
[IP_ADDRESS] Dosage
Patient s in the Implant Treatment A rms
Patients will have theImplant (prefilled with approximately 20 Lof either the 10- mg/m L 
(approximately 0.2 mg dose), 40-mg/mL (approximately 0.8 mg dose) ,or 10 0-mg/mL 
formulation (approximat ely 2 -mg dose) of ranibizumab ) surgically inserted in the study 
eye at the Day 1 visit following their randomization visit.  Starting at the Month 1 visit, 
patients will be eval uated monthly for the need for Implant refill with the10 -mg/mL, 
40-mg/mL,or 100 -mg/mL formulations of ranibiz umab according to their randomization
as per protocol -specified refill criteria (see Section 3.1.1 ).  If the criteria are not met, no
Implant refill will be given. At each refill, avolume of approximately 100L of 
ranibizumab will be injected in situ into the Implant through the septum to exchange the
remaining contents of the Implant withnewly introduced ranibizumab.  During the refill 
procedure, the contents of the Implant will be collected in the fluid collection reservoir of 
Ranibizumab Port Delivery System —Genentech, Inc.
55/Protocol GX28228 , Version 8the R efill Needle , if applicable (see the RPDS IFU for further details) . The volume of 
newly introduced ranibizumab remaining in the Implant after the refill procedure will be 
approximately 20 L.  After the initial fill of the Implant with ranibizumab, patients will be 
evalua ted for their Implant refill according to protocol -specified refill criteria 
(see Section 3.1.1 ) at each of their scheduled visit suntil the study treatment completion 
(see Section 3.2for the definition) .  Missed tr eatments will not be made up.
If a study patient meets criteria for lack of clinical efficacy, he or she will receive a rescue 
injection with open -label ranibizumab .  After that, he or she will receive the 100 -mg/mL 
formulation for all future refills (see Section [IP_ADDRESS] for more details ).
Study visits for the Implant treatment arms will be scheduled to occur according to the 
schedule in Appendix 1and have to be relative to the Day 1 (the first study treatment) 
visit date until patients complete the study.
Patients in the ITV In jection Treatment (Control) A rm
Patients will receive their first ITV injection of 50 L of the 10 -mg/mL ranibizumab 
(0.5mg dose) formulation at the Day 1 visit, which may occur (if feasible) at the 
conclusion of the randomization visit.  Afterward s, patients will receive monthly ITV 
injections of 50 L of 10 -mg/mL formulation.  Patients will be receiving the study 
treatment at each scheduled monthly visit until the study treatment completion (see
Section 3.2for the definition) .  Missed treatments will not be made up.
Study visits for the ITV treatment arm will be scheduled to occur according to the 
schedule in Appendix 2and have to be relative to the Day 1 ( the first study treatment) 
visit date until patients complete the study .
Ranibizumab d osing should not occur earlier than 2 2days after the previous dosing.  
Guidelines for treatment interruption or discontinuation are provided in Section [IP_ADDRESS]
and Table
6.
Pre-Screening
Pre-screening is available for newly diagnosed nAMD patients who are treatment naïve 
in the study eye.  Patients eligible for the pre -screening will receive their first ITV 
injection of 50 L of the 10 -mg/mL ranibizumab (0.5 mg dose) formulation at the 
Pre
-Screening visit 1, and their second injection 307days later (Pre -Screening visit 2).  
Athird pre -screening treatment may be allowed after consultation with the Medical 
Monitor.  Afterwards, patients will undergo the screening vis it, which will occur at least 
7days following administration of the last pre -screening ITV ranibizumab treatment to 
the study eye (see Appendix 3).
Ranibizumab Port Delivery System —Genentech, Inc.
56/Protocol GX28228 , Version 8Run- In
Run-inis available for patients diagnosed with nAMD in the study eye within 9months 
prior to screening who have been treated with a single anti- VEGF ITV injection, or with 
no more than eight anti-VEGF ITV injections and with the most rec ent dose being 
aflibercept or bevacizumab.  Patients eligible for therun-intreatment will rece ive their 
single ITV injection of 50 L of the 10 mg/mL ranibizumab (0.5 mg dose) formulation in 
the study eye at the time of consent.  In exceptional cases , a second run- in treatment 
may be allowed after consultation with the Medical Monitor.  Afterwards, patients will 
undergo the screening visit, which will occur at least 7 days f ollowing administration of 
the run -inITV ranibizumab treatment to the study eye (see Appendix 4).
[IP_ADDRESS] Administration
Implant Treatment A rms
Prior to Implant insertion or explantation , patients will be required to verify that they have 
self-administered antimicrobial eye drops to the study eye 4 times within the previous 
24hours .  As per investigator ’sdiscretion , patients may also be required to have 
self-administered antimicrobial eye drops to the study eye [ADDRESS_667283] be checked after the patient has been in a resting 
state (
i.e., supi[INVESTIGATOR_103169] )for at least 15 minutes. If blood pressure exceeds the 
recommended levels (i.e.,between 100/60 mmHg and 155/95 mmHg ), the Implant 
insertion surgery must be rescheduled .
Patients in the Implant treatment arms will have the Implant ,prefilled with ranibizumab ,
surgically inserted into the study eye at the Day 1 visit and subsequently refilled at 
mont hly visits only if the protocol -specified refill criteria ar e fulfilled (see Section 3.1.1 ).  
The insertion and ex plantation procedures must be perfo rmed in the surgery room while 
the refill procedure is permitted in the physician office setting.  For detail edinstructions 
on the Implant initial fill, insertion, refill, and explantation procedures , refer to the 
RPDS IFU.
Ranibizumab Port Delivery System —Genentech, Inc.
57/Protocol GX28228 , Version 8ITV Injection A rm
Patients’ self-administered antimicrobial treatments will be prescribed at the 
investigator’s discretion. Prior to the monthly ITV injections, patients who are prescribed 
antimicrobials will be required to verify that they have self -administered their 
antimicrobials eye drop s to the study eye pre- and post -injection. For detailed 
instructions on pre -injection preparation, administering the ITV injection, and post -ITV 
injection procedures for the study eye , consul tAppendix 7to Appendix 9.
Guidelines for dosage modification and treatment interruption or discontinuation are 
provided in Section 5.1.
All Treatment Arms
Adverse events associated with an overdose or incorrect administration of ranibizumab
should be re corded on the Adverse Event electronic Case Report Form (eCRF) .
ITV Injection of Open -Label Ranibizumab 
Patients’ self-administered antimicrobial treatments will be prescribed at the 
investigator’s discretion.
[IP_ADDRESS] Storage
[IP_ADDRESS].[ADDRESS_667284] be refrigerated at 2°C to 8°C (36°F to 46°F).  Sites 
must monitor and record refrigerator temperature at all times (24 hours per day, 7 days 
per week).  DO NOT FREEZE. Vial content should not be frozen or shaken and should 
be protected from direct light.  Store in original carton before and after use.
RPDS .Each Implant is held by [CONTACT_514877] a steril e barrier 
system pouch.   The Initial Fill Needle and Explant Tool are each packaged separately in
asterile barrier pouch system . The Refill Needles are packaged separately and 
individually in a tray. The Implant , Insertion Tool, Initial Fill Needle, Refill Needle, and 
Explant Tool should be maintained at a room temperature of 15 Cto 30C(59Fto 
86F).  The storage location at the clinical site must have restricted access and be
available only to study personnel. The Implant , Initial Fill Needle, Insertion Tool, and 
Explant Tool are supplied steril ized by [CONTACT_178773]. The Refill Needles 
are sterilized by e -beam.
DO NOT RESTERILIZE .
The RPDS components (see Table 1 ) mustnot be resterilized because of the possibility 
of damaging the mechanical integrity of the Implant and ancillary devices .
The packages should be opened only immediately prior to use.
Ranibizumab Port Delivery System —Genentech, Inc.
58/Protocol GX28228 , Version 8DO NOT USE if th e package is damaged , punctured, or broken as sterility may be 
compromised.  Do not use beyond the expi[INVESTIGATOR_320].
[IP_ADDRESS].[ADDRESS_667285] and RPDS A ccountability
All investigational medicinal products (IMPs )(ranibizumab) and RPDS required for 
completion of this study (including all the components o f the RPDS , see Table 1) will be 
provided by [CONTACT_1034] .  The investigational site will acknowledge receipt of IMPs using 
the IxRS to confirm the shipment condition and content.  Any dama ged shipments will be 
replaced.
RPDS (Initial F ill Needle , Refill Needle with its content, explanted Implant with its 
remaining content, Explant Tool,and Insertion Tool)must be returned to the Sponsor or 
Sponsor’s designee with t he appropriate documentation.
In order to ensure traceability, each device component of t he RPDS will be identified by 
a batch number.
Accurate records of all IMPs and RPDS received at, dispensed from, returned to, and
destroyed and/or disposed of by [CONTACT_514878] s.  See the Study Manual for further details.
IMPs(used , damaged drug kits) will either be disposed of at the study site according to 
the study site’s institutional standard operating procedure or returned to the Sponsor 
with the appropriate documentation.  The site’s method of IMP destruction must be 
agreed to by [CONTACT_1034].  The site must obtain written authorization from the Sponsor 
before any IMP is destroyed.  IMP destruction must be documented on the appropriate 
form. See site Pharmacy binder for further details.
[IP_ADDRESS].3 Ranibizumab (Non- Study Eye)
At the discretion of the evaluating investigator, study patients may receive ITV injection 
of ranibizumab for their fellow (non- study) eye.  The drug will be open -label ranibizumab 
and will be supplied by [CONTACT_1034].   If a change in therapy is clinically indicated for the 
fellow eye per investigator judgment, the change must be discussed and agreed with the 
Medical Monitor prior to being made.   
[IP_ADDRESS].[ADDRESS_667286] QUA LITY A SSESSMENTS
4.4.1 Ranibizumab in Contents Retrieval from Implant
[IP_ADDRESS] Explanted Implants with Contents
Following explantation, the Implants containing a mixture of ranibizumab drug product 
(along with the vitreous components, which may have diffused into the Implant) will be 
preserved and forwarded by [CONTACT_514879] —Genentech, Inc.
59/Protocol GX28228 , Version 8potential future analysis.  A method to retrieve the contents from explanted Implants is in 
place and protocol s to characterize drug product are under development.  In addition, 
the explanted Implants may undergo physical inspection and/or functional testing.
[IP_ADDRESS] Ancillary  Devices
The Initial Fill Needle, Insertion Tool, Refill Needle, and Explant Tool must be returne d to 
the Sponsor or Sponsor’s designee for possible physical inspection and/or functional 
testing.
4.4.[ADDRESS_667287] their 
Implants explanted.
4.5 CONCOMITA NT THERA PY
4.5.1 Permitted Therapy  
Concomitant medications are any prescription drugs or over -the-counter preparations 
other than protocol -specified procedural medications (e.g., dilating drops, fluorescein 
dyes, cefazolin or van comycin, or medications associated with Implant insertion, refill ,
and extraction procedures) and pre -and post study treatment medi cations (e.g., 
proparacaine, antimicrobials, steroids) used by a patient within 7 days preceding the 
randomization visit until conclusion of the patient’s study participation or early 
termination visit.
Patients who use other maintenance therapy should continue its use unless prohibited 
as indicated in Section 4.5.2 .  All concomitant medications should be reported to the 
investigator and recorded on the appropriate eCRF:
Following randomization, if a patient’s fellow eye require streatment for nAMD, 
treatment with ITV ranibizumab injection may be administered at the discretion of 
the evaluating investigator .If a change in therapy is clinically indicated for the fellow 
eye per investigator judgment, the change must be discussed and agreed with the 
Medical Monitor prior to being made.  
All patients randomized to the Implant arm and receiving ongoing aspi[INVESTIGATOR_514823] 7days prior to i mplant insertion 
or explantation. These medications can be restarted , if appropriate ,after the Day2
safetyvisit.
Ranibizumab Port Delivery System —Genentech, Inc.
60/Protocol GX28228 , Version 8As pe r investigator discretion, the I mplant arms patients who had the I mplant 
explanted may receive ITV ranibizumab for their study eye treatment .
Cataract surgery in the study eye may be performed if clinically indicated and should 
occur [ADDRESS_667288] study treatment; the next study treatment will be 
held for [ADDRESS_667289] one study treatment 
(e.g., monthly ITV injection treatment arm) may be missed af ter cataract surgery is 
performed.
The onset of increased IOP and/or glaucoma in the study eye during a patient’s 
study participation should be treated as clinically indicated. 
Use of topi[INVESTIGATOR_178724] -implant insertion or post -explantation surgery in the 
study eye is permitted.
In a limited fashion, intra -articular or intramuscular corticosteroids may be allowed 
after consultation with the Medical Monitor.
4.5.[ADDRESS_667290] treatments administered for other conditions except in the following instances:
Concurrent use of any systemic anti -VEGF agents
Concurrent use of oral corticosteroids (prednisone 10mg/day or equivalent)
Concurrent study eye treatment for nAMD with anti-VEGFs other than the study 
drug treatment
Concurrent fellow eye treatment for nAMD with anti -VEGFs other than ranibizumab .  
If a change in therapy is clinically indicated for the fellow eye per investigator 
judgment, the change must be discussed and agreed with the Medical Monitor prior 
to being made.
Concurrent treatment with focal laser photocoagulation for nAMD in the study eye
Concurrent treatment with Visudynefor nAMD in either eye
Concurrent use of ITV or subtenon corticosteroids in the study eye
Concurrent useof and participation in other experimental therapi[INVESTIGATOR_014] (except those 
with minerals and vitamins) are not allowed.  
Note:  If patients receive the above listed treatments at any time during the study, the 
Sponsor willdetermine if discontinuation of the study treatment is required .
Concurrent use of anticoagulants, antiplatelets (other than aspi[INVESTIGATOR_248]), or medications 
known to exert similar effects are prohibited at study entry, but may be initiated after 
the Day 14 safety visit if medically necessary and in consultation with the Medical 
Monitor.  Oral anticoagulants include vitamin K antagonists (e.g., warfarin), direct 
factor Xa inhibitors (e.g., rivaroxaban, api[INVESTIGATOR_3822], edoxaban, fondaparinux), and 
direct thrombin in hibitors (e.g., dabigatran).  Antiplatelet therapi[INVESTIGATOR_514824], prasugrel, dipyridamole, ticagrelor, and ticlodipi[INVESTIGATOR_050].
Ranibizumab Port Delivery System —Genentech, Inc.
61/Protocol GX28228 , Version 8Concurrent use of aspi[INVESTIGATOR_514825] (see Section 4.5.1 and Secti on4.3.2.3 for aspi[INVESTIGATOR_514826])
Use o f magnetic resonance imaging ( MRI)scans for patients in the Implant
treatment arms is conditional.  Investigators should discuss with the Medical Monitor 
if MR Iuse is required prior to this procedure being performed.   For additional 
information refer to RPDS IFU .
4.6 STUDY ASSESSMENTS 
4.6.1 Medical History , Concomitant Medication, and Demographic 
Data
Medical history includes clinically significant diseases, surgeries, smoking history , and
use of alcohol .
All medications (e.g., prescription drugs, over -the-counter drugs, herbal/homeopathic 
remedies, nutritional supplements) other than protocol -specified procedural medications 
(e.g., dilating drops, fluorescein dyes, cefazolin or vancomycin, Implant insertion, refill 
and extraction procedures medications ,and pre- and post -treatment medications 
[e.g., proparacaine, antimicrobials, steroids ])used by [CONTACT_25701] 7 days prior to 
the randomization visituntil the study completion will be recorded on theeCRF 
concomitant medication log.
Demographic data will include age, sex, and self -reported race/ethnicity.
4.6.2 Vital Signs
Vital signs will include measurements of pulse and systolic and diastolic blood pressure 
obtained with the patient in a seated position after resting for 5 minutes.   Height and 
weight will also be recorded at screening.  Atvisits when a patient receives study 
treatment, vital signs w ill be measured pre- treatment.
4.6.3 Physical Examinations
A targeted physical examination should include an evaluation of the head, eyes, ears, 
nose, throat, and cranial nerves.  A patient’s height and weight will be recorded as well. 
Ifanyabnormalities are noted during the study , the patient may be referred to another 
doctor .
Changes from baseline abnormalities should be recorded in patient notes.  New or
worsened clinically significant abnormalities should be recorded as adverse events on 
the Adverse Event eCRF.
Ranibizumab Port Delivery System —Genentech, Inc.
62/Protocol GX28228 , Version 84.6.4 Ocular A ssessments
Except where noted, all ocular assessments should be performed for both eyes:
BCVA on ETDRS chart at a starting distance of 4 m (perform prior to dilating eyes; 
seeAppendix 10)
BCVA on ETDRS chart under low luminance conditi ons at a starting distance of 4 m 
(perform prior to dilating e yes; see Appendix 11)
The following measurement will be performed in both eyes of the patients in the 
Implant treatment arms ,from sites that have ultrasound or optical biometry, andwill
berecorded on the appropriate eCRF: 
–Axial length measurement ( ultrasound or optical biometry)
IOP measurement
–At each monthly visit, perform IOP measurement prior to dilating eyes or 
procedure; the method used for a patient must remain consistent throughout the 
study for visits in the office
–Before Implant insertion or explantation surgery, the treating physician must 
check IOP for the study eye using Tono- Pen tonometry . 
–Upon completion of the Implant insertion or explantation surgery, the treating 
physician must check IOP for the study eye only by[CONTACT_514880].  
Slitlamp examination (for grading scales for flare/cells and vitreal hemorrhage 
density; see Appendix 12)
Dilated binocular indirect hi gh-magnification ophthalmoscopy
In addition, examinations will also be perform edfor patients in the Implant
treatment arms after Implant insertion in the study eye , and then on Days 2, 7 
(2 days), and 14 ( 2 days) after the Day 1 visit; afterward ,dilated 
ophthalmoscopy examinations will be performed at each monthly visit to 
monitor th e Implant placement, to evaluate visible clogging of the RCE tip, and 
to evaluate other Implant problems .
Finger counting test, followed by [CONTACT_178784] (as 
applicable ) performed within 15 minutes following Implant refill or ITV ranibizumab
for the study eye only by [CONTACT_1963]
After each treatment, t he patients will remain in the office orin the surgical center
(as applicable) for approximately 40 minutes.  If there are no safety concerns 
40(10) minutes following t reatment, the patient will be allowed to leave.  If any 
safety concerns or immediate toxicity is noted, the patient will remain and will be 
treated according to the designated physician’s clinical judgment.  If applicable, the 
adverse event and the adverse event treatment must be report ed on the appropriate 
eCRF page.
Ranibizumab Port Delivery System —Genentech, Inc.
63/Protocol GX28228 , Version 8Additional non-invasive ocular assessments may be performed by [CONTACT_514881] s, regardless of 
whether a safety event occurred in a particular patient or not .Results of the 
additional ocular assessments will be forwarded to the Sponsor for evaluation 
and/or storage.
4.6.5 Ocular Imaging
Note:  All ocular images will be forwarded to the central reading center for grading and/or 
storage , starting from the screening visit .See central reading center manual for details.
The f ollowing ocular images of both eyes with be collected from all study patients:
Fundus photographs (see Appendix 14) 
Lens photograph (fundus reflex photograph)
Fluorescein angiograms (to be performedafter laboratory samples are obtained ; 
see Appendix 15)
SD-OCT scans ( Heidelberg; see Appendix 16)
Fundus autofluorescence (Heidelberg; seeAppendix 13)
The f ollowing ocular images of both eyes will be c ollected only from patients in the 
Implant treatment arms from sites that have a Humphrey Visual Field machine and will 
be forwarded to the reading center for evaluation and/or storage:
Visual field testing (Humphrey Automated Visual Field testing using Swedish 
interactive threshold algorithm Fast 24-2protocol )
The following ocular imageswill be collected only from thestudy eye of patients in the 
Implant treatment arms and forwarded to the reading center for evaluation and/or 
storage:
External photogr aphs (high -magnification Implant and conjunctiva , scleral surface; 
see Appendix 17)
Implant photograph (high -magnification Implant in the eye, through dilated pupil; 
seeAppendix 17)
The following ocular images of both eyes will be collected from all study patients at
selected sites that have OCT angiography equipment :
OCT angiography (Optovue; see Appendix 18)
Additional non-invasive ocular assessments (e.g., ocular B -scan ultrasonog raphy or 
ultrasound biomicroscopy) may be performed by [CONTACT_514882], regardless of whether a safety event 
occurred in a particular patient or not. 
Ranibizumab Port Delivery System —Genentech, Inc.
64/Protocol GX28228 , Version 84.6.[ADDRESS_667291] prior to the sample 
collection.
Hematology:  hemoglobin, hematocrit, quantitative platelet count, RBCs , WB Cs, and 
differentials including neutrophils, bands, lymphocytes, basophils, eosinophils, and 
monocytes (absolute and percent)
Serum chemistry:  sodium, potassium, chloride, bicarbonate , glucose, blood urea 
nitrogen, creatinine, calcium, phosphorus, total and direct bilirubin, total protein, 
albumin, AST, ALT, lactic dehydrogenase, alkaline phosphatase, and uric acid
Urinalysis:  s pecific gravity, pH, blood, protein, ketones, glucose, bilirubin, 
urobilinogen, and microscopic examination (if any of the prec eding urinalysis tests, 
other tha n glucose and ketones, are abnormal)
Coagulation: aPTT and PT
Serum pregnancy test ( -human chorionic gonadotropin) at screening for women of 
childbearing potential, including those who have had tubal ligation. If positive, study 
treatment will not be administered.
Urine pregnancy test at Day [ADDRESS_667292] is positive, study treatment will not be administere d (see 
Section 5.1.1 ).
Instructions for obtaining, processing, storing, and ship pi[INVESTIGATOR_514827]. 
The following samples will be collected from patients who consent to the [COMPANY_002] Clinical 
Repository (RCR) sampling collection (see Section 4.6.12) and will be t ested by [CONTACT_229306] a selected designee:
Optional serum samples at the R andomization Visit and visits atMonth 4 and 
Month 9, for the evaluation of circulating biomarkers.
Optional plasma samples at the R andomization Visit and V isits at Month 4 and 
Month 9, for the evaluation of circulating biomarkers.
Optional whole blood for DNA extraction (genetic analysis) at the R andomization
Visit
Ranibizumab Port Delivery System —Genentech, Inc.
65/Protocol GX28228 , Version 8The following samples will be collected from patients in the I TVarm and will be tested by 
[CONTACT_18484] a selected designee:
Serum samples will be obtained for measurement of anti- therapeutic antibodies to 
ranibizumab (see Appendix 2). 
Serum samples will be obtained to measure ranibizumab concentrations (see 
Appendi x 2).
The following samples will be collected from patients in the Implant treatment arms and 
will be tested by [CONTACT_18484] a selected designee:
Serum samples will be obtained for measurement of anti- therapeutic antibodies to 
ranibizumab (see Appendix 1). 
Serum samples will be obtained to measure ranibizumab concentrations (see 
Appendix 1).
Note:  For patients who prefer not tovisit the clinic for the sample collection 
1day after each Implant refill, provision will be made for this timepoint sample 
collection to be collected at their home.  Training will be provided to site staff on 
how to perform this task.  The sample will be sent to a central laboratory.
Vitreous or aqueous humor sample swillbe obtained to measure ranibizumab 
concentrations at the start of explantation for patients undergoing an explantation 
procedure (see Appendix 1and Appendix 21).
Optional anterior cham ber (aqueous humor) samples will be collected prior to or 
immediately following oneor more refills and at the Day [ADDRESS_667293] refill for 
the exploratory analysis for VEGF ,ranibizumab concentrations, anti -therapeutic 
antibodies to ranibizumab and other exploratory biomarkers (see Appendix 1and 
Appendix 21).
The following samples will be obtained from patients in the Implant treatment arms only 
and may be analyzed in the future:
Explanted Implant with contents (explanted Implant containing a mixture of 
ranibizumab drug product and vitreal components diffused into the Implant ) will be 
preserved for potential analysis upon explant procedure .
Residual content of the Implant present in the Refill Needle may be collected during
therefill procedure (if applicable) to evaluate the possible association of vitreous or 
aqueous humor biomarkers with disease characteristics and response to 
ranibizumab.  
Unless the patient gives specific consent for the leftover of their samples to be stored for 
optional exploratory research (see Section 4.6.12 ), biological samples will be destroyed 
when the final clinical study report has been completed, with the following exception{s}:
Aqueous humor , vitreous, serum PK and ATA samples for assay developme nt, 
validation, or for additional characterization will be stored no longer than 5 years 
after the final Clinical Study Report has been completed.
Ranibizumab Port Delivery System —Genentech, Inc.
66/Protocol GX28228 , Version 8See Laboratory Manual for sample processing, storing, and shippi[INVESTIGATOR_3931].
4.6.[ADDRESS_667294] be administered to patient sby [CONTACT_2702] (for patients who speak 
English or Spanish by [CONTACT_514883]), before the patient 
completes any other study visit procedures (see Appendix 19).
The MacTSQ is a 14 -item questionnaire designed to assess treatment satisfaction in 
patients with AMD. Scoring of the MacTSQ results in two subscale scores (information 
provision and convenience; impact of treatment) and a total score.  Subscale scores 
range from 0 to 36 and tot al scores range from 0 to 72.  A higher score indicates greater 
satisfaction.
Two versions of the questionnaire will be used, differing only in recall period.  At 
randomization the questionnaire will refer to “since diagnosis”.  For interim assessments 
at Months 1, 6,and 9, and at the final/early termination visit s,the questionnaire will refer 
to “sinc e you enrolled in this study”.
4.6.[ADDRESS_667295] that prohib it 
these procedures being video captured. The Implant refill procedure video capture is 
optional.
4.6.9 Exploratory  Substudies
The Sponsor ma y propose exploratory substudies associated with the Study GX28228 
protocol.  Each substudy will be documented in a separate substudy protocol and 
associated ICF(s).
4.6.10 Timing of Study  Assessments
[IP_ADDRESS] Screening and Pretreatment A ssessments
The study will randomiz e approximately [ADDRESS_667296] be obtained before performing any study -specific screening tests or evaluations.  
Informed Consent Form s (ICFs) for all screened patients ,including those who are not 
subsequently randomized, will be maintained at the study site.
Screening Visit
Screening visit assessments cannot be performed sooner than [ADDRESS_667297] IxRS for the patient’s screening number assignment.  
All screening visit evaluations must be completed and reviewed to confirm that patients 
Ranibizumab Port Delivery System —Genentech, Inc.
67/Protocol GX28228 , Version 8meet all eligibi lity criteria before they are scheduled for their randomization visit.
Screening visit assessments may be performed on multiple days. 
Note:  If a patient fails screening assessments , he or she may be re- screened once if 
deemed appropriate by [CONTACT_17062].  A new screening number will be a ssigned to 
thepatient through the IxRS. The investigator will maintain a screening log to record 
details of all patients screened and to confirm eligibility or record reasons for screening 
failure, as applicable.
For the schedule of screening assessments, refer to the schedule of assessments in
Appendix 1and Appendix 2. 
Randomization Visit and Day  1 Treatment
The randomization visit and the Day 1 treatment can occur on the same day for ITV 
treatment arm patients; the Implant arm patients may have these two visits separated 
due to the medication washout period (see Section 4.1) and the surgery room availability .
However, for all study patients, theRandomization visit and Day [ADDRESS_667298] 
occur between 28 days and 37 days after t he patient’s last study eye ITV ranibizumab 
treatment.  Unless noted otherwise, all procedures and assessments should be 
performed prior to contact[CONTACT_514884]’s randomization number assig nment 
and prior to the first study treatment administration to confirm that the patient is still 
eligible to be randomized to the study.  All randomization study visit assessments must 
be performed on the same day.  A patient can only be randomized to the study once.
When a patient has satisfied all eligibility criteria at both the screening and the 
randomization visit, including the receipt and evaluat ion of historical and screening visit 
images by[CONTACT_73475], the patient will be assigned arandomization
number (a number different from the patient’s screening number) by [CONTACT_514885].  It is recommended that the patients 
randomized to the ITV -injection arm receive their Day [ADDRESS_667299] to be relative to the Day 1 (first study treatment) visit date until 
patients complete the study or the study is terminated early.
Ranibizumab Port Delivery System —Genentech, Inc.
68/Protocol GX28228 , Version 8Pre-Screening (if applicable)
Pre-screening is available for newly diagnosed nAMD patients who are treatment naïve 
in the study eye.  After a patient has signed the informed consent form, the site will 
contact [CONTACT_514886]’s pre-screening number assignment .  A patient may only 
participate once in the pre -screening.  For the schedule of assessments in the pre -
screening, refer toAppendix 3.
Run- In (if applicable)
“Run -in” is available for patients diagnosed with nAMD in the study eye within 9months 
prior to scre ening who have been treated with a single anti -VEGF ITV injection, or with 
no more than eight anti-VEGF ITV injections and with the most recent dose being 
aflibercept or bevacizumab.  After a patient has signed the informed consent form, the 
site will cont act IxRS for the patient’s number assignment.  A PK sample will be collected 
prior to receipt of the “run -in” ranibizumab ITV treatment.   For the schedule of 
assessments in the “run -in”, refer to Appendix 4.
[IP_ADDRESS] Assessments d uring Treatment
All assessments mus t be performed on the day o f the specified visit, unless a time 
window is specified in the schedule of assessments (see Appendix 1and Appendix 2).  
Assessments scheduled on the day of study treatment administration should be 
performed prior to administra tion of study treatment, unless otherwise noted in the 
schedule of assessments.  The MacTSQ assessment should be administered prior to 
the completion of other study assessments.
Please see Appendix 1and Appendix 2forthe schedule of assessments performed
during the treatment period.
Study visits will be scheduled according to the schedule in Appendix 1and Appendix [ADDRESS_667300] to be relative to the Day 1 (first study treatment) visit date until patients 
complete or are early terminated from the study.  Ranibizumab dosing should occur no 
earlier than 22days following the previous dosing.
[IP_ADDRESS] Assessments at Early Study Treatment Discontinu ation
The ITV treatment arm patients who are discontinued from study treatment prematurely 
will be asked to undergo the sched uled monthly visits u ntil the LPI [CONTACT_43380] 9 visit ,after 
which they will be scheduled for their final study visit 30 ( 7) days later .  The patients 
who are discontinuing study treatment from the Implant treatment arms will be scheduled, 
within 7 days after the treatment discontinuation decision is made, for Implant 
explantation followed by [CONTACT_514869] 1 and 7 (2) days post -explantation.  Afterwards 
they will be followed in the study, attending their monthly scheduled visits, until LPI
[CONTACT_43380] 9 visit, afte r which they will be scheduled for the early termination visit (see 
Appendix 1).  As per investigator judgement, these patients may start an approved 
anti-VEGF for their AMD once the need for Implant explantation is confirmed and, 
preferably, after explant ation is completed .  All ex planted Implants ,with remaining 
Ranibizumab Port Delivery System —Genentech, Inc.
69/Protocol GX28228 , Version 8content ,will be returned to the designee of the Sponsor for storage and potential future 
exploratory analysis (see Section 4.4).  A vitreous or aqueous humor sample will be 
collected at the start of explantation for patients undergoing an explantation procedure
(see Appendix 20 ).
[IP_ADDRESS] Assessments at Early Study  Discontinuation
Patients withdrawing from the study early should return for an early termination 
evaluation 30 ( 7) days following the last study drug treatment for monitoring of all 
adverse events (serious and non -serious), as well as for early termination assessments
if they are in the ITV treatment arm . The patients who are discontinuing the study from 
the Implant treatment arms will be sc heduled for Implant explantation within 7 days of 
the study discontinuation decision .  This will be followed by [CONTACT_514870] 1, 7 (2), 
30(7),and 60 (7)days post -explantation, after which they will be scheduled for the
early termination visit 30 ( 7) days later.  As per investigator judgment, these patients 
may start an approved anti -VEGF treatment for their AMD once the need for Implant 
explantation is confirmed and, preferably, after explantation is completed .  All explanted
Implant s,with remai ning content ,will be returned to the designee of the Sponsor for 
storage and potential future exploratory analysis (see Section 4.4).  Avitreous or 
aqueous humor sample will be collected at the start of explantation for patie
nts 
undergoing an explantatio n procedure (see Appendix 20).
[IP_ADDRESS] Assessment at Study C ompletion
Study completion is defined as a p atient completing the final study visit assessments .  
Please see Appendix 1and Appendix 2forthe schedule of assessments performed at 
thefinal/ early termination visit.
Patients in the ITV treatment arm will return for the final study visit evaluation 30 ( 7) 
days following the last study drug treatment for monitoring of all adverse events (serious 
and non- serious), as well as for final study visit assessments , unless they enter into the 
RPDS Extension Study ( Section 4.4.2).
Patients in the Implant arms who complet ethe study will be scheduled for theImplant
explantation 30 (7) days following the last refill (if app licable) , unless they enter intothe 
RPDS Extension Study (Section 4.4.2 ). Explantation will be followed by [CONTACT_514870] 1, 
7 (2), 30 (7),and 60 ( 7)days post -explantation ,after which patients will be 
scheduled for the final study visit 30 ( 7) days later . As per investigator judgment, these 
patients may start an approved anti -VEGF treatment for their AMD once the need for 
Implant explantation is confirmed and, preferably, after explantation is completed .All 
explanted Implant s,with remaining content ,willbe returned to the designee of the 
Sponsor for storage and potential future exploratory analysis (see Section 4.4).  A 
vitreous or aqueous humor sample will be collected at the start of explantation for 
patients undergoing an explantation procedure (seeAppendix 20).
Ranibizumab Port Delivery System —Genentech, Inc.
70/Protocol GX28228 , Version [IP_ADDRESS] Follow -Up A ssessments 
After the study completion/early termination visit, adverse events should be followed as 
outlined in Sections 5.5and 5.6.
[IP_ADDRESS] Assessments at Unscheduled Visits 
Refer to Appendix 5for unscheduled safety assessments that can be utilized for all 
study patients .  All listed assessments are to be performed if determined to be 
necessary by [CONTACT_093].
4.6.11 Refill Needle Sample Collection
The following samples will be collected from patients in the Implant treatment arms and 
may be analyzed by [CONTACT_514887]:
Residual content of the Implant present in the Refill Needle may becollected during 
refill procedure (if applicable) to evaluate the possible association of vitreous or 
aqueous humor biomark ers with disease characteristics and response to 
ranibizumab.  
4.6.12 Samples for [COMPANY_002] Clinical Repository
[IP_ADDRESS] Overview  of the [COMPANY_002] Clinical Repository
The [COMPANY_002] Clinical Repository (RCR) is a centrally administered group of facilities used 
for the long -term storage of human biologic specimens, including body fluids, solid 
tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides).  The collection and 
analysis of RCR specimens will facilitate the rational design of new pharmaceutical 
agents and the developm ent of diagnostic tests, which may allow for individualized drug 
therapy for patients in the future.
Specimens for the RCR will be collected from patients who give specific consent to 
participate in this optional research.  RCR specimens will be used to ac hieve the 
following objectives:
To study the association of biomarkers with efficacy, adverse events, or disease 
progression
To increase knowledge and understanding of disease biology
To study drug response, including drug effects and the processes of drug absorption 
and disposition
To develop , validate, and characterize biomarker ,diagnostic , pharmacokinetic, or 
anti-therapeutic antibody assays and establish the performance characteristics of 
these assays
[IP_ADDRESS] Approval by [CONTACT_514888]'s Institutional Review Board or Ethics Committee (I RB/EC) 
Ranibizumab Port Delivery System —Genentech, Inc.
71/Protocol GX28228 , Version 8and, if applicable, an appropriate regulatory body.  If a site has not been granted 
approval for RCR sampling, this section of the protocol (Section 4.6.12 ) will not be 
applicable at that site.
[IP_ADDRESS] Sample Collection
The following RCR samples will be col lected for research purposes, including but not 
limited to research on dynamic (non -inherited) biomarkers related to Ranibizumab mode 
of action, VEGF biology, AMD biology, and/or related diseases biology:
Serum samples at the R andomization Visit and V isitsatMonth 4 and Month 9, for 
the evaluation of circulating biomarkers.
Plasma samples at the R andomization Visit and V isits atMonth 4 and Month 9, for 
the evaluation of circulating biomarkers.
The following RCR samples will be collected for research purp oses, including but not 
limited to research on genetic (inherited) biomarkers related to Ranibizumab mode of 
action, VEGF biology, AMD biology and/or related diseases biology:
Whole blood for DNA extraction at the R andomization Visit
For all samples, date s of consent and specimen collection should be recorded on the 
associated RCR page of the eCRF.  For sampling procedures, storage conditions, and 
shipment instructions, see the laboratory manual.  
RCR specimens will be destroyed no later than 15 years aft er the date of final closure of 
the associated clinical database.  The RCR storage period will be in accordance with the 
IRB/EC approved Informed Consent Form and applicable laws (e.g., health authority 
requirements).
The dynamic biomarker specimens will be subject to the confidentiality st andards 
described in Section 8.4.  The genetic biomarker specimens will undergo additional 
processes to ensure confidentiality, as described below.  
[IP_ADDRESS] Confidentiality
Given the sensitive nature of genetic data, [COMPANY_002] has implemented additional processes 
to ensure patient confidentiality for RCR specimens and associated data.  Upon receipt 
by [CONTACT_25736], each specimen is "double -coded" by [CONTACT_70144] a new independent number.  Data generate d from the use of these 
specimens and all clinical data transferred from the clinical database and considered 
relevant are also labeled with this same independent number.  A "linking key" between 
the patient identification number and this new independent n umber is stored in a secure 
database system.  Access to the linking key is restricted to authorized individuals and is 
monitored by [CONTACT_25738].  Legitimate operational reasons for accessing the linking key are 
documented in a standard operating procedure.   Access to the linking key for any other 
reason requires written approval from the Pharma Repository Governance Committee 
and [COMPANY_002]'s Legal Department, as applicable.
Ranibizumab Port Delivery System —Genentech, Inc.
72/Protocol GX28228 , Version 8Data generated from RCR specimens must be available for inspection upon request by 
[CONTACT_514889], and [COMPANY_002] monitors, 
representatives, and collaborators, as appropriate.
Patient medical information associated with RCR specimens is confidential and may be 
disclosed to third parties only as permitted b y the Informed Consent Form (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Data derived from RCR specimen analysis on individual patients will generally not be 
provided to study investigators unless a request for research use is granted.  The 
aggregate results of any research conducted using RCR specimens will be available in 
accordance with the effective [COMPANY_002] policy on study data publication.
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RCR data will become and remain the exclusive and unburdened property 
of [COMPANY_002], except where agreed otherwise.
[IP_ADDRESS] Consent to Participate in the [COMPANY_002] Clinical Repository
The Info rmed Consent Form will contain a separate section that addresses participation 
in the RCR.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RCR.  Patients will be 
told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage period.  A separate, specific signature [CONTACT_20030] a patient's agreement to provide optional RCR specimens.   
Patients who decline to participate will not provide a separate signature.
The investigator should document whether or not the patient has given consent to 
participate by [CONTACT_26806].
In the event of an RCR pa rticipant's death or loss of competence, the participant's 
specimens and data will continue to be used as part of the RCR research.
[IP_ADDRESS] Withdrawal from the [COMPANY_002] Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their 
specimens from the RCR at any time for any reason.  If a patient wishes to withdraw 
consent to the testing of his or her specimens, the investigator must inform the Medical 
Monitor in writing of the patient's wishes through use of the RCR Subject W ithdrawal 
Form and, if the trial is ongoing, must enter the date of withdrawal on the RCR Research 
Sample W ithdrawal of Informed Consent eCRF.  The patient will be provided with 
instructions on how to withdraw consent after the trial is closed.  A patient's withdrawal 
from Study GX28228 does not, by [CONTACT_5071], constitute withdrawal of specimens from the 
RCR.  Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from 
Study GX28228.
Ranibizumab Port Delivery System —Genentech, Inc.
73/Protocol GX28228 , Version [IP_ADDRESS] Monitoring and Oversight
RCR specimens will be tracked in a manner consistent with Good Clinical Pr actice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
management system, to ensure compliance with data confidentiality as well as 
adherence to authorized use of specimens as specified in this protocol and in the 
Informed Consent Form.  [COMPANY_002] monitors and auditors will have direct access to 
appropriate parts of records relating to patient participation in the RCR for the purposes 
of verifying the data provided to [COMPANY_002].  The si te will permit monitoring, audits, IRB/EC 
review, and health authority inspections by [CONTACT_26807].
4.[ADDRESS_667301] the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include, but are not limited to, the fol lowing:
Patient withdrawal of consent at any time
Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient’s safety if he or she continues in the study
Investigator or Sponsor determines it is in the best interest of the patient
Patient non -compliance:  If apatient misses more than two consecutive monthly 
visits within any 6- month treatment period, the investigator and the Sponsor may 
consider withdrawing the patient from the study.
Every effort should be made to obtain information on patients who withdraw from the 
study.  The primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  However, patients will not be followed for any reason after consent 
has been withdrawn.  Patients who wit hdraw from the study will not be replaced.
SeeAppendix 1and Appendix 2forthe assessments that are to be performed for 
patients who discontinue early from the study.  The reason for treatment discontinuation 
and early withdrawal from the study should be recorded on the appropriate eCRF.
Discontinued patients will not be allowed to re -enter the study.
4.7.[ADDRESS_667302] discontinue study treatment if they become pregnan t.
The ITV treatment arm patients who are discontinued from study treatment prematurely 
will be asked to undergo the scheduled monthly visits unti ltheLPI [CONTACT_43380] 9 visit ,after 
which they will be scheduled f or their final study visit 30 ( 7) days later .  The patients 
who are discontinuing study treatment from the Implant treatment arms will be scheduled, 
within 7 days after the treatment discontinuation decision is made, for Implant 
Ranibizumab Port Delivery System —Genentech, Inc.
74/Protocol GX28228 , Version 8explantation followed by [CONTACT_514869] 1 and 7 (2) days post -explantation.  Afterwards 
they will be followed in the study, att ending their monthly scheduled visits, until LPI 
[CONTACT_43380] 9 visit, after which they will be scheduled for the early termination visit 
(see Appendix 1).  As per investigator discretion, explanted patients may start an 
approved anti -VEGF agent for their nAMD once the need for Implant explantation is 
confirmed and, preferably, after explantation is completed .  The sponsor will provide 
explanted patients with ranibizumab IT V treatment until the LPI [CONTACT_43380] 9 visit (if 
applicable).  Allexplanted Implants with remaining content will be returned to the
designee of the Sponsor for storage and potential future exploratory analysis (see 
Section 4.4).  A vitreous or aqueous humor sample will be collected at the start of 
explantation for patients underg oing an explantation procedure (see Appendix 19).
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  Patients who discontinue study treatment prematurely will not be 
replaced.
4.7.3 Early  Withdrawal from Study  
Every effort should be made to obtain information on patients who arewithdraw ingfrom 
the study.  The primary reason for withdrawal from the study should be documented on 
the appropriate eCRF .
Patients withdrawing from the study early should return for an early termination 
evaluation 30 ( 7) days followi ng the last study drug treatment for monitoring of all 
adverse events (serious and non- serious), as well as for early term ination assessments
if they are in the ITV treatment arm. The patients who are dis continuing study from the 
Implant treatment arms will be scheduled for Implant explantation within 7 days of the 
treatment discontinuation decision, followed by [CONTACT_514870] 1, 7 (2), 30(7), and 
60(7)days post -explantation, after which they will be scheduled for the  early 
termination visit 30 ( 7) days later .As per investigator judgment, these patients may 
start an approved anti -VEGF treatment for their AMD once the need for Implant 
explantation is confirmed and, preferably, after explantation is completed .All explanted
Implant s,with remaining content ,will be returned to the designee of the Sponsor for 
storage and potential future exploratory analysis (see Section 4.4).  A vitreous or 
aqueous humor sample will be collected at the start of explantation for patients 
undergoing an explantation procedure (
see Appendix 19).
The primary reason for premature study discontinuation (which may differ from study 
treatment discontinuation) should be documented on the appropriate eCRF.  Patients 
who discontinue from the study prematurely will not be replaced and cannot re- enter the 
study .
Ranibizumab Port Delivery System —Genentech, Inc.
75/Protocol GX28228 , Version 84.7.4 Study and Site Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons fo r terminating 
the study may include, but are not limited to, the following:
The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients
Patient enrollment is unsatisfactory
Data record ing is inaccura te or incomplete
The Sponsor will notify the investigator if the study is placed on hold, or if the Sponsor 
decides to discontinue the study.
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limit ed to, the following:
Excessively slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Conference on Harmonisation (ICH) guideline 
for Good Clinical Practice
No study activity (i.e., all pat ients have completed and all obligations have been 
fulfilled)
5. ASSESSMENT OF SA FETY
5.[ADDRESS_667303] been investigated in 
previous Phase I, I/II, III, and IIIb studies in patients with AMD.  Potential safety issues 
associated with the route of administration or the pharmacology of ranibizumab in the 
study population include VA reduction, intraocular inflammation, transient and/or 
sustained elevation of IOP, cataract development or progre ssion, retinal hemorrhage, 
vitreous hemorrhage, macular edema, endophthalmitis, retinal tear or detachment, 
hypersensitivity reactions, and arterial thromboembolic events (ATEs).  Adverse events
that should be considered ATEs include, but are not limited t o, myocardial infarction and 
cerebrovascular accident (ischemic and /orhemorrhagic). Please see RPDS IB for 
further details.
Ranibizumab Port Delivery System —Genentech, Inc.
76/Protocol GX28228 , Version 8In this study ,GX28228 ,the p atients in the Implant treatment arms will return after 
Implant insertion for safety evaluation visits on Day 2 (0), Day 7 ( 2), and Day 14 (2); 
subsequently, the safety visit w ill be scheduled 7 ( 2) days postimplant refill with 
ranibizumab ;andsafety visits on 1 (0)and 7 (2)days post explantation of the Implant
for the patients who will continue to be followed up in the study ;and for the patients who 
are exiting the study, safety visits on 1 (0), 7 ( 2),30 (7),and 60 (7)days 
post-explantation of their Implant prior to being scheduled for the final/early ter mination 
visit 30 ( 7) days later.
All ranibizumab -treated patients will be contac ted by [CONTACT_26271] 3 (1) days 
after each treatment to elicit reports of any decrease in vision, eye pain, unusual redness, 
or any other new ocular symptoms in the study eye. Patients will also be asked whether 
they have taken the prescribed, self -administered, post -injection antimicrobials (if 
applicable) for their study eye as directed by [CONTACT_093] .
If warranted, patients will be asked to return to the clinic as soon as possible for a n 
unscheduled safety assessment visit and will be instructed to contact [CONTACT_514890]- related concerns.
Upon completion of i mplant insertion or expla ntation procedure, patients will have 
indirect ophthalmoscopy performed to monitor the Implant placement and to evaluate 
any potential Implant problems.  The treating physician will check IOPfor the study eye 
only digital palpation .  These assessment smust be performed prior to placing apatch on 
the eye. The patients will remain at the surgical center for approximately [ADDRESS_667304] the 
surgical center after 40 (10)minutes.  If any safety concerns or immediate toxicity is 
noted, the patient will remain at the surgical center and will be treated according to the 
designated physician’s clinical judgment.  If applicable, the adverse event and t reatment 
of adverse event (if applicable) will be reported on the appropriate eCRFs.
Following each treatment with ranibizumab, administered either intravitreally or as an 
Implant refill, patients will undergo a finger counting test, followed by [CONTACT_514891] (when necessary) performed within [ADDRESS_667305] -treatment for 
the study eye only by [CONTACT_514892] ; the patients in the Implant treatment 
arms will have indirect ophthalmoscopy performed after each implant refill to monitor the 
Implant and its RCE end for visible clogging and other Implant problems.  The p atients
will rem ain at the clinic for approximately [ADDRESS_667306] the clinic after 40 (10)minutes .  If 
any safety concern sor immediate toxicity is noted, the patient will remain at the clinic 
and will be treated according to the designated physician’s clinical judgment. If 
applicable, t headverse event and t reatment of adverse event (if applicable) will be 
reported o n the appropriate eCRF s. 
Ranibizumab Port Delivery System —Genentech, Inc.
77/Protocol GX28228 , Version 8Detailed ocular examinations, including indirect ophthalmoscopy and slit lamp 
examination, will be performed throughout the study.  For patients in the Implant
treatment arm, the monthly d ilated binocular indire ct high -magnification ophthalmoscop ic
examination will in clude visual monitoring of the Implant placement, evaluation of visible 
clogging of the RCE tip, and evaluation of any other Implant -related problems ,as well as 
data collection on the associated eCRF and/or Medical Device Complaint Form.  Routine 
hematologic, serum chemistry, coagulation, and urinalysis profiles will be obtained from 
all study patients at the screening visit .  Blood samples for assessing serum ranibizumab 
concentrations and antibodie s to ranibizumab will be obtained from all study patients 
throughout the study.  In addition, optional aqueous humor samples will be obtained 
from patients in the Implant treatment arms only throughout the study.  The sample 
content retrieved during Implant refill (if applicable) and explant procedures will be 
collected and forwarded to the Sponsor designee and may be analyzed in the future.
Ranibizumab admi nistration by [CONTACT_514893] (if applicable) will be 
interrupted or discontinued as per the dose -interruption criteria listed in Table 6and at 
the investigator’s discretion if he or she suspects any safety or other treatment -related 
issues.  If the investigator decides to int errupt a dose, the reason will be recorded on the 
corresponding eCRF, and if appropriate, on the Adverse Event eCRF.  In the event a 
patient experiences an adverse event in the study eye that is considered by [CONTACT_514894] s erious in nature, consideration should be given 
to interrupt ingthe treatment or discontinuing the patient from study drug treatment or the
study.  This decision will be at the investigator’s discretion and should be recorded on 
the eCRF.
The ITV treatment arm patients who are discontinued from the study treatment 
prematurely will be encouraged to undergo the scheduled monthly visits until the LPI
[CONTACT_43380] 9 visit ,after which they will be scheduled f or their final study visit 30 ( 7) days 
later.  The patient s who are discontinuing study treatment from the Implant treatment 
arms will be scheduled, within 7 days after the treatment discontinuation decision is 
made, for Implant explantation followed by [CONTACT_514869] 1 and 7 (2) days 
post-explantation.  Afterwa rds they will be followed in the study, attending their monthly 
scheduled visits, until LPI [CONTACT_43380] 9 visit, after which they will be scheduled for the early 
termination visit (see Appendix 1).  As per investigator judgement, these patients may 
start an appr oved anti -VEGF for their AMD once the need for Implant explantation is 
confirmed and, preferably, after explantation is completed .  All explanted Implants ,with 
remaining content ,will be returned to the designee of the Sponsor for storage and 
potential future exploratory analysis (see Section 4.4).  A vitreous or aqueous humor
sample will be collected at the start of explantation for patients undergoing an 
explantation procedure (see Appendix 19).
Patients discontinuing the stu dy early should return for an early termination evaluation 
30(7)days following the last study drug treatment for monitoring of all adverse events
(serious and non -serious), as well as for early termination assessments if they are in the 
Ranibizumab Port Delivery System —Genentech, Inc.
78/Protocol GX28228 , Version 8ITV treatment a rm.  The patients who are discontinuing the study from the Implant
treatment arms will be scheduled for Implant explantation within 7 days of the 
discontinuation decision .  This will be f ollowed by [CONTACT_49874] v isits 1, 7 (2), 30 (7),and 60 
(7)days post -explantation, after which they will be scheduled for the early termination 
visit 30 (7)days later . As per investigator judgment, these patients may start an 
approved anti -VEGF treatment for their AMD once the need for Implant explantation is 
confirmed and, preferably, after explantation is completed .Allexplanted Implant s,with
remaining content ,will be returned to the designee of the Sponsor for storage and 
potential future exploratory analysis (see Section 4.4).  A vitreous or aqueous humor
sample will be collected at the start of explantation for patients undergoing an 
explantation procedure (see Appendix 19).
The incidence of all adverse events (serious and non -serious) will be recorded on 
eCRFs for the duration of this study. Serious adverse ev ents will be collected and 
reported to the Sponsor in complian ce with Good Clinical Practice guidelines.
Ongoing review of s afety data will be performed by [CONTACT_514895], Clinical Scientists, Drug Safety Scientist, and Bio statistician.  External 
experts may be consulted. Following implementation of Protocol GX28228, version 5, if 
warranted, enrollment and Implant insertion surgeries may be paused to enable 
real-time review of post -implant insertion safety data by [CONTACT_27904]. 
5.1.1 Management of Specific A dverse Events
[IP_ADDRESS] Dosing Interruption /Study Treatment or Study Discontinuation 
Criteria
Study treatment dose interruption and/or study treatment or study discontinuation 
following an adverse event will be determin ed according to the cr iteria in Table 6.  The 
reason for interrupting the treatment should be recorded on the associated eCRF and, if 
applicable, on the adverse event eCRF.
Ranibizumab Port Delivery System —Genentech, Inc.
79/Protocol GX28228 , Version 8Table 6Dose Interruption/Study  Treatment or Study Discontinuation 
Criteria 
Event Dose Interruption Criteria
Intraocular 
inflammationInterrupt dose if intraocular inflammation is 2in the study 
eye (see the definitions of intraocular inflammation in 
Section 5.3.5 and Appendix 12) 
VA loss Interrupt dose if there is a decrease in BCVA of  30letters in 
the study eye compared with the last assessment of VA prior to 
the most recent treatment.
IOP Interrupt dose if IOP in the study eye is 30 mmHg.  Treatment 
will be permitted when IOP has been lowered to 30 mmHg, 
either spontaneously or by [CONTACT_3148], as determined by [CONTACT_24201].
Sensor y 
rhegmatogenous retinal 
break or detachment 
(including macular 
hole)Interrupt dose if a retinal bre ak is present in the study eye.  
Treatment may be resumed 28 days after the retinal break 
has been successfully treated.  Patients with a 
rhegmatogenous retinal detachment or Stage 3 or 4 macular 
holes may require discontinu ation from the study after 
consultation with the Medical Monitor .
Local or severe 
systemic infectionInterrupt dose if any of the following are present:  infectious 
conjunctivitis, infectious keratitis, infectious scleritis, or 
endophthalmitis in either eye, or if the patient is currently 
receiving treatment for a severe s ystemic infection.
Oral corticosteroids 
(prednisone 10mg/kg 
or equivalent)Dose may be interrupted after consultation with the Medical 
Monitor if a patient needs to take oral corticosteroids 
(prednisone  10mg/day or equivalent).  Study treatment may  
be resumed when oral corticosteroids dosing is prednisone 
10mg/day or equivalent.
IV corticosteroids Dose may  be interrupt ed after consultation with the Medical 
Monitor if patients need to take IV corticost eroids.  Study 
treatment may  be resumed when the patient has finished IV 
corticosteroid course.
Intraocular surger y Dose may  be interrupt edafter consultation with the Medical 
Monitor if intraocular surgery has been performed in the study 
eye within the p revious 28 days.
Observed damage to 
the ImplantIf damage to the Implant is observed by [CONTACT_093], the 
Implant will be explanted even if it did not cause any AE to the 
patient.  The patient will be discontinued from the study 
treatment.
Pregnancy Explant the Implant and discontinue patient’s study treatment in 
the case of positive serum pregnancy test during the study.
Malignanc y At the discretion of the investigator and after consultation with 
the Medical Monitor, patients may discontinue from th e study 
drug treatment.
AEadverse event; BCVA best corrected visual acuity; CFT central foveal thickness; 
IOPintraocular pressure; VA visual acuity.
Ranibizumab Port Delivery System —Genentech, Inc.
80/Protocol GX28228 , Version [IP_ADDRESS] Rescue Treatment with Open -Label Ranibizumab For Implant 
Patients
Rescue treatment with open -label ranibizumab (0.5-mg ITV injections of 10 -mg/mL 
formulation) for patients in the Implant arm isallowed only under the following 
circumstances:
Approximately 1 month and /or2 months after occurrence of vitreous hemorrhage, if 
vitreous hemorrhage causes loss in BCVA, and neither assessment of the macula 
nor SD -OCT can be performed successfully (see Section [IP_ADDRESS] )
At the time a patient meets criteria for lack of clinical efficacy (see Section [IP_ADDRESS] )
In the case of progressive worsening of BCVA and/or CFT due to wet AMD activity 
across twoconsecutive scheduled visits, only if the patient does not meet refill 
criteria.  If a treatment is clinically necessary due to the progressive clinical 
worsening per the investigator’s judgment , rescue treatmen t must be discussed and 
agreed upon by [CONTACT_514896] .  
[IP_ADDRESS] Management of Patients Who Meet Lack of Clinical Efficacy
Criteria
Criteria for meeting lack clinical efficacy are shown in Table 7 , and Table 8 describes 
how to manage patients who meet such criteria.  Patients who meet criteria for lack of 
clinical efficacy willreceive rescue treatment with ITV injection of open -label ranibizumab 
as described in Section [IP_ADDRESS] .  One month after meeting criteria for lack of clinical 
efficacy and receiving arescue ITV ranibizumab injection, the patient will receive a 
mandatory refill with the 100 -mg/mL ranibizumab formulation. At the next monthly visit 
and until the end of the study, the patient will receive arefill with the 10 0-mg/mL 
ranibizumab formulation if the patient meets protocol -defined refill criteria.
For information regarding patient discontinuation or early study treatment discontinuation 
refer to Section 4.7.
Ranibizumab Port Delivery System —Genentech, Inc.
81/Protocol GX28228 , Version 8Table 7Lack of Clinical Efficacy Criteria 
Event
Lack of clinical efficacy Loss in BCVA of [ADDRESS_667307] recorded BCVA on 
study following two consecutive ranibizumab Implant refills (as 
per protocol -specified refill criteria) occurring 1 month apart due 
to nAMD disease activity and not attributable to a change in the 
ocular media (i.e., cornea, lens, aqueous or vitreous humor, 
epi[INVESTIGATOR_514828], etc.) unless there is at least 
a five -letter increase in BCVA, in which case a refill will occur.
and/or
Increase in CFT 150 m from the lowest CFT measurement 
on study following two consecutive ranibizumab Implant refills 
(as per protocol -specified refill criteria) occurring 1 month apart 
due to nAMD disease activity and not attributable to a change
in the ocular media (i.e., cornea, lens, aqueous or vitreous 
humor, epi[INVESTIGATOR_514828], etc.) unless there is 
a decrease in CFT 75microns from the last refill, in which 
case a refill will occur.
Table 8 Management of Patients Who Meet Lack of Clinical Efficacy  
Criteria
Time of event Treatment to be performed
Atthetime ofmeeting
lack of clinical efficacy  criteriaPerform rescue treatment with intravitreal
injection of open -label ranibizumab
Atthestudy visitonemonthafter meeting
lack of clinical efficacy  criteriaPerform a mandator yrefill with the
100-mg/mL ranibizumab formulation
At subsequent study visits
(from Month 2 after meeting lack of clinical 
efficacy  criteria and onwards)Perform a refill with100-mg/mL
ranibizumab formulation 
ONLY if refill criteria aremet
Ranibizumab Port Delivery System —Genentech, Inc.
82/Protocol GX28228 , Version [IP_ADDRESS] Recommended Management of Cases of Vitreous Hemorrhage 
Cases of vitreous hemorrhage secondary to Implant -related procedures throughout the 
study should be managed following the recommendatio ns in Table 9 .  
Table 9Recommended Management of Cases of Vitreous Hemorrhage 
Timing Patient’s examination/management/determination of refill requirements
Day of vitreous 
hemorrhage 
diagnosisIf the diagnosis of vitreous hemorrhage is made during a 
scheduled visit, if possible perform ocular B- scan 
ultrasonography in addition to the assessments scheduled for 
that specific visit
If the diagnosis of vitreous hemorrhage is made during an 
unscheduled visit, if possible perform ocular ultrasonography in 
addition to the assessments listed in the Appendix 5
A safety assessment visit (scheduled or unscheduled) should 
be performed approximately 2 weeks after occurrence of 
vitreous hemorrhage (see Appendix 5for unscheduled visit). If 
possible, perform ocular B -scan ultrasonography.
Approximately 
1 month after 
occurrence 
(scheduled 
visit)If possible, perform ocular B -scan ultrasonography in addition to 
the assessments scheduled for that specific visit
If vitreous hemorrhage causes loss in BCVA, but assessment of 
the macula or SD -OCT can be performed successfully, 
determine if Implant refill is needed according to the protocol -
defined refill criteria (see Section 3.1.1 )
If vitreous hemorrhage causes loss in BCVA, and neither 
assessment of the macula nor SD -OCT can be performed 
successfully, perform rescue treatment with ITV injection of 
open- label ranibizumab 
An unscheduled safety assessment visit should be performed 
between month 1 and month 2 after occurrence of vitreous 
hemorrhage (see Appendix 5).
Approximately 
2 months after 
occurrence 
(scheduled 
visit)If possible, perform ocular B -scan ultrasonography
If vitreous hemorrhage causes loss in BCVA, but assessment of 
the macula or SD -OCT can be performed successfully, 
determine if Implant refill is needed according to the protocol -
defined refill criteria (see Section 3.1.1 )
If vitreous hemorrhage causes loss in BCVA, and neither 
assessment of the macula nor SD -OCT can be performed 
successfully:
operform rescue treatment with ITV injection of open -label 
ranibizumab 
odiscuss a pars plana vitrectomy with the patient as a 
possibility to remove the vitreous hemorrhage.  Consultation 
with the Medical Monitor is required prior to perform pars 
plana vitrectom y.
BCVA best corrected visual acuity ; ITV intravitreal ; SD-OCT spectral domain optical 
coherence tomography .
Ranibizumab Port Delivery System —Genentech, Inc.
83/Protocol GX28228 , Version [IP_ADDRESS] Implant Clogging A ssessment
If an Implant is explanted, it willbe analyzed for possible clogging using the following
assessments :
Serum pharmacokinetic sof ranibizumab will be used to help judge whether Implant
clogging may have occurred. Aqueous humor orvitreous PK samples willbe 
collected at explantation and may be used to further assess possible Implant 
clogging .  For each individual patient, possible Implant clogging will be documented 
if at least one of the following conditions are met:
At Implant insertion and prior to the first refill : serum ranibizumab 
concentrations are below the lower limit of quantification (BLQ) or below the 
baseline serum ranibizumab concentration value at all time -points prior to refills, 
that is, Day 1 (within 60 min of insertion ), Day 2, Day 7, Day 14, and all monthly 
time po ints after Implant insertion and prior to the first refill or to the end of the 
study visit for this patient if no refill occurs .
After the first refill: serum ranibizumab concentrations are BLQ or below the 
last pre -refill serum ranibiz umab concentration value at all time -points post 
refills, that is, Day 7, and all monthly time points prior to the next refill for 
2consecutive refills or to the end of the study visit for this patient if no further 
refill occurs
.
Implant s identified that meet PK criteria for possible clogging will then undergo 
further diagnostics if explanted .  The Implant “complete clogging” failure statistics 
will be summarized across all Implant patients based on the first [ADDRESS_667308] of monitoring and recording adverse events , including
serious adverse events and AESIs ; measurement of protocol -specified safety laboratory 
assessments; measurement of prot ocol-specified vital signs; and other protocol -
specified tests that are deemed critical to the safety evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
5.2.[ADDRESS_667309] and/or medical device regardless of causal attribution.  An 
adverse event cantherefore be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product or 
device , whether or not considered related to the medicinal product or thedevice
Ranibizumab Port Delivery System —Genentech, Inc.
84/Protocol GX28228 , Version 8Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition), except as described in 
Section [IP_ADDRESS] .
Recurrence of an inte rmittent medical condition (e.g., headache) not present at 
baseline
Any deterioration in a laboratory value or other clinical test (e.g. , fluorescein 
angiography) that is associated with symptoms or leads to a change in study 
treatment or concomitant treatment or discontinuation from study drug
Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assig nment of study treatment (e.g., screening invasive 
procedures such as biopsies)
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
5.2.2 Serious A dverse Events (Immediately  Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Is fatal (i.e., the adverse event actually causes or leads to death)
Is life threatening (i.e., the adverse event , in the view of the investigator, places the 
patient at immediate risk of death)
This does not include any adverse event that had it occurred in a more severe 
form or was allowed to continue might have caused death.
Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS])
Results in persistent or significant disability/incapacity (i.e., the adverse event
results in substantial disruption of the patient’s ability to conduct normal life 
functions)
Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug
Is a sig nificant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the out comes 
listed above)
The terms "severe" and "serious" are notsynonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe ; see Section 5.3.3 ); the event 
itself may be of relatively minor medical significance (such as severe headache without 
any further findings).
Severity and seriousness need to be independently assessed for each adverse event
recorded on the eCRF.
Ranibizumab Port Delivery System —Genentech, Inc.
85/Protocol GX28228 , Version 8Serious adverse events are required to be reported by [CONTACT_514897] y (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).
5.2.[ADDRESS_667310] (Immediately  Reportable to 
the Sponsor)
AESI scan be serious or non- serious andare required to be reported by [CONTACT_453410] 24 hours after learning of the event (see Sect ion5.4.2 for reporting 
instructions).  AESI sfor this study include the following:
a)Adverse events resulting from medication errors
Examples of medication errors include, bu t are not limited to, overdose (see 
further details in the Section [IP_ADDRESS] ), incorrect dose, incorrect route, incorrect 
drug, incorrect administration, or incorrect kit.
If the medication error did result in an adverse event , the primary event term 
should reflect the adverse event that occurred as a result of the medication 
error .  The “Other” suspected causes of adverse event data field on the adverse 
event record should be reported as a medication error.
b)Sight -threatening adverse events
An adverse event is considered to be sight threatening and should be reported 
expeditiously if it meets one or more of the following criteria:
It causes a decrease of 30 letters in VA (compared with the last 
assessment of VA prior to the m ost recent assessment) lasting more than 
1hour
It requires surgical intervention (i.e., conventional surgery, vitreous tap, or 
biopsy with ITVinjection of anti -infective agent s, or laser or retinal cryopexy 
with gas or explantation of Implant ) to prevent permanent loss of sight
It is associated with severe intraocular inflammation (i.e., 4 anterior 
chamber cell/flare or 4 vitritis; see the definitions for intraocular 
inflammation, iritis, iridocyclitis, and vitritis in Section 5.3.5 and inflammation 
grading scales in Appendix 12).
In the opi[INVESTIGATOR_871], it may require medical intervention to 
prevent permanent loss of sight.
c)Suspected transmission of an infectious agent by [CONTACT_5257], as defined below
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings tha t indicate an 
infection in a patient exposed to a medicinal product.  This term applies only 
when a contamination of the study drug is suspected
Ranibizumab Port Delivery System —Genentech, Inc.
86/Protocol GX28228 , Version 8d)ADEs ;that is, adverse events that are considered to be related to the RPDS and to 
the use of the RPDS.  They include, but are not limited to:
Adverse events resulting from insufficient or inadequate device RPDS IFU
Adverse events related to the Implant insertion procedure 
Adverse events related to the Implant refill procedure
Adverse events related to the Implan t explantation procedure
Adverse events related to the presence of the Implant within the eye
Adverse events caused by [CONTACT_514898]
Adverse events resulting from use error or from intentional misuse of the 
RPDS
A lack of efficacy of ranibizumab due to inadequate r elease of ranibizumab 
from the I mplant
In addition ,any adverse event considered causally related to the RPDS must also 
always be reported a sa Medical Device Complaint ( Section 5.4.4 ).
5.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all adverse events (whether associated 
with the drug, with the Implan t or one of the ancillary devices, with any of the study 
procedures ,and all adverse events not associated with any of these elements), are 
recorded on the adverse event eCRF and reported to the Sponsor in accordance with 
instructions provided in this sect ion and in Section 5.4to Section 5.6.  
In addition, t he investigator is also responsible for reporting medical device complaints 
(see Section 5.4.4 )associated with any of the components (see Table 1 ) of the RPDS.
For a device defect with an associated adverse event this means that the investigator 
must report both an adverse event and a Medical Device Complaint (see Section 5.4.4 ).
For each adverse event recorded on the adverse event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see 
Section 5.3.3 ), and causality (see Section 5.3.4 ).
5.3.[ADDRESS_667311].  All 
adverse events, whether reported by [CONTACT_25743], will be 
recorded in the patient’s medical record and on the adverse event eCRF.
Ranibizumab Port Delivery System —Genentech, Inc.
87/Protocol GX28228 , Version 8After informed consent has been obtained but prior to initiation o f study  drug
(Day 1), only serious adverse events related to a protocol -mandated intervention 
(e.g., invasive procedures such as biopsies, discontinuation of medications , or ITV 
ranibizumab given as part o f pre-screening ) should be reported (see Section 5.4.2 for 
instructions for reporting serious adverse events ).
After initiation of study drug , all adverse events , regardless of relationship to study 
drug, Implant ,or ancillary devices, or study procedures, will be reported until the 
patient’s study compl etion or early termination from the study. After completion or early 
termination from the study , the investigator should report any serious adverse events
that are believed to be related to prior study treatment (study drug and/or RPDS , 
seeSection 5.6).
5.3.2 Eliciting A dverse Ev ent Information
A consistent methodology of non -directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:
"How have you felt since your last clinic visit? "
"Have you had any new or changed health problems since you were last here? "
5.3.[ADDRESS_667312] normal daily activity
Severe Incapacitating with inability to work or to perform normal daily activity
Note:  Regardless of severity, some events may  also meet seriousness criteria.  Refer to 
definition of a serious adverse event (see Section 5.2.2 ).
5.3.4 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes .
Patients in the Implant arms:  The investigator will assess whether there is a 
potential association with each of the following “components” of the study 
intervention:  
–Each component of the RPDS (i.e., a separate assess ment for the Implant, the 
Initial Fill Needle, the Insertion Tool, the Refill Needle ,andthe Explant Tool)
–The study procedures (including the procedures to insert, refill , or explant the 
Implant )
–Ranibizumab (study drug)
Ranibizumab Port Delivery System —Genentech, Inc.
88/Protocol GX28228 , Version 8Investigators will assess any relationship between the adverse event andeach 
component separately, indicating “yes” or “no” as applicable on Adverse Event eCRF .
Patients in the ITV arm :  The investigator will assess whether there is a potential 
association with each of the following “components” of the study intervention: 
–The ITV procedure 
–Ranibizumab (study drug )
The following guidance should be taken into consideration when assessing causality :
Temporal relationship of event onset to the initiation of study drug, implant and its 
insertion, refill, or explantation procedures or due to other RPDS components (see 
Table 1 ) or due to ITV injection procedure.  
Course of the event, considering especially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)
Known association of the event wit h study drug, Implant or other RPDS 
components/procedures, or with similar treatments
Known association of the event with the disease under study
Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of non treatment -related factors that are known to be associated with the 
occurrence of the event
5.3.[ADDRESS_667313] medical terminology/concepts when recording adverse 
events on the adverse event eCRF.  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the adverse event
eCRF.
For the purposes of reporting events of infection and inflammation, the following terms 
and definitions should be used:
Iritis:  the presence of inflammatory cells in the anterior chamber
The presence of aqueous humor flare alone will not constitute iritis but should 
be documented as an anterior chamber flare for adverse event reporting 
purposes.
Iridocyclitis:  the presence of inflammatory cells in both the aqueous humor 
andvitreous
Vitritis:  the presence of active inflammation in the vitreous, demonstrated by [CONTACT_66347] (trace or greater)
Active inflammation in the vitreous shou ld be clinically differentiated 
from cellular debris from prior epi[INVESTIGATOR_66299], hemorrhage, or other 
causes.
Ranibizumab Port Delivery System —Genentech, Inc.
89/Protocol GX28228 , Version 8Endophthalmitis:  diffuse intraocular inflammation predominantly involving the 
vitreous cavity but possibly also involving the anterior c hamber, implying a 
suspected underlying infectious cause. A culture is required prior to initiating 
antibiotic treatment for presumed endophthalmitis.
Note:  Trace benign, aqueous humor pi[INVESTIGATOR_514829] W BCs or the result of any ocular disorder 
should not be recorded as an adverse event .
[IP_ADDRESS] Diagnosis versus Signs and Sy mptoms
Adiagnosis (if known) should be recorded on the adverse event eCRF rather than 
individual signs and symp toms (e.g., record only liver failure or hepatitis rather than 
jaundice, asterixis, and elevated transaminases).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a single diagnosis or syndrome 
at the time of report ing, each individual event should be recorded on the adverse event
eCRF.  If a diagnosis is subsequently established, all previously reported adverse events 
based on signs and symptoms should be nullified and replaced by [CONTACT_514899] t he single diagnosis, with a starting date that corresponds to the starting 
date of the first symptom of the eventual diagnosis.
[IP_ADDRESS] Adverse Events That A reSecondary  to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event
that is separated in time from the initiating event should be recorded as an independent 
event on the adverse event eCRF.  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.
If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.
If neutropenia is accompanied by a ninfection, both events should be reported 
separately on the eCRF.
All adverse events should be recorded separately on the adverse event eCRF if it is 
unclear as to whether the events are associated.
[IP_ADDRESS] Persis tent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 
adverse event eCRF.  The initial severity (intensity) of the event will be recorded at the 
Ranibizumab Port Delivery System —Genentech, Inc.
90/Protocol GX28228 , Version 8time the event is first reported.  If a persistent adverse event becomes more severe, the 
most extreme severity should also be recorded on the adverse event eCRF.  If the event 
becomes serious, it should be reported to the Sponsor immediately (i.e., no more than 
24 hours after learning that the ev ent became serious; see Section 5.4.2 for reporting 
instructions).  The adverse event eCRF should be updated by [CONTACT_25748] 
"non- serious" to "serious," providing the date that the event became serious, and 
completing all data fields related to serious adverse events .
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the adverse event eCRF.
[IP_ADDRESS] Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an adverse event .  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator’s judgm ent
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnorm ality should be classified as an adverse event .
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 the upper limit of normal [ULN]associated 
with chole
stasis), only the diagnosis (i.e., chole stasis ) should be recorded on the 
adverse event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the adverse event eCRF, along with a 
descrip tor indicating if the test result is above or below the normal range (e.g., "elevated 
potassium, "as opposed to "abnormal potassium ").  If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical ter m should 
be recorded as the Ae .  For example, an elevated serum potassium level of 7.0 mEq/L 
should be recorded as "hyperkalemia. "
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on th e adverse event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent adverse event ).
Ranibizumab Port Delivery System —Genentech, Inc.
91/Protocol GX28228 , Version [IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event .  A vital sign result must
be reported as an adverse event if it meets a ny of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Is clinically significant in the investigator’s judgment
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be class ified as an adverse event .
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood press ure), only the diagnosis (i.e., hypertension) should be recorded on 
the adverse event eCRF.
Observations of the same cli nically significant vital sign abnormality from visit to visit 
should only be recorded once 
on the adverse event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent adverse events ).
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3the U LN) in combination with either an 
elevated total bilirubin ( 2the U LN) or clinical jaundice in the absence of cholestasis or 
other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury
(as defined by [CONTACT_25742]’ s law).  Therefore, investigators must report as a serious adverse 
event the occurrence of either of the following:
Treatment -emergent ALT or AST 3the U LNin combination with total bilirubin 
2the U LN
Treatment -emergent ALT or AST 3the U LN in combination with clinical jaundice
Themost appropriate diagnosis or, if a diagnosis cannot be established ,the abnormal 
laboratory values should be recorded on the adverse event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event ).
[IP_ADDRESS] Deaths
All deaths that occur during the protocol -specified adverse event reporting period (see 
Section 5.3.1 ), regardless of relationship to study drug, must be recorded on the adverse 
event eCRF and immediately reported to the Sponsor (see Section 5.4.2 ).
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
Ranibizumab Port Delivery System —Genentech, Inc.
92/Protocol GX28228 , Version 8concept on th e adverse event eCRF.  Generally, only one such event should be reported.  
If the cause of death is unknown and cannot be ascertained at the time of reporting, 
"unexplained death "should be recorded on the adverse event eCRF.  If the cause of 
death later b ecomes available (e.g., after autopsy), "unexplained death "should be 
replaced by [CONTACT_25749].   The term "sudden death " should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death ").
[IP_ADDRESS] Preexisting Medic al Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the Medical History and Baseline Conditions 
eCRF s.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  W hen 
recording such events on the adverse event eCRF, it is important to convey the concept 
that the preexisting condition has changed by [CONTACT_9672] 
(e.g., "more frequent headaches ").
[IP_ADDRESS] Worsening of Neovascular Age-Related Macular Degeneration
in Study  Eye
Study eye m edical occurrences or symptoms of deterioration that are anticipated as part 
of the nAMD disease state should only be recorded as an adverse event if judged by [CONTACT_178810].  When recording an unanticipated worsening of
study eye nAMD on the adverse event eCRF, it is important to convey the concept that 
the condition has changed by [CONTACT_9672] (e.g., "accelerated 
nAMD").
[IP_ADDRESS] Hospi[INVESTIGATOR_26663] (i.e., in- patient admission to a hospi[INVESTIGATOR_307])
or prolonged hospi[INVESTIGATOR_514830] (per the definition of serious adverse event in Section 5.2.2 ), except as outlined 
below.  
There are some hospi[INVESTIGATOR_514831] e reporting as a serious 
adverse event when there is no occurrence of an adverse event .  These scenarios 
include a planned hospi[INVESTIGATOR_514832] a diagnostic or 
elective surgical procedure for a preexisting medical conditi on other than ocular that has 
not changed.
[IP_ADDRESS] Adverse Events A ssociated with an Overdose or Error in 
Drug Administration
An overdose is the accidental or intentional use of a drug in an amount higher than the 
dose being studied.  An overdose or incorrect administration of study treatment is not 
itself an adverse event , but it may result in an adverse event .  All adverse event s
Ranibizumab Port Delivery System —Genentech, Inc.
93/Protocol GX28228 , Version 8associated with an overdose or incorrect administration of study drug should be 
recorded on the adverse event eCRF andshould be reported to the Sponsor 
immediately (i.e., no more than 24 hours after lea rning of the event; see Section 5.4.2 ).
Defect s in the device that are not associated with adverse event s are captured 
according to Section 5.4.4 .
[IP_ADDRESS] Patient -Reported Outcome Data
Adverse event reports will not be derived from patient -reported outcome (PRO )data by 
[CONTACT_1034], and safety analyses will n ot be performed using PRO data.  However, if 
any PRO responses suggestive of a possible adverse event are identified during site 
review of the PRO data, the investigator will determine whether the criteria for an 
adverse event have been met and, if so, wil l report the event on the adverse event eCRF.
5.[ADDRESS_667314] report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_667315] report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:
Serious adverse events (see Section 5.4.2 for further details)
AESI (see Section 5.4.2 for further details)
Pregnancies (see Section 5.4.3 for further details)
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:
New signs or symptom s or a change in the diagnosis
Significant new diagnostic test results
Change in causality based on new information
Change in the event’s outcome, including recovery
Additional narrative information on the clinical course of the event
Investigators must a lso comply with local requirements for reporting serious adverse 
events to the local health authority (HA) and Institutional Review Board (IRB)/Ethics 
Committee ( EC).
Ranibizumab Port Delivery System —Genentech, Inc.
94/Protocol GX28228 , Version 85.4.[ADDRESS_667316] Information for Sponsor’s Medical Resp onsible 
Contact
[CONTACT_25290]: , M.D. (primary)
Email:
Telephone No.:
Mobile Telephone No.:
Medical Monitor: , M.D ., PhD .(secondary)
Email:
Mobile Telephone No.:
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the [COMPANY_002] Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if n ecessary), connect the investigator with a [COMPANY_002] Medical 
Monitor, and track all calls.  The Emergency Medical Call Center Help Desk will be 
available [ADDRESS_667317]
[IP_ADDRESS] Events That Occur Prior toInitiation of Study  Drug (Day 1)
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events related to a protocol -mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications, or ITV ranibizumab given 
aspart of pre -screening) should be reported.  The Serious Adverse Event/Adverse 
Event of Special Interest Reporting Form provided to investigators should be completed 
and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours 
after learning of the event ), either by [CONTACT_40880].
[IP_ADDRESS] Events That Occur AfterStudy  Drug Initiation
After initiation of study drug, serious adverse events , and any AESI will be reported until 
30 (7) days after the last study drug administration for the ITV injecti on treatment arm 
and until 90 ( 7) days after the Implant explantation for the Implant treatment arms. 
However, if any patient continues to be follo wed in the study after an early 
discontinuation of the treatment, the adverse event swill be report ed until their study 
completion.  Investigators should record all case details that can be gathered 
immediately (i.e., within 24 hours after learning of the event) on the adverse event eCRF 
and submit the report via the electroni c data capture (EDC) system.  A report will be 
generated and sent to [COMPANY_002] Safety Risk Management by [CONTACT_27950].

Ranibizumab Port Delivery System —Genentech, Inc.
95/Protocol GX28228 , Version 8In the event that the EDC system is unavailable, theSerious Advers eEvent/ Adverse 
Event of Special Interest Reporting Form provided to investigators should be completed 
and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours 
after learning of the event), either by [CONTACT_33477] e mailing the form using 
the fax number or email address provided to investigators .  Once the EDC system is 
available, all information will need to be entered and submitted via the EDC system.  
Instructions for reporting post-study adverse event sare provided in Section 5.6.
5.4.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study or within [ADDRESS_667318] 
dose of study drug.  A Pregnancy Report eCRF should be completed by [CONTACT_64095] (i.e., no more than 24 hours after learning of the pregnancy) and submitted 
via the EDC system.  A pregnancy report will automatically be g enerated and sent to 
[COMPANY_002] Safety Risk Management.  Pregnancy should not be recorded on the adverse 
event eCRF.  The investigator should discontinue study drug and counsel the patient,
discussing the risks of the pregnancy and the possible effects on the f etus.  Monitoring 
of the patient should continue until conclusion of the pregnancy.   Any serious adverse 
event sassociated with the pregnancy (e.g., an event in the fetus, an event in the mother 
during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be 
reported on the adverse event eCRF.
In the event that the EDC system is unavailable, theClinical Trial Pregnancy Reporting 
Form provided to investigators should be completed and submitted to the Sponsor or its 
designee immediately (i.e., no more than 24 hours after learning of the pregnancy), 
either by [CONTACT_123567].   Once the EDC system is available, all information will 
need to be entered and submitted via the EDC system.
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the ICFto immediately inform the investigator if 
their p artner becomes pregnant during the study or within [ADDRESS_667319] dose of 
study drug.  A Pregnancy Report eCRF should be completed by [CONTACT_64095] (i.e., no more than 24 hours after learning of the pregnancy) and submitted 
via the E DC syst em.  Attempts should be made to collect and report details of the course 
and outcome of any pregnancy in the partner of a male patient exposed to study drug.  
The pregnant partner will need to sign an Authorization for Use and Disclosure of 
Pregnanc y Health Information to allow for follow -up on her pregnancy.  Once the 
authorization has been signed, the investigator will update the Pregnancy Report eCRF 
with additional information on the course and outcome of the pregnancy.  An investigator 
who is contact[CONTACT_514900] —Genentech, Inc.
96/Protocol GX28228 , Version 8the risks of the pregnancy and the possible effects on the fetus, to support an informed 
decision in cooperation with the treating physician and/or obstetrician.
In the event th at the EDC system is unavailable, follow reporting instructions provided in 
Section [IP_ADDRESS] .
[IP_ADDRESS] Abortions
Any abortion should be classified as a serious adverse events (as the Sponsor considers 
abortions to be medically significant), recorded on the adverse event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after lea rning of the 
event; see Section 5.4.2 ).  
[IP_ADDRESS] Congenital A nomalies /Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug orthefemale partner of a male patient exposed to study drug should be classified 
as a serious adverse event, recorded on the adverse event eCRF, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section5.4.2 ).
5.4.[ADDRESS_667320] report all RPDS medical device complaints related to the Implant and 
ancillary devices (see Table 1) to the Sponsor.  
The investigator should provide as much information as possible to the personnel 
completing the IMP Deviation Form, including the product batch number.  The form will 
be forwarded to the Sponsor or its designee immediately (i.e. ,no more than 24 hours 
after learning of the event )(refer to the Study manual for further details).  
If the device com plaint is also associated with an adverse event in a study participant, 
then the adverse event must additionally be reported on the adverse event eCRF
submitted through the EDC system.  If the event is serious or an AESI , the adverse 
event eCRF must be completed immediately (i.e., no more than 24 hours after learning 
of the event), as outlined in Section 5.4.2 . 
If the medical device causes an adverse event to an individual other than the study 
patient (e.g., study site personnel) , the event sho uld be reported on the Medical Device 
Complaint form and the adverse event to [COMPANY_002] Safety Risk Management via telephone 
(see Study Manual for more details).
[IP_ADDRESS] Device Defects or Deficiencies that Could Have Led to Medical 
Occurrence
Device deficiencies (inadequacy with respect to identity, quality, durability, reliability, 
safety or performance and including malfunctions, and inadequate labeling) that did not 
lead to an adverse event but could have led to a medical occurrence if suitable action 
Ranibizumab Port Delivery System —Genentech, Inc.
97/Protocol GX28228 , Version 8had not been taken, if intervention had not been made, or if circumstances had been 
lessfortunate must be reported via the medical device complaints process immediately 
(i.e., no more than 24 hours after learning of the event) (refer to the Study manual for 
further details ). 
5.[ADDRESS_667321] to follow -up, or the patient withdraws consent.  Every effort should be mad e to 
follow all serious adverse events considered to be related to study drug or trial -related 
procedures until a final outcome can be reported.
During the study period, resolution of adverse event s(with dates) should be documented 
on the Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification.
All pregnancies reported during the study should be followed until pregnancy outcome.  
If the EDC system is not available at the time of pregnancy outcome, follow reporting 
instructions provided in Section 5.4.3 .
5.5.2 Sponsor Follow -Up
For serious adverse events , non -serious AESI , and pregnancies, the Sponsor or a 
designee may follow -up by [CONTACT_756], fax, electronic mail, and/or a monitoring visit to 
obtain additional case details and outcome information (e.g., from hospi[INVESTIGATOR_123444], consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.
5.[ADDRESS_667322] -STUDY ADVERSE EVENTS
The Sponsor should be notified if the investigator bec omes aware of any serious 
adverse event that occurs after the end of the adverse event reporting period (defined as 
30(7)days after the last dose of study drug for ITV treatment arm and 90 (7)days 
after the Implant explantation for patients in the Implant treatment arms ),if the event is 
believed to be related to prior study drug treatment or due to the Implant .
These events should be reported through use of the Adverse Event eCRF.  However, if 
the EDC system is not available, t he investigator should report these events directly to 
the Sponsor or its designee , either by [CONTACT_514901]/ Adverse Event of Special Interest Reporting Form using the fax number
or email address provided to investigators .
Ranibizumab Port Delivery System —Genentech, Inc.
98/Protocol GX28228 , Version 85.[ADDRESS_667323] experience to identify and expeditiousl y communicate 
possible new safety findings to investigators, IRBs, ECs, and applicable health 
authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following reference document:
RPDS IB
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].
6. STATISTICA L CONSIDERA TIONS AND ANAL YSIS PLA N
The primary analyses will take place after LPI [INVESTIGATOR_514833] [ADDRESS_667324] refill (TTFR) 
for each of the RPDS treatment arms ( 10mg/mL, 40 mg/mL, and 100mg/mL) enrolling 
60 patients in each of the RPDS treatment arms.  The sample size of approximately 
220randomized patients will be adequate to evaluate the primary objective of the study. 
PK/PD modeling and simulation wasperformed to inform key assumptions used in 
sample size calculation. Given the simulation results, the HR for comparing the 
100-mg/mL arm with the10-mg/mL arm was estimated to be 0.[ADDRESS_667325] 125 events from all three Implant groups is expected at the 
primary analysis time (approximately 85 events in the 10 -mg/mL group and a higher 
dose group).  With [ADDRESS_667326] approximately 80% power to detect an
HR0.[ADDRESS_667327] at a one -sided significance 
level of 15%. No multiplicity adjustment is planned for this Phase II study.
Forty patients in the ITV arm are considered sufficient to compare each device arm 
versus the ITV arm in change in BCVA from baseline thr ough Month 9 (assuming an 
estimated SD 10 letters, a two- sided 80% CI will extend approximately 2.62 letters from 
the observed mean). 
Ranibizumab Port Delivery System —Genentech, Inc.
99/Protocol GX28228 , Version 86.[ADDRESS_667328] OF STUDY
The demographic and baseline characteristics, such as age, sex, race/ethnicity, baseline 
VA, angiographic and clinical evaluation of CNV, time since diagnosis of nAMD , 
andstratification factors including baseline BCVA score andnumber of prior
anti-VEGF injections will be summarized by [CONTACT_2070].
6.3 SUMMA RIES OF TREA TME NT GROUP COMPA RABILITY
The demographic and baselin e characteristics, such as age, sex, race/ethnicity, baseline 
VA, angiographic and clinical evaluation of CNV, time since diagnosis of nAMD, baseline 
safety (patients outside the expected normal range for vital signs and laboratory test 
results), and baseline disease characteristics (i.e., BCVA and OCT parameters) will be 
summarized by [CONTACT_2939]. 
6.[ADDRESS_667329] patient’s entry into the 
study. For patients without any refills prior to or on the cut -off date of9 months after LPI , 
the time of refill will be censored. The censoring date will be defined as the date of a 
patient’s last visit before the cut -off date of [ADDRESS_667330] at a one -sided significance level of 15%. The stratification factors to be 
included are baseline BCVA score ( 65letters vs. 6
6letters ) and number of anti -VEGF 
ITV injections ( 3 vs.4).
Implant with 100 mg/mL versus Implant with 10 mg/mL
Implant with 100 mg/mL versus Implant with 40 mg/mL
Implant with 40 mg/mL versus Implant with 10 mg/mL
In addition, the HR for each pair -wise comparison of the treatment arms wi ll be 
estimated using a Cox proportional hazards regression model stratified by [CONTACT_514902] (65letters vs. 66letters ) and number of prior anti -VEGF ITV injections 
(3 vs. 4)with main effects for treatment.  Estimated HRs for each pair -wise 
comparison will be presented with the corresponding 80% CIs.  
Ranibizumab Port Delivery System —Genentech, Inc.
100/Protocol GX28228 , Version 8Kaplan Meier plots will be provided showing TTFR by [CONTACT_514854]. Median time to 
first meeting refill criteria will be calculated for each treatment arm with the Kaplan Mei er 
method, and the corresponding 80% confidence intervals will also be reported.
Moreover, for each treatment group, percentage of patients not meeting the 
protocol -defined first refill criteria by [CONTACT_49158] 4, 5, 6, 7, 8, and 9, derived from 
Kaplan -Meier est imates will be provided.
6.4.2 Secondary  Efficacy Analy sis
Asecondary efficacy outcome measure isthe change in BCVA from baseline through 
Month 9(by [CONTACT_24473]). Missing BCVA data, prior to or at Month [ADDRESS_667331] (LOCF) .  Comparison of implant arms 
(10mg/mL , 40mg/mL , and 100 mg/mL) versus the monthly ITV arm will be assessed 
using an analysis of covariance (ANCOVA) model with an effect for treatment and with 
covariate adjustments for bas eline stratification factors:  baseline BCVA score 
(65letters vs. 66letters ) and number of anti -VEGF ITV injections (3 vs. 4).  
Separate models will be fit for each pairwise comparison and each study month.  The 
dependent variables will be change from baseline in BCVA at each of Months 1 9.  
Model -based (least squares) estimates of the pairwise treatment differences will be 
provided and 80% CIs.  Figures showing mean and median change in BCVA over time, 
by [CONTACT_1570], will be provided.
The AN COVA model above will be repeated using change from baseline in CFT from 
baseline through Month 9 (by [CONTACT_24473]) as the outcome.  The stratification factors and 
baseline CFT will be included in the model as covariates.  Mean change from baseline in 
CFT from ba seline through Month 9 (by [CONTACT_24473]) will be compared between the implant 
arms and the monthly ITV arm.
Inorder to evaluate whether the I mplant clogging rate exceeds 10% within the first 
9months, the proportion of clogged I mplants will be estimated and the 80% CI will be 
calculated based on the binomial distribution.  All clogging data from patients in the 
implant arms will be pooled for this analysis.
Additional statistical summaries will be reported for the secondary efficacy outcome 
measures as listed in Section 3.5.2 .Detailed specifications of the statistical methods will 
be described in the SAP.
Ranibizumab Port Delivery System —Genentech, Inc.
101/Protocol GX28228 , Version 86.[ADDRESS_667332] one study treatment will be included in the safety analysis.  
Counts and incidence rates by [CONTACT_514903]:
Ocular and non -ocular adverse event s and serious adverse events
"Prespecified RPDS -associated adverse event s"(see Section 6.5.1 )
Positive serum antibodies to ranibizumab
For " prespecified RPDS -associated adverse event s”, the incidence in all implant arms 
patients will also be summarized.  
6.5.1 Adverse Events
Verbatim descriptions of treatment -emergent adverse event s will be mapped to 
thesaurus terms.  Treatment -emergent adverse eve nts will be defined as events 
beginning during or after surgical insertion/explantation of the Implant or the first 
ranibizumab ITV injection through the completion of the study or until a patient 
discontinues prematurely.  Adverse event s will be tabulated by [CONTACT_6764], high -level 
term, and preferred term.  Separate summaries will be prepared for non- ocular and 
ocular adverse event s, with events in the study eye and fellow eye summarized 
separately.  Serious adverse events will be summarized similarly.  Adverse events
leading to discontinuation from the study or treatment will be listed and tabulated.
ADEs are adverse event s that are considered to be related to the RPDS and to the use 
of the RPDS. Of particular interest are the following “Prespecified RPDS associated 
adverse event s”:  
Vitreous hemorrhage associated witha30-letter decrease of BCVA on ETDRS 
chart compared withthe last assessment of BCVA prior to the onset of vitreou s 
hemorrhage lasting 1 month
Reduced VA (30letters loss from previous scheduled visit)
Traumatic cataract
Endophthalmitis
Damage to sclera
Retinal detachment
Interference of the I mplant with visual field
In addition to the “Prespecified RPDS associated adverse event s”, any other ocular 
adverse event s and serious adverse events attributed by [CONTACT_238977]:  
1)Implant insertion procedure, 2) Implant refill procedure, 3) Implant explantation 
procedure, and 4) study drug, will be reported.
Ranibizumab Port Delivery System —Genentech, Inc.
102/Protocol GX28228 , Version 86.5.[ADDRESS_667333] change from baseline in vital signs will be tabulated.  If an
imbalance between treatment groups is observed, the summaries of the correspondin g 
vital signs over the course of the study will be provided .
6.5.5 Ocular A ssessment s
Results of the following ocular assessments will be summarized by [CONTACT_178819] 
(study vs. non -study) as applicable, using descr iptive summaries:  IOP , fluorescein 
angio graphy, and fundus photography.   Changes from baseline for selected ocular 
assessments will be tabulated .  The presence of intraocular inflammation and vitreous 
hemorrhage, as determined from the slitlamp examination, will be tabulated by [CONTACT_479] 
(according to grading scales for flare/cells and vitreal hemorrhage density in
Appendix 12).  The presence of retinal break or detachment as determined from 
ophthalmoscopy will be tabulated.
6.6 PHA RMA COKINETIC A NALYSES
Individual and mean serum ranibizumab concentration over time will be tabulated and 
plotted by [CONTACT_514904].  The serum pharmacokinetics of ranibizumab 
will be characterized by [CONTACT_514905], Cmax,tmax, t1/2,andCtroughbetween dose intervals.  
Estimates for these parameters will be tabulated and summarized by [CONTACT_84814].  Additional PK analyses may be conducted as appropriate.  More details are 
described in Section 3.5.4 .
6.7 PATIENT -REPORTED OUTCOME A NALYSES
For each scheduled assessment, descriptive statistics will be computed for the total 
MacTSQ score and for the two subscales: 1) information provision and convenience 
and 2) impact of treatment.  The scoring algorithm and rules for handling missing data 
willbe provided in the SAP.
PRO data will be presented separately from adverse events data.
Ranibizumab Port Delivery System —Genentech, Inc.
103/Protocol GX28228 , Version 86.8 EXPLORA TORY ANALYSES
Detailed specifications of the statistical methods for the exploratory analyses will be 
described in the SAP.
6.8.1 Time to Event Analysis with Data after Month 9
In case the required number of events (first refills) is not reached by [CONTACT_43380] 9, the 
primary analysis will be repeated as a follow -up analysis using all of the data collected 
up to the time when the required number of events is m et. 
In addit ion, the primary efficacy analysis described in Section 6.4.[ADDRESS_667334] an optional interim analysis and the timing of 
the analysis will be documented in the Sponsor’s trial master file prior to the conduct of 
the inte rim analysis.  The interim analysis will be performed by [CONTACT_514906]’s unmasked study team and will be interpreted by [CONTACT_514907].  Access to treatment assignment information 
will follow the Spons or’s standard procedures.  The details of the timing and scope of the 
interim analysis, if any, will be specified in the IMC Agreement.
7. DATA COLLECTION A ND M ANAG EMENT
7.[ADDRESS_667335] data clarification from the sites, which the sites will resolve 
electronically in the EDC system.  
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Ce ntral laboratory and reading center 
data will be sent directly to the Sponsor ,using the Sponsor’s standard procedures to 
handle and process the electronic transfer of these data.
eCRFs and correction documentation will be maintained in the EDC system’s au dit trail.  
System backups for data stored by [CONTACT_40892]’s standard procedures. Data from PRO 
Ranibizumab Port Delivery System —Genentech, Inc.
104/Protocol GX28228 , Version 8questionnaires will be forwarded to the Sponsor electronically.  The Sponsor will s upply 
eCRF specifications for this study.  For additional details of the data quality assurance
please see the Data Quality Review Plan .
7.[ADDRESS_667336] disc is required.
7.3 PATIENT -REPORTED OUTCOME DATA
Data from paper PRO questionnaires will be entered into the EDC system by [CONTACT_6624] .
7.4 SOURCE DA TA DOCUMENT ATION
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by [CONTACT_26831], compl ete, and verifiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, PRO s, evaluation checkl ists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_70069], 
microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient fil es, 
and records kept at pharmacies, laboratories, and medico- technical departments 
involved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan (TMP) .  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eC RFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.6.
Ranibizumab Port Delivery System —Genentech, Inc.
105/Protocol GX28228 , Version 8To facilitate source data verification, the investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for trial -related 
monitoring, Sponsor audits, and IRB/EC review.  The study site must also allow 
inspection by [CONTACT_25756]. Please see TMP for additional details.
7.5 USE OF COMPUTERIZED SYSTEMS
When clinical obs ervations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with HA
requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name [CONTACT_33508], and date of the change.
7.[ADDRESS_667337] of this study and the distribution of 
IMP, including eCRFs, ePRO data (if applicable), ICFs , laboratory test results, and 
medication inventory records, must be retained by [CONTACT_079] [INVESTIGATOR_25653] 
15years after completion or discontinuation of the study, or for the length of time 
required by [CONTACT_514908] l or local health authorities, whichever is longer.  After that 
period of time, the documents may be destroyed, subject to local regulations.
No records may be disposed of without the written approval of the Sponsor .  Written 
notification should be provide d to the Sponsor prior to transferring any records to 
another party or moving them to another location.
8. ETHICA L CONSIDERA TION S
8.1 COMPLIA NCE WITH LA WSAND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guide line for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  It will also follow ISO [ZIP_CODE] for the RPDS Clinical 
Investigation Plan (see Appendix 21for details).  The study will comply with the 
requirements of the ICH E2A guideline (Clinical Safety Data Management:  Definitions 
and Standards for Expedited Reporting).  Studies conducted in the [LOCATION_002] or 
under a U .S. Investigational New Drug (IND ) Application will comply with FDA 
regulations and applicable local, state, and federal laws.
8.2 INFORMED CONSENT
The Sponsor’s sample ICFwill be provided to each site.  If applicable, it will be provided 
in a certified translation of the local language.  The Sponsor or its designee must review 
and approve any proposed deviations from the Sponsor's sample ICFs or any alternate 
Ranibizumab Port Delivery System —Genentech, Inc.
106/Protocol GX28228 , Version 8cons ent forms proposed by [CONTACT_779] (collectively, the “Consent Forms”) before IRB/EC 
submission.  The final IRB/EC -approved Consent Forms must be provided to the 
Sponsor for HAsubmission purposes according to local requirements.
The benefit and risks associated with participation in this study is outlined and will be 
explained to the patient by [CONTACT_093]. 
The ICFwill contain a separate section that addresses the collection and use of the 
optional aqueous humor samples for optional exploratory research.  The in vestigator or 
authorized designee will explain to each patient the objectives of the exploratory 
research.  Patients will be told that they are free to refuse to participate and may 
withdraw their specimens at any time and for any reason during the 15-year storage 
period.  A separate, specific signature [CONTACT_22862] a patient's 
agreement to allow the optional aqueous humor sample to be collected and used for 
exploratory research.  Patients who decline to participate will check a “no” box in the 
appropriate section and will not provide a separate signature.
Patients’ compensation for costs resulting from participation in the study 
(e.g., transportation) may be provided if allowed by [CONTACT_2091]. Subject to 
national regulations, arrangement for additional healthcare for patients who suffer from 
an adverse event as a result of participation will be explained and documented in the
ICF.
The Consent Forms must be signed and dated by [CONTACT_514909].   The case history or clinical records for each patient shall 
document the informed consent process and that written informed consent was obtained 
prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC and HA(if applicable) -approved Consent Forms 
must be provided to the Sponsor for HAsubmission purposes.
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC /HApolicy) during their participation in the study.  For any updated or revised 
Cons ent Forms, the case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.
A copy of each sig ned Consent Form must be provided to the patient.  All signed and 
dated Consent Forms must remain in each patient’s study file or in the site file and must 
be available for verification by [CONTACT_9534].
Ranibizumab Port Delivery System —Genentech, Inc.
107/Protocol GX28228 , Version 8Each Consent Form may also include pati ent authorization to allow use and disclosure 
of personal health information in compliance with the U.S. HIPAA of 1996.  If the site 
utilizes a separate Authorization Form for patient authorization for use and disclosure of 
personal health information unde r the HIPAA regulat ions, the review, approval, and 
other processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
8.[ADDRESS_667338] be submitted to the IRB/EC by [CONTACT_079] [INVESTIGATOR_162412]/EC bef ore the study is initiated.  In addition, any 
patient recruitment materials must be ap proved by [CONTACT_1201]/EC.
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by [CONTACT_1201]/EC.  I nvestigators are also responsible 
for promptly informing the IRB/EC of any protoc ol amendments (see Section 9.6).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting ser ious adverse events to the 
local HAand IRB/EC.  Investigators may receive written IND safety reports or other 
safety-related communications from the Sponsor .  Investigators are responsible for 
ensuring that such reports are reviewed and processed in accordance with HA
requirements and the policies and procedures established by [CONTACT_11577]/EC, and archived 
in the site’s study file. 
8.[ADDRESS_667339] parties only as permitted b y the ICF (or separate authorization for use and 
disclosure of personal health information) signed by [CONTACT_102], unless permitted or 
required by [CONTACT_2371].
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare, for treatment purposes.
Data generated by [CONTACT_70178], Sponsor
monitors, representatives, and collaborators, and the IRB/EC for each study site, as 
appropriate.
Ranibizumab Port Delivery System —Genentech, Inc.
108/Protocol GX28228 , Version 88.[ADDRESS_667340] of 
the study to be fully documented, including but not limited to the protocol, protocol 
amendments, ICFs , and documentation of IRB/EC and governmental approval.  In 
addition, at the end of the study, the investigator will receive the patient data, includ ing
an audit trail containing a complete record of all changes to data.
9.[ADDRESS_667341] on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.
9.3 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], patients’ medical records, and eCRFs.  The investigator will 
permit national and local HAs, Sponsor monitors, representatives, and collaborators, and 
the IRBs/ECs to inspect facilities and records relevant to this study .  The Sponsor will 
review all protocol deviations and assess whether any represent a serious breach 
of Good Clinical Practice guidelines and require reporting to health authorities. As per 
the Sponsor's standard operating procedures, prospective requests to deviate from the 
protocol, including reque sts to waive protocol eligibility criteria, are not allowed.
9.4 ADMINISTRA TIVE STRUC TURE
This study issponsored by [CONTACT_8229], Inc.
Genentech and/or its designee will perform study management, oversight of data 
management, statistical programming , project management, monitoring, vendor 
management, and data management (quality checking of the data).
Ranibizumab Port Delivery System —Genentech, Inc.
109/Protocol GX28228 , Version 8Procedures used for data review, database cleaning, issuing and resolving data queries, 
verificat ion and validation are detailed i n the Data Management Plan and in the Internal 
Data Review Plan documents.
AnIxRS will be used for patient enrollment and for management of study drug /device
requests and shipments. Enrollment will be competitive.
A central laboratory will be used for most laboratory assessments (e.g., saf ety laboratory 
assessments) and for storage of other laboratory samples ( e.g., serum samples for PK 
assessments) prior to being shipped to Genentech or Genentech -selected designee for 
analysis .
Data will be recorded by [CONTACT_66360] (see Section 5.4.2 ).
A central reading center will be used for ocular imaging analyses and storage
(fluorescein angiography, fundus photography and SD -OCT). 
9.5 PUBLICA TION OF DATA  AND PROTECTION OF 
TRADESECRETS
Regardless of the outcome of a trial, the Sponsor i s dedicated to openly providing 
information on the trial to healthcare professionals and to the public, both at scientific 
congresses and in peer -reviewed journals.  The Sponsor will comply with all 
requirements for publication of study results.   For more information, refer to the [COMPANY_002] 
Global Policy on Sharing of Clinical Trials Data at the following W eb site:
www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented a t scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial resul ts within [ADDRESS_667342] editorial and ethical practice, the Sp onsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_12992].
Ranibizumab Port Delivery System —Genentech, Inc.
110/Protocol GX28228 , Version 8Authorship will be determined by [CONTACT_159134] d in line with International 
Committee of Medical Journal Editors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_26834].
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor , excep t where agreed otherwise.
9.6 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_3031]).
Ranibizumab Port Delivery System —Genentech, Inc.
111/Protocol GX28228 , Version 810. REFERENCES
Age-Related Eye Disease Study Research Group. A randomized, placebo controlled, 
clinical trial of high -dose supplementation with vitamins C and E, beta carotene, 
and zinc fo r age- related macular degeneration and vision loss: AREDS Report 8. 
Arch Ophthalmol 2001;119:141 36.
Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual 
impairment avoided using ranibizumab for choroidal neovascularization: non-
Hispanic white population in the [LOCATION_002] with age -related macular 
degeneration. Arch Ophthalmol. 2011 Jun;129(6):709 -17.
Buys YM.  Trabeculectomy with ExPRESS: weighing the benefits and cost. Curr Opin 
Ophthalmol. 2013 Mar;24(2):111- 8.
Chakravar thy U, Wong TY, Fletcher A, et al.  Clinical risk factors for age -related macular 
degeneration: a systematic review and meta -analysis. BMC Ophthalmol. 2010 Dec 
13;10:31.
Dunn JP, Van Natta M, Foster G, et al.  Complications of ganciclovir implant surgery i n 
patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus 
Retinitis Trial. Retina. 2004 Feb;24(1):41 -50.
Gedde SJ , Singh K, Schiffman JC, et al. The Tube Versus Trabeculectomy Study: 
interpretation of results and application to clinical practice. Curr Opin Ophthalmol. 
2012 Mar;23(2):118- 26.
Jager RD, Mieler W F, Miller JW .  Age-related macular degeneration. N Engl J Med. 
2008;358(24):2606 -2617.
Lalwani GA, Rosenfeld PJ, Fung AE, et al.  A variable -dosing regimen with intravitreal 
ranibizumab for neovascular age -related macular degeneration: year 2 of the 
PrONTO Study. Am J Ophthalmol. 2009 Jul;148(1):43 -58
Rudnicka AR , Jarrar Z, W ormald R, et al.  Age and gender variations in age -related 
macular degeneration prevalence in populatio ns of European ancestry: a meta -
analysis.  Ophthalmology. 2012 Mar;119(3):571 -80. 
Smith AF. The growing importance of pharmacoeconomics: the case of age -related 
macular degeneration.  Br J Ophthalmol. 2010 Sep;94(9):[ADDRESS_667343];30(9): 1441 –1454.
Ranibizumab Port Delivery System —Genentech, Inc.
112/P rotocol GX28228 , Version 8Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visit s,and Final/ Early  Termination Visits
AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
Written informed 
consent x
Review of 
inclusion and 
exclusion criteria x x
Medical and 
surgical histor y, 
tobacco and 
alcohol use x
Demographic 
Information x
Physical 
Examination x xx
MacTSQ fx x x x x
Site to contact 
[CONTACT_23624] (as 
applicable)gx x x x x x x x x x x x x x x
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
113/Protocol GX28228 , Version 8AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
Vital signshx x x x x x x x x x x x x x x
Central laboratory 
samples 
(hematology, 
coagulation, 
serum chemistry , 
and urinaly sis)ix
Serum pregnanc y 
sample j
xIf urine pregnancy test is positive, collect serum pregnancy 
sample and do not perform study treatment until the final 
results are available. x
Urine pregnancy 
test k
xlIf a patient meets criteria for Implant refill, collect urine 
pregnancy test prior to the refill. If urine pregnanc y test is 
positive, collect serum pregnancy sample and do not 
perform study treatment until the final results are available.
Serum PK sample 
for ranibizumab 
concentration xm
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
114/Protocol GX28228 , Version 8AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
Serum PK sample 
for ranibizumab 
concentration 
PRIOR to 
treatment nxCollect serum PK sample for ranibizumab concentration at 
each monthly visit PRIOR to the treatment, even if treatment is 
not subsequently given. x
Serum PK sample 
for ranibizumab 
concentration 
POST treatment oxpx x xIf Implant refill is performed, collect PK sample 1 to 2 days 
after refill, and 7 days after refill x
Serum anti -
ranibizumab 
antibody sample qx x x x x x x
Optional whole 
blood for DNA 
(RCR Sample) x
Optional serum 
sample for 
candidate 
biom arkers x x x
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
115/Protocol GX28228 , Version 8AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
Optional plasma 
(EDTA) sample 
for candidate 
biom arkers x x x
Optional aqueous 
humor samplerObtain prior to or immediately following one or more refills and 
at the safety visit [ADDRESS_667344] refill
BCVA testing 
(starting at 4 m) x x x x x x x x x x x x x x x x x
Low luminance 
BCVA testing sx x x x x x x x x x x x x x x x x
Visual Field 
testing 
(Humphrey  24-2)txux x
Axial Length 
Measurement
(ultrasound or 
optical biometry )vxu
Intraocular 
pressure (IOP) wx x xxx x x x x x x x x x x x x x x
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
116/Protocol GX28228 , Version 8AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
Slit-lamp 
examination x x x x x x x x x x x x x x x x x
Dilated binocular 
indirect 
ophthalmoscopyyx x x x x x x x x x x x x x x x x x
Historical OCT
images 
collectionzx
SD-OCT w,aax x x x x x x x x x x x x x
Fundus 
photography w, aax x x
Fluorescein 
angiography w, aax x x x x
Fundus 
Autofluorescencew, aax x x x
OCT Angiography 
(at selected 
sites) abx x x x x x x x x x x x x x
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
117/Protocol GX28228 , Version 8AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
External Photo -
study eye only
(High 
magnification 
Implant and 
conjunctiva, 
scleral surface) x x x x x x x x x x x x x
Lens Photo
(fundus reflex 
photo) x x x x x x x x x x x x x x
Implant Photo -
study eye only 
(High 
magnification 
Implant in eye, 
through dilated 
pupil) acx x x x x x x x x x x x x
Pre-study  
treatment 
antim icrobials (as 
applicable)adx x x x x x x x x x x
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
118/Protocol GX28228 , Version 8AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
Post- study  
treatment 
antim icrobialsadx x x x x x x x x x x
Video of Implant 
insertion and 
explantation and, 
if feasible, video 
of refill aexVideo of Implant insertion and explantation and, if feasible, 
video of refill (if applicable)
Ranibizumab 
filled Implant 
insertion x
Implant refill with 
ranibizumabafRefill if refill criteria are met (see Section 3.1.1 )
Post- treatment 
finger counting 
(as applicable) agAs applicable per treatment
Post- treatment 
IOP measurement xah
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
119/Protocol GX28228 , Version 8AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
Refill Needle 
collection after 
Implant refill for 
vitreous 
biom arkers aiCollect Refill Needle with its content if Implant refill is 
performed, if applicable
Implant insertion 
evaluationajx
Concomitant 
medicationsakx x x x x x x x x x x x x x x x x x
Adverse event alx x x x x x x x x x x x x x x x x
Concurrent ocular 
procedures or 
additional 
assessmentsamx x x x x x x x x x x x x x x x x
Follow -up call (if 
applicable) anx As applicable per treatment x
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
120/Protocol GX28228 , Version 8AssessmentScreen a
7 days 
after 
RBZ txRand b
28 and 
37 
days 
after 
RBZ txDay Month
Month X 
Visit dSafety 
Visit cFinal/
ETe1 b2 c7 c14 c1 2 3 4 5 6 7 8 9
Window (Day s) 022777777777 7See 
footnote cSee 
footnote e
Eye fluid sample 
collectionaoCollect vitreous or aqueous humor sample at the start of 
explantation for patients undergoing an explantation procedure
AMD age-related macular degeneration; AREDS Age-Related Eye Disease Study; BCVA best corrected visual acuity; ET end of treatment; 
IOPintraocular pressure; ITV intravitreal; IxRS interactive Voice/W eb response sy stem; MacTSQ Macular Degeneration Treatment 
Satisfaction Questionnaire; NAnotapplicable; PKpharmacokinetic ; Randrandomization ; RBZ ranibizumab; SAsafety visit; 
SD-OCT spectral domain optical coherence tomography; txtreatment.
Notes:  All ocular assessments are to be performed for both eyes prior to study treatment unless noted otherwise.  All assessments for a visit are to 
be performed on the same day, except those at screening.
aScreening cannot occur earlier than [ADDRESS_667345] -of-care of ITV ranibizumab treatment in the study eye. 
bPatients randomized to Implant treatment arms will be scheduled at the conclusion of their randomization visit for their Implant insertion surgery 
(Day 1) on such a date that no less than 28days and no more than [ADDRESS_667346] -of-care
ITV rani bizumab treatment in the study eye , unless a patient needs more time to interrupt as pi[INVESTIGATOR_514817] 7 days before Day 1 (see 
Section [IP_ADDRESS] ).  For these patients, Day [ADDRESS_667347] occur no later than 45 days after the patient’s last I TV ranibizumab 
treatment.   In the case of a pause of enrollment and implant insertion surgeries, patients who have been randomized but have not yet received 
the study drug must repeat all randomization assessments ( except for the randomization transaction i n IxRS) after enrollment and implant 
insertion surgeries re commence ,before receiving the study drug.
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
121/Protocol GX28228 , Version 8cImplant treatment arms safety assessment visits will be scheduled on Day s 2, 7 ( 2 day s), and 14 ( 2 days) after Implant insertion; 7 (2)days 
after each Implant refill; 1 and 7 (2) day s post -explantation if a patient is continuously followed in the study (prior to study Last Patient In 
Month 9 visit); and 1, 7( 2), 30 (7), and 60 ( 7)days post -explantation if a patient is exiting the stud y, after which a patient will be scheduled 
for the early termination visit 30 ( 7) days later.
dAfter completion of the Month 9 visit, the Implant arms study patients will continue monthly study visits according to Month X (i.e., Month 10, 
Month 11, Mont h 12, etc.) schedule of assessments until the Sponsor decides, based on the primary  analy sis results, to either terminate the 
study and discontinue study treatment ,or offer patients entry into the RPDS Extension Study .
eFor patients who are completing th e study or withdrawing early, perform 90 ( 7) days after the Implant explantation.
fMacTSQ should be interviewer -administered by [CONTACT_8786] (other than VA examiner) prior to any other study procedures.
gRefer to the IxRS Manual for further details.
hVital signs consist of blood pressure and pulse measurement.  Height and weight will also be performed at the screening visit.  On the visits 
when a patient receives treatment, including Day [ADDRESS_667348] prior to fluorescein angiography (if applicable) for women of childbearing potential, including those who have ha d 
tubal ligation. If the urine pregnancy test is positive, collect serum pregnanc y sample and do not perform fluorescein angiography  or study 
treatment until the final results are available. If the serum pregnancy test is positive, do not administer the st udy treatment.
kCollect and perform locally the urine pregnancy test prior to fluorescein angiography and/or study treatment (if applicable) for women of 
childbearing potential, including those who have had tubal ligation. If urine pregnancy test is posit ive, collect serum pregnancy sample and do not 
perform study treatment until the final results are available. If the serum pregnancy test is positive, do not administer the study  treatment.
lMay be collected up to [ADDRESS_667349] explantation safety visit (see protocol Section 4.7.2 and Section 4.7.3 ).
nCollect serum PK sample for ranibizumab concentration from Implant treatment arms patients at the Randomization visit and then at eac h 
monthly visit PRIOR to the treatment, even if treatment is not subsequently given. 
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
122/Protocol GX28228 , Version 8oCollect serum PK sample for ranibizumab concentration from Implant treatment arms patients ≥ [ADDRESS_667350] treatment on Day 1 visit (if 
possible) and then on Days 2, 7(2 days), and 14 ( 2 days) after Day 1 visit; afterwards collect serum PK sample 1 and 7 ( 2) day s after each 
refill.  Collect a serum PK sample at the early termination visit if applicable.  Note:  for patients who are unable to visit the clinic for the PK 
sample collection 1 day after each Implant refill, provision will be made for this timepoint sample collection to be collected at their home.  
Alternatively, the sample may be collected 2 days after the refill.   Training will be provided to site staff on how to perform this task.  The sample 
will be sent to a central laboratory.
pPerform only if possible.
qObtain serum anti -ranibizumab antibody sample from the Implant treatment arms patients prior to the study treatment and prior to fluorescein 
angiography (if applicable) on the Randomization visit, Visits Day 14, Month 1, 3, 6, and [ADDRESS_667351] u ltrasound or optical biometry capability at your site.
wPerform pre -treatment.
xShould be performed in the surgical center using Tono -Pen tomometry  prior to the Implant insertion surger y.
yDilated ophthalmoscopy examinations will be performed for patien ts in the Implant treatment arms after Implant insertion in the study eye at the 
Day 1 visit , and then on Days 2, 7 ( 2 days), and 14 ( 2 day s) after the Day 1 visit; afterward, perform dilated ophthalmoscopy examinations at 
each monthly visit to monitor the Implant and its release control element for visible clogging and other Implant problems.
zHistorical OCT taken at the time of diagnosis of nAMD will also be required to determine patient’s eligibility at the screening visit.  If fluorescein 
angiogram s were taken at the time of diagnosis of nAMD, they must be submitted to the reading center as well . If available, h istorical fluorescein 
angiograms will be evaluated by [CONTACT_171120], but are not required to determine patient’s eligibility.  Refer t o the Reading Center Manuals 
for details.
aaThe central reading center will evaluate fundus photography, fluorescein angiograms, and SD -OCT taken at the screening visit for determination 
of a patient’s eligibility , together with the historical OCT taken at the time of diagnosis of nAMD. Refer to the Reading Center Manual for details.
abOnly at selected sites. Perform pre -treatm ent.
acIn addition to the timepoints listed, the photo will also be taken at any visit if there are concerns with Implant function.
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
123/Protocol GX28228 , Version 8adThe pre -Implant insertion or explantation use of self -administered antimicrobials is required.  The pre- Implant refill use of self -administered 
antim icrobials is per the investigator’s discretion. The post -Implant insertion, explantation, or refill use of self-administered antimicrobials is 
required.
aeThe video of the implant/explant procedure (if applicable) should be recorded. The video of the refill is optional.
afInitially fill the Implant with IxRS as signed kit of ranibizumab prior to its insertion into the study eye.  Afterwards, starting at Month 1 visit, if refill 
criteria are met (see Section 3.1.1 ), refill the Implant with IxRS assigned ranibizumab kit.
agFollowing each Implant refill, patients w ill have a finger counting test, followed by [CONTACT_178784] (when necessary ) 
performed by [CONTACT_514910] [ADDRESS_667352] -treatment for the study eye only; the patients will remain at the clinic for approximately 
40minutes.  I f there are no safety concerns 40 ( 10) minutes following treatment, the patient will be allowed to leave the clinic.  If any safety 
concerns or immediate toxicity is noted, the patient will remain at the clinic and will be treated according to the design ated physician’s clinical 
judgment.  If applicable, the adverse event will be reported on the appropriate eCRF page.  
ahUpon completion of the Implant insertion or explantation procedure, patients will have indirect ophthalmoscopy performed to m onitor th e Implant 
placement and to evaluate any potential Implant problems.  Intraocular pressure will be checked for the study eye only by [CONTACT_514911] .  These assessments must be performed prior to placing a patch on the eye.  If a ny safety concerns or immediate toxicity is 
noted, the patient will remain at the surgical center and will be treated according to the designated physician’s clinical ju dgment.  If applicable, 
the adverse event will be reported on the appropriate eCRF page .
aiFollow Refill Needle return instructions from the laboratory manual if Implant refill has been performed (if applicable).
ajUpon completion of the Implant insertion procedure, complete the Implant insertion evaluation to indicate surgical details of the insertion 
procedure. Information captured in the evaluation will be reported on the appropriate eCRF page.
akRecord any concomitant medications (i.e., any prescription medications or over -the-counter preparations other than protocol -specified 
procedu ral medications, and pre -treatment and post -treatment medications, such as proparacaine, antimicrobials) used by [CONTACT_25701] 
7days preceding the randomization visit date and through the conclusion of the patient’s study participation or early termi nation visit.
alAfter informed consent has been obtained but prior to initiation of study treatment, only serious adverse events related to a protocol -mandated 
intervention (e.g., procedures such as fluorescein angiography, medication wash -out, etc.) shou ld be reported.  Adverse events will be recorded 
starting on Day [ADDRESS_667353] as related to Impla nt 
insertion/refill/explantation should be followed until the event resolves or th e event is assessed as irreversible, chronic, or stable, even if the 
patient’s participation in the study is over.
amRecord all concurrent ocular procedures or additional assessments performed on the study or fellow eye. Results of the additional ocular 
assessments must be forwarded to the Sponsor for evaluation and/or storage.
Appendix 1
Schedule of A ssessments for Implant A rms:  Screening, Randomization, Day 1, Month 1 through 
Month 9, Month X, Safety  Visits, and Final/Early  Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
124/Protocol GX28228 , Version 8anAll study patients will be contact[INVESTIGATOR_530] 3 ( 1) days following study treatment to elicit reports of any decreases in vision, occurrence of eye pain, 
unusual redness, or any other n ew ocular sy mptoms.  Patients will also be asked whether they have taken the prescribed, self -administered, post 
treatment antimicrobials.
aoAqueous humor or vitreous sample collection must be performed at the start of explantation for all patients undergoing an explantation procedure.  
The choice between aqueous humor collection or vitreous collection is per investigator’s discretion (see Appendix 19 ).
Ranibizumab Port Delivery System —Genentech, Inc.
125/P rotocol GX28228 , Version 8Appendix 2
Schedule of A ssessments for ITV arm:  Screening, Randomization /Day 1, Month 1 through 
Month 9, Month X, and Final/Early  Termination Visits
AssessmentScreen 
a
7 
days 
after 
RBZ txRand/
Day 1 b
28 
and 
37 
days 
after 
RBZ txMonth
Month 
X visit cFinal/
ETd1 2 3 4 5 6 7 8 9
Window (Day s) 7 7 7 7 7 7 7 7 7 7 [ADDRESS_667354] IxRS (as 
applicable)fx x x x x x x x x x x x x
Vital signsgx x x x x x x x x x x x x
Central laboratory 
samples (hematology, 
coagulation, serum 
chemistry , and 
urinaly sis)hx
Appendix 2
Schedule of A ssessments for ITV arm:  Screening, Randomization/Day 1, Month 1 through 
Month 9, Month X, and Final/Early Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
126/Protocol GX28228 , Version 8AssessmentScreen 
a
7 
days 
after 
RBZ txRand/
Day 1 b
28 
and 
37 
days 
after 
RBZ txMonth
Month 
X visit cFinal/
ETd1 2 3 4 5 6 7 8 9
Window (Day s) 7 7 7 7 7 7 7 7 7 7 [ADDRESS_667355] 
serum pregnancy sample and do not perform study  treatment until the final results are 
available
BCVA testing (starting at 
4m) x x x x x x x x x x x x x
Low luminance BCVA 
testinglx x x x x x x x x x x x x
Intraocular pressure
(IOP) mx x x x x x x x x x x x x
Slit-lamp examination x x x x x x x x x x x x x
Appendix 2
Schedule of A ssessments for ITV arm:  Screening, Randomization/Day 1, Month 1 through 
Month 9, Month X, and Final/Early Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
127/Protocol GX28228 , Version 8AssessmentScreen 
a
7 
days 
after 
RBZ txRand/
Day 1 b
28 
and 
37 
days 
after 
RBZ txMonth
Month 
X visit cFinal/
ETd1 2 3 4 5 6 7 8 9
Window (Day s) 7 7 7 7 7 7 7 7 7 7 [ADDRESS_667356] Angiography px x x x x x x x x x x x
Lens Photo
(fundus reflex photos) x x x x
Optional whole blood for 
DNA (RCR Sample) x
Appendix 2
Schedule of A ssessments for ITV arm:  Screening, Randomization/Day 1, Month 1 through 
Month 9, Month X, and Final/Early Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
128/Protocol GX28228 , Version 8AssessmentScreen 
a
7 
days 
after 
RBZ txRand/
Day 1 b
28 
and 
37 
days 
after 
RBZ txMonth
Month 
X visit cFinal/
ETd1 2 3 4 5 6 7 8 9
Window (Day s) 7 7 7 7 7 7 7 7 7 7 7
Optional serum sample for 
candidate biomarkers x x x
Optional plasma (EDTA) 
sample for candidate 
biom arkers x x x
Pre- and post -study  
treatment antimicrobials 
(as applicable) qx x x x x x x x x x x
Administration of 
ranibizumab to ITV 
injection arm x x x x x x x x x x x
Post- treatment finger 
counting (as applicable) rx x x x x x x x x x x
Concomitant 
medications sx x x x x x x x x x x x x
Adverse event tx x x x x x x x x x x x
Appendix 2
Schedule of A ssessments for ITV arm:  Screening, Randomization/Day 1, Month 1 through 
Month 9, Month X, and Final/Early Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
129/Protocol GX28228 , Version 8AssessmentScreen 
a
7 
days 
after 
RBZ txRand/
Day 1 b
28 
and 
37 
days 
after 
RBZ txMonth
Month 
X visit cFinal/
ETd1 2 3 4 5 6 7 8 9
Window (Day s) 7 7 7 7 7 7 7 7 7 7 7
Concurrent ocular 
procedures ux x x x x x x x x x x x
Follow -up call (if 
applicable) vx x x x x x x x x x x
AMD age-related macular degeneration; AREDS Age-Related Eye Disease Study ; BCVA best corrected visual acuity; ETend of treatment; 
IOPintraocular pressure; ITV intravitreal; IxRS interactive Voice/W eb response sy stem; MacTSQ Macular Degeneration Treatment 
Satisfaction Questionnaire; NAnot applicable; PK pharmacokinetic; Rand randomization; RBZ ranibizumab; SA safety visit; 
SD-OCT spectral domain optical coherence tomography ; txtreatment.
Notes:  All ocular assessments are to be performed for both eyes prior to study trea tment unless noted otherwise.  All assessments for a visit are to 
be performed on the same day, except those at screening.
aScreening cannot occur earlier than [ADDRESS_667357] study treatment (Day 1) at the conclusion of the ran domization visit 
or later; however no less than [ADDRESS_667358] -
of-care ITV ranibizumab treatment in the study eye.
cAfter completion of the Month 9 visit, the ITV armpatients will continue monthly study visits according to Month X (i.e., Month 10, Month 11, 
Month 12, etc.) schedule of assessments until the Sponsor decides, based on the primary analysis results, to either terminate the study and 
discontinue study treat ment, or offer patients entry into the RPDS Extension Study .
dPatients final study visit or early term ination visit will be scheduled 30 ( 7) days following the last study treatment.  
eMacTSQ should be interviewer -administered by [CONTACT_8786] (other than VA examiner) prior to any other study procedures.
Appendix 2
Schedule of A ssessments for ITV arm:  Screening, Randomization/Day 1, Month 1 through 
Month 9, Month X, and Final/Early Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
130/Protocol GX28228 , Version 8fRefer to the IxRS Manual for details.
gVital signs consist of blood pressure and pulse measurement.  Height and weight will also be performed at the screening visit.  On the visits 
when a patient re ceives treatment ,perform vital s igns measurements pre -treatment.
hObtain from all study patients pre -treatment and prior to fluorescein angiography, if applicable, except early term ination (no time requirement).  
For a description of the laboratory asses sments to be performed, see Section 4.6.6 or the separate laboratory manual.
iObtain sample prior to the study treatment and prior to fluorescein angiography (if applicable).
jCollect serum pregnanc y sample prior to fluorescein angiography (if applicable ) for women of childbearing potential, including those who have 
had tubal ligation. If the serum pregnancy test is positive, do not administer the study treatment .
kCollect and perform locally the urine pregnanc y test prior to fluorescein angiography and study  treatment for women of childbearing potential, 
including those who have had tubal ligation. If urine pregnancy test is positive, collect serum pregnanc y sample and do not perform study 
treatment until the final results are available. If the serum pre gnancy test is positive, do not administer the study treatment.
lPerform low luminance BCVA testing after standard BCVA testing.
mPerform pre -treatment.
nHistorical OCT taken at the time of diagnosis of nAMD will also be required to determine patient’s eligibility at the screening visit.  If fluorescein 
angiograms were taken at the time of diagnosis of nAMD, they must be submitted to the reading center as well . If available, h istorical fluorescein 
angiograms will be evaluated by [CONTACT_171120], but are not required to determine patient’s eligibility .  Refer to the Reading Center Manuals 
for details.
oThe central reading center will evaluate fundus photography, fluorescein angiograms ,and SD -OCT taken at the screening visit for determination
of a patient’s eligibility , together with the historical OCT taken at the time of diagnosis of nAMD .  Refer to the Reading Center Manual for details.
pOnly at selected sites.  Perform pre -treatm ent.
qThe pre -and post -treatment use of self -administered antimicro bials for the ITV injection arm is per the investigator discretion.
rFollowing each ITV treatment with ranibizumab, patients will have a finger counting test, followed by [CONTACT_178799] p erception tests 
(when necessary) performed by [CONTACT_099] w ithin [ADDRESS_667359]- treatment for the study eye only; the patients will remain at the clinic for 
approximately 40 minutes.  If there are no safety concerns 40 ( 10) minutes following treatment, the patient will be allowed to leave the clinic.  If 
any safety concerns or immediate toxicity is noted, the patient will remain at the clinic and will be treated according to th e designated physician’s 
clinical judgment.  If applicable, the adverse event will be reported on the appropriate eCRF page.  
sRecord any concomitant medications (i.e., any prescription medications or over -the-counter preparati ons other than protocol -specified 
procedural medications, and pre- treatm ent and post -treatment medications, such as proparacaine, antimicrobials) used by [CONTACT_25701] 
7days preceding the randomization visit date and through the conclusion of the patient’s study participation or early terminat ion visit.
Appendix 2
Schedule of A ssessments for ITV arm:  Screening, Randomization/Day 1, Month 1 through 
Month 9, Month X, and Final/Early Termination Visits (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
131/Protocol GX28228 , Version 8tAfter informed consent has been obtained but prior to initiation of study treatment, only serious adverse events related to a protocol -mandated 
intervention (e.g., procedures such as fluorescein angiography etc.) should be reported.  Adverse events will be recorded sta rting on Day [ADDRESS_667360] as related to ranibizumab and ITV inj ections should be 
followed until the event resolves or the event is assessed as irreversible, chronic, or stable, even if the patient’s participation in the study is over.
uRecord all concurrent ocular procedures performed on the study or fellow eye.
vAll study patients will be contact[INVESTIGATOR_530] 3 ( 1) day s following study treatment to elicit reports of any decreases in vision , occurrence of eye pain, 
unusual redness, or any other new ocular sy mptoms.  Patients will also be asked whether they have taken the prescribed, self -administered, 
post treatment antimicrobials (if applicable).
Ranibizumab Port Delivery System —Genentech, Inc.
132/P rotocol GX28228 , Version 8Appendix 3
Pre-Screening Visits (if applicable )
AssessmentsaPre-Screening Visit 1 
(Month -2)Pre-Screening Visit 2 
(Month -1)
Window (da ys) +7 [ADDRESS_667361] IxRS X X
Administration of ITV ranibizumab X X
Adverse eventsdX X
IxRS interactive Voice/W eb response s ystem ; PKpharmacokinetic; SD-OCT spectral 
domain optical coherence tomography 
aA pre -screening will be available for newly diagnosed nAMD patients who are treatment 
naïve.  Patient s must satisfy pre -screening eligibility criteria and sign consent to study 
participation before entering the pre -screening.  
bPre-screening evaluations for inclusion/exclusion criteria will only be performed and 
evaluated locally by [CONTACT_514912]; these images will be 
used as historical images for patient’s eligibility at the screening visit.  
dDuring the pre -screening, only serious adverse events related to a protocol -mandated
intervention (e.g .,ITV injection procedure, or ITV ranibizumab) should be reported. Adverse 
events assessed by [CONTACT_514913], 
chronic, or stable, even if the patient’s participation in the study is over.
Ranibizumab Port Delivery System —Genentech, Inc.
133/P rotocol GX28228 , Version 8Appendix 4
Run-In Visit (if applicable)
AssessmentsaRun-In Treatment 
(Month -1)
Window (da ys) +[ADDRESS_667362] IxRS X
Administration of ITV ranibizumab X
Adverse eventsdX
IxRS interactive Voice/W eb response s ystem .
aRun-In treatment will be available for patients who have been: 
odiagnosed with nAMD in the study  eye within 9months prior to screening and treated 
with a single anti -VEGF ITV injection, OR 
odiagnosed with nAMD in the study eye within 9months prior to screening and treated 
with no more than eight anti-VEGF ITV injections, with aflibercept or bevacizumab
being the most recent injection.
Patien ts must satisfy  run-in eligibility criteria and sign consent to study participation before 
completing any study procedures or receiving run- in treatment.
bRun-In evaluations for inclusion/exclusion criteria will only be performed and evaluated locally 
by [CONTACT_737].
cCollect prior to administration of the run- in ITV ranibizumab treatment.
dOnly serious adverse events related to a protocol -mandated intervention (e.g., ITV injection 
procedure, or ITV ranibizumab) should be reported.  Adverse events assessed by [CONTACT_514914] f ollowed 
until the event resolves or the event is assessed as irreversible, chronic, or stable, even if the 
patient’s participation in the study is over.
Ranibizumab Port Delivery System —Genentech, Inc.
134/P rotocol GX28228 , Version 8Appendix 5
Unscheduled Safet y Assessment Visit
Assessmentsa
Vital signs (blood pressure, respi[INVESTIGATOR_1487], pulse, and temperature) x
Best corrected visual acuity (4 -m starting distance)bx
Slit-lamp examination x
Dilated binocular indirect high- magnification ophthalmoscopy x
Intraocular pressurecx
SD-OCT x
Adverse eventsdx
Concurrent ocular procedures x
Concomitant medications x
IOPintraocular pressure ; SD-OCT spectral domain optical coherence tomography .
aAn unscheduled safety visit is applicable to any randomized study patients.  If determined to 
be necessary by [CONTACT_099], perform the listed assessments.  All ocular assessments 
should be performed on both eyes.
bPerform finger -counting test followed by [CONTACT_514915].
cThe method used for the IOP measurement for a patient must remain consistent throughout 
the study.
dAdverse event causality to be evaluated by [CONTACT_178837] .
Ranibizumab Port Delivery System —Genentech, Inc.
135/Protocol GX282 28, Version 8Appendix 6
Implant Treatment A rms Procedures
Please consult Instruction for Use (IFU) Manual for the Implant fill, insertion, refill, and 
explantation details as well as preparation of study drug (ranibizumab) for the Implant 
treatment arms.
Surgeons will be qualified ophthalmologists trained in the management of retinal 
diseases and retinal surgery who will be certified by a [COMPANY_002] -selected vendor prior to 
performing the Implant insertion, its fill, refill, and explantation.
Ranibizumab Port Delivery System —Genentech, Inc.
136/P rotocol GX28228 , Version 8Appendix 7
Pre-Injection Procedures for ITV Treatment A rm
The following procedures will be used to minimize the risk of potential adverse events 
associated with intravitreal (ITV) injections (e.g., endophthalmitis).  Aseptic technique will 
be observed by [CONTACT_514916], anesthetic preparation, 
and study drug preparation and administration.  In addition to the procedures outlined 
below, any additional safet y measures in adherence to specific institutional policies 
associated with ITV injections will be observed. Physician should wear surgical face 
mask and refrain from talking, coughing ,or sneezing during the injection.
The following procedures (except where noted) will be conducted by [CONTACT_514917].  
Patients self -administer edantimicrobials will be prescribed for this treatment arm at the 
investigator’s discretion.  At the discretion of the investigator, site s may use either 
ophthalmic drops or lidocaine injection for study eye anesthesia.
PROCEDURE FOR PROPA RACA INE OR TETRA CAINE-BASED 
ANESTHESI A
Note: Topi[INVESTIGATOR_514834].
If using propa racaine or tetracaine -based ophthalmi c drops for anest hesia, the injecting 
physician or technician (if applicable) assembles the supplies and prepares a sterile field 
with supplies that include the following:
10% povidone iodine swabs, sterile surgical gloves
44 sterile pads
Apack of sterile cotton- tipped applicators
Eyelid speculum
Sterile ophthalmic drape, sterile 0.5% proparacaine hydrochloride or 0.5% 
tetracaine hydrochloride drops (topi[INVESTIGATOR_514835])
5% povidone iodine ophthalmic solution
Injection supplies
PROC EDURE
Instill two drops of proparacaine or tetracaine ophthalmic drops into the study eye.
Wait 5 minutes.
Instill two more drops of proparacaine or tetracaine ophthalmic drops into the study 
eye.
Appendix 7
Pre-Injection Procedures for ITV Treatment A rm (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
137/Protocol GX28228 , Version 8Disinfect the periocular skin and eyelid of the study eye in preparation for injection.  
Scrub the eyelid, lashes, and periorbital skin with 10% povidone iodine swabs, 
starting with the eyelid and lashes and continuing with the surrounding periocular 
skin.  Ensure that the eyelid margins and lashe s are swabbed, and proceed in a 
systematic fashion, from medial to temporal aspects.
The physician will glove, place sterile ophthalmic drape to isolate the field, and place 
the speculum underneath the eyelid of the study eye .
Instill two drops of 5% povidone iodine ophthalmic solution in the study eye, 
ensuring that the drops cover the planned injection site on the conjunctiva.
Wait 90 seconds.
Saturate a sterile, cotton -tipped applicator with propara caine or tetracaine 
ophthalmic drops and hold the swab against the planned intravitreal injection site for 
10 seconds.
Use a sterile 4 4 pad in a single wipe to absorb excess liquid and to dry the 
periocular skin.
Instruct the patient to direct gaze away from syringe prior to study drug injection.
PROCEDURE FOR LIDOCA INE-BASED ANESTHESIA
If using lidocaine injection for anesthesia, physician or technician (if applicable) 
assembles the supplies and prepares a sterile field with supplies that include the
following:
10% povidone iodine swabs, sterile surgical gloves
4 x 4 sterile pads
Apack of sterile cotton tipped applicators
Eyelid speculum
Sterile ophthalmic drape, sterile 0.5% proparacaine hydrochloride or 0.5% 
tetracaine hydrochloride 
5% povidone iodine ophthalmic solution
1% or 2% lidocaine for injection
Injection supplies
PROCEDURE
Instill two drops of proparacaine or tetracaine ophthalmic drops into the study eye.
Disinfect the periocular skin and eyelid of the study eye in preparation for injection.  
Scrub the eyelid, lashes, and periorbital skin with 10% povidone iodine swabs, 
starting with the eyelid and lashes and continuing with the surrounding periocular 
skin.  Ensure that the eyelid margins and lashes are swabbed, and proceed in a 
systematic fashion, from medial to temporal aspects.
Appendix 7
Pre-Injection Procedures for ITV Treatment A rm (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
138/Protocol GX28228 , Version 8The physician will glov e, place sterile ophthalmic drape to isolate the field, and place 
the speculum underneath the eyelid of the study eye.
Instill two drops of 5% povidone iodine ophthalmic solution in the study eye, 
ensuring that the drops cover the planned injection site on the conjunctiva.
Wait 90 seconds.
Saturate a sterile, cotton -tipped applicator with 0.5% proparacaine hydrochloride 
drops and hold the swab against the planned intravitreal injection site for 
10seconds in preparation for the subconjunctival injection of 1% or 2% lidocaine 
hydrochloride ophthalmic solution for injection (without epi[INVESTIGATOR_238]).
Inject 1% or 2% lidocaine (without epi[INVESTIGATOR_238]) subconjunctivally.
Use a sterile 4 x 4 pad in a single wipe to absorb excess liquid and to dry the 
periocular skin.
Instruct patient to direct gaze away from syringe prior to study drug injection.
Ranibizumab Port Delivery System —Genentech, Inc.
139/Protocol GX28228 , Version 8Appendix 8
Preparation and A dministration of Ranibizumab ITVInjection
The physician will prepare the ranibizumab injection as outlined below .
Vials of ranibizumab in aqueous humor solution should remain refrigerated at 2 Cto 8C 
(36Fto 46F) until just prior to use.  DO NOT FREEZE vials.  Protect from direct light.  
Do not use beyond the expi[INVESTIGATOR_320].  In order to minimize the risk of microbial growth, 
dose solutions should be prepared immediately before dosing.  Dose solutions are for 
single use only.
After preparing the stu dy eye as outlined in Appendix 7, withdraw 0.2- mL ranibizumab 
dose solution through a 5 -m filter needle.  Remove the filter needle, replace it with a 
30-gauge , 1/2-inch Precision Glideneedle, and expel excess ranibizumab so that the 
syringe contains 0.[ADDRESS_667363] -injection procedures.
All injection materials (i.e., syringes, needles) wil l be discarded in a sharps container 
immediately following each ranibizumab injection.  
A patient ’s study eye will be monitored with a finger count test within 15minutes of the 
ranibizumab injection by [CONTACT_099].  A measureme nt of IOP in the study eye will be 
obtained 40 (10) minutes post -injection. If there are no safety concerns, the patient will 
be allowed to leave the clinic.  If any safety concerns or immediate toxicity is noted, the 
patient will remain at the clinic and will be treated according to the designated 
physician’s clinical judgment .  The following table provides specific instr uctions for the 
preparation and administration of ranibizumab in aqueous humor solution.
Appendix 8
Preparation and A dministration of Ranibizumab ITVInjection (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
140/Protocol GX28228 , Version 8Step Procedures Materials Methods
1. Filter study drug.
Withdraw 0.2 -mL ranibizumab dose solution 
through a 5 -m filter needle attached to 
provided 1mL syringe.
After withdrawing ranibizumab through the 
filter, remove filter needle, replace it with a 
30-gauge, ½ -inch Precision Glideneedle, 
and expel exc ess ranibizumab so that the 
syringe contains 0.05 -mL ranibizumab 
solution.5-m filter needle (needle is 19 -gauge, 1.5 
TW)
1-mL syringe
Ranibizumab dose solution in the 2-mL
ranibizumab vialTo minimize contamination from skin, 
sterile gloves should be use d before 
handling the study drug vial and other 
supplies.
Use aseptic technique to maintain 
sterility of the surface of the rubber 
stopper.
2. Administer ranibizumab .
Inject 0.05 mL ranibizumab into the eye 
3.5–4.0mm posterior to the limbus.30-gauge, 1/2-inch Precision Glide needle
Ranibizumab dose solution in the s yringe Avoid the horizontal meridian and aim 
toward the center of the globe.  Inject 
slowly.  Remove the needle slowly to 
ensure that all drug solution is in the eye.
3. Discard the syrin ge and all needles on the 
sterile tray in the Sharps container 
immediately following each ranibizumab 
injection.Sharps container 
Ranibizumab Port Delivery System —Genentech, Inc.
141/P rotocol GX28228 , Version 8Appendix [ADDRESS_667364] all syringes and needles in the 
sharps container.
As per investigator’s discretion, i nstruct the patient to self -administer antimicrobial drops 
following each injection of study drug (ranibizumab).
Ranibizumab Port Delivery System —Genentech, Inc.
142/P rotocol GX28228 , Version 8Appendix [ADDRESS_667365] corrected visual acuity (BCVA) will be measured by [CONTACT_514918].  The visual acui ty (VA) examiner will be masked to the patient study 
eye assignment and patient treatment assignment .  The VA examiner will have no 
access to apatient’s previous visits ’VA scores; the VA examiner willonly be aware of
the patient’s refraction data from previous visits .  The VA examiner is not permitted to 
perform any other tasks involving direct patient care except for VA refraction and VA 
examination .  VA will be measured at the intervals specified in the protocol (see 
Section 4.6of the protocol andAppendix 1and Appendix 2).  
EQUIPMENT
The following is needed at minimum to conduct the examination:
Examination lane of adequate dimensions to allow testing at required distances
Standard chair with a firm back
Set of three Precision Vision or Lighthouse distance acuity charts (modified Early 
Treatment Diabetic Retinopathy Study Charts 1, 2, and R)
Retro -illuminated box
Trial frame
Trial lens set
TRAINING A ND CERTIFI CATION
A VA specifications document, procedure manual, and training materia ls will be provided 
to the investigational sites, and VA examiner certification will be obtained.  The VA 
examination room also must be certified before any VA examinations are performed. If 
new VA personnel or VA rooms are added to the study, certification must be obtained 
prior to performing study assessments.
Ranibizumab Port Delivery System —Genentech, Inc.
143/P rotocol GX28228 , Version 8Appendix [ADDRESS_667366] corrected visual acuity described in 
Appendix 10; however, the low luminance visual acuity will be measured by [CONTACT_1299] a 
2.0-log-unit neutral density filter over the best correction for that eye and havin g the 
participant read the normally illuminated Early Treatment Diabetic Retinopathy Study 
chart.
Ranibizumab Port Delivery System —Genentech, Inc.
144/P rotocol GX28228 , Version 8Appendix 12
Grading Scales
GRA DING SCA LE FOR A NTERIOR CHA MBER FLA REOR CELLS
Flare
0 No protein is visible in the anterior chamber when viewed by [CONTACT_514919] -lamp biom icroscopy; a small, bright, focal slit -beam  of white light; and high 
magnification.
Trace Trace amount of protein is detectable in the anterior chamber:  This protein is visible 
only with careful scrutiny by [CONTACT_514920] -lamp biomic roscopy; a 
small, bright, focal slit-beam of white light; and high mag nification.
1 Slight amount of protein is detectable in the anterior chamber:  the presence of protein 
in the anterior chamber is immediately apparent to an experienced observer using 
slit-lamp biomicroscopy  and high magnification, but such protein is detected only with 
careful observation with the naked eye and a small, bright, focal slit -beam of white 
light.
23 Moderate amount of protein is detectable in the anterior chamber.  These grades are 
similar to 1 but the opacity would be readily visible to the naked eye of an observer 
using any source of a focused beam of white light.  This is a continuum of moderate 
opacification, with 2 being less apparent than 3 .
4 A large amount of protein is detectable in the anterior chamber.  This grade is similar 
to 3, but the density of the protein approaches that of the lens.  Additionally, frank 
fibrin deposition is frequently seen in acute circumstances.  It should be noted that 
because fibrin may persist for a period of time after partial or complete restoration of 
the blood aqueous humor barrier, it is possible to have resorbing fibrin present with 
lower numeric assignations for flare (e.g., 1flare with fibrin).
Cells
0 No cells are seen in any optical section when a large slit -lamp beam  is swept across 
the anterior chamber.
Trace Few (1 3) cells are observed when the slit -lamp beam is swept across the anterior 
chamber.  When the instrument is held stationar y, not ever y optical section contains 
circulating cells.
1 310 cells/opt ical section are seen when the slit -lamp beam is swept across the 
anterior chamber.  When the instrument is held stationary, ever y optical section 
contains circulating cells.
2 1025 cells are seen when the slit -lamp beam is swept across the anterior chamber.  
When the instrument is held stationar y, ever y optical section contains circulating cells.
3 2550 cells are seen when the slit -lamp beam is swept across the anterior chamber.  
When the instrument is held stationar y, ever y optical section cont ains circulating cells.  
Keratic precipi[INVESTIGATOR_66306].
4 More than [ADDRESS_667367] 1 circulating cells in the anterior chamber 
with a resolving hypopyon.
Modified from:  Hogan MH, Kimura SJ, Thygeson P. Signs and sy mptoms of uveitis. I. Anterior 
uveitis. Am J Ophthalmol 1959;47(5, Part 2):155 –70.
Appendix 12
Grading Scales (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
145/Protocol GX28228 , Version 8GRA DING SCA LE FOR VITREA L HEMORRHA GE DENSITY
None (0) Retina is visible.
Trace Retina is visible and red blood cells are visible only on slitlamp 
examination.
1 Retinal detail is visible; some hemorrhage is visible by [CONTACT_66366].
2 Large retinal vessels are visible, but central retinal detail is not visible by 
[CONTACT_66366].
3 Red reflex is visible, but no central retinal detail is seen posterior to the 
equator by [CONTACT_66366].
4 No red reflex by [CONTACT_66366].
GRA DING SCA LE FOR VITREOUS CELLS
Cells in 
Retroilluminated Field Description Grade
0 Clear 0
120 Few opacities Trace
2150 Scattered opacities 1
51100 Moderate opacities 2
101 250 Many  opacities 3
251 Dense opacities 4
Modified from:  Nussenblatt RB, W hitcup SM, Palestine AG. Uveitis. Fundamentals and clinical 
practice. 2nd rev. ed. [LOCATION_001]: Mosby, 1996, p. 64.
Ranibizumab Port Delivery System —Genentech, Inc.
146/P rotocol GX28228 , Version 8Appendix 13
Fundus Autofluorescence
SCOPE
Fundus autofluorescence (FAF) will be performed at the study sites by [CONTACT_514921] r eading center.  FAF imaging will be performed for each 
patient at the intervals specified in the protocol (see Appendix 1and Appendix 2) and will 
be forwarded to the central reading center for analysis and/or storage.  Analysis (if 
applicable) of FAF imag es will be performed by [CONTACT_73475].   The list and 
timepoints at which images will be analyzed are recorded in the reading center manual .
EQUIPMENT
Equipment utilized during this trial is described in the Central Reading Center Manual.  
The ability to transfer images to electronically export digital files is required (i.e., no 
printed FAF images will be sent to the central reading center).
PROCEDURES A ND CERTI FICA TION
The central reading center will provide the study manual and training materials.  FAF 
operators, systems, and software will be certified prior to any evaluation of patients.
Ranibizumab Port Delivery System —Genentech, Inc.
147/P rotocol GX28228 , Version 8Appendix 14
Color Fundus Photographs
SCOPE
Color fundus photographs (CFP) will be taken by [CONTACT_178843].
CFP imaging will be performed for each patient at the intervals specified in the protocol 
(see Appendix 1and Appendix 2) and will be forwarded to the central reading center for 
analysis and/or storage. Analysis (if applicable) of fundus photographs will be performed 
by [CONTACT_73475] .
The list and timepoints at which images will be analyzed are recorded in the reading 
center manual. 
EQUIPMENT
See the reading center manual.
PROCEDURE
The central reading center will provide a study manual and training materials.  
Thephotographer and equ ipment will be certified by [CONTACT_514922].
Ranibizumab Port Delivery System —Genentech, Inc.
148/P rotocol GX28228 , Version 8Appendix 15
Fluorescein Angiography
SCOPE
Fluorescein angiography (FA) will be performed at the study sites by [CONTACT_178841].  The FAs will be obtained at the intervals 
specified in the protocol (see Section 4.6of the protocol andAppendix 1and Appendix 2)
and will be forwarded to the central reading center for analysis and/or storage .
The list and timepoints at which images will be analyzed are recorded in the reading 
center manual. 
EQUIPMENT
Digitally based angiograms must be used while conducting an angiographic evaluation 
for the study.
FILM -BASED ANGIOGRA PHY AND CERTIFICA TION
Film-based angiography is not acceptable. 
DIGITA L IMA GING SYST EMS A ND CERTIFICA TION
Digital imaging systems are required .  The system and software at the site will be 
certified by [CONTACT_514923].  This 
certification and validation process will ensure that the central reading center will be able 
to correctly calculate the required measurements.
PROCED URES
The central reading center will provide a study manual and training materials.  
Photographers, systems, and software will be certified prior to obtaining patient 
angiograms.
Ranibizumab Port Delivery System —Genentech, Inc.
149/P rotocol GX28228 , Version 8Appendix 16
Spectral Domain Optical Coherence Tomography
SCOPE
Spectral domain optical coherence tomography ( SD-OCT) will be performed at the study 
sites by [CONTACT_514924] .  SD-OCT 
imaging will be performed for each patient at the intervals specified in the protocol (see 
Section 4.6and Appendix 1and Appendix 2) and will be forwarded to the central reading 
center for analysis and/or storage .
The list and timepoints at which images will be analyzed are recorded in the reading 
center manual. 
EQUIPMENT
Equipment utilized during this trial is described in the central reading center manual.   
Theability to transfer images to electronically expor t digital files is required 
(i.e., noprinted SD-OCT images will be sent to the central reading center).
PROCEDURE S AND CERTIFICA TION
The central reading center will provide the study manual and training materials.  
SD-OCT operators, systems, and software will be certified prior to any evaluation of 
patients.
Ranibizumab Port Delivery System —Genentech, Inc.
150/P rotocol GX28228 , Version 8Appendix 17
External and Implant Photographs
SCOPE
External and Implant photographs will be taken by [CONTACT_514925].
Implant imaging will be performed for Implant patients only at Day 2 after Day 1 visit and 
at each study visit as specified i n the protocol (see Appendix 1) and will be forwarded to 
the central reading center for analysis and/or storage.  Analysis (if applicable) of fundus 
photographs will be performed by [CONTACT_73475].
The list and timepoints at which images will be analyzed are recorded in the reading 
center manual.
EQUIPMENT
See the reading center manual.
PROCEDURE
The central reading center will provide a study manual and training materials.  The 
photographer and equipment will be certified by [CONTACT_178844].
Ranibizumab Port Delivery System —Genentech, Inc.
151/Protocol GX28228 , Version 8Appendix 18
Optical Coherence T omography Angiography  (at Selected Sites)
SCOPE
Optical coherence tomography ( OCT ) angiography will be performed only at selected 
study sites that have OCT angiography equipment by[CONTACT_514926]. OCT angiography imaging will be performed for each 
patient at the intervals specified in the protocol (see Appendix 1and Appendix 2) and will 
be for warded to the central reading center for analysis and/or storage.
The list and timepoints at which images will be analyzed are recorded in the reading 
center manual. 
EQUIPMENT
Equipment utilized during this trial is described in the central reading center manual.  
OCT a ngiography will be performed using Optovue AngioVueTMImaging System only
with the AngioVueTMsoftware. The ability to transfer images to electronically export 
digital files is required (i.e., no printed OCT a ngiography images will be sent to the 
central reading center).
PROCEDURES A ND CERTI FICA TION
The central reading center will provide the study manual and training materials. OCT 
angiography operators, systems, and software will be certified prior to any evaluation of 
patients.
Ranibizumab Port Delivery System —Genentech, Inc.
152/P rotocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
153/P rotocol GX28228 , Version 8

Ranibi zumab Port Delivery System —Genentech, Inc.
154/P rotocol GX28228 , Version 8

Ranibi zumab Port Delivery System —Genentech, Inc.
155/P rotocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
156/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
157/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
158/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
159/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
160/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
161/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
162/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
163/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
164/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
165/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
166/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
167/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, In c.
168/P rotocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
169/P rotocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
170/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
171/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
172/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
173/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
174/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
175/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
176/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
177/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
178/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
179/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
180/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
181/Protocol GX28228 , Version 8

Ranibizumab Port Delivery System —Genentech, Inc.
182/P rotocol GX28228 , Version 8Appendix 20
Central Laboratory  Sample Collection and Shippi[INVESTIGATOR_514836] L SAMPLES
Serum for assessment of laboratory safety (hematology, serum chemistry, coagulation, 
pregnancy test) and urinalysis will be collected at screening visit.  Urine pregnancy test 
will be coll ected and performed at Day [ADDRESS_667368] is positive, the study 
treatment will be discontinued.  Serum for assessment of ranibizumab concentrations 
(pharmacokinetics) and anti -ranibizumab antibodies, residual content of the Implant f rom 
the Refill Needle (if applicable), and aqueous humor or vitreous samples (at the start of 
explantation for patients undergoing an explantation procedure) will be collected at the 
timepoints specified in Section 4.6.6 of the protocol and the schedule of assessments
(see Appendix 1and Appendix 2).  The optional aqueous humor samples prior to one or 
more refills and at the Day [ADDRESS_667369] refill will be collected as well.
Allsample sshould be collected and shipped initially to the central labora tory.  The 
laboratory safety (hematology, serum chemistry, coagulation, and urinalysis) samples 
will be analyzed by [CONTACT_2237].  The rest of the collected samples will be 
analyzed by [CONTACT_178850]. All necessary transfer tubes, labels, forms, 
and shippi[INVESTIGATOR_178739].   
OPTIONA L ANTERIOR CH AMBER ( AQUEOUS HUMOR ) SAMPLE 
COLLECTION FROM IMPLA NT TREA TMENT A RMS
The optional aqueous humor paracentesis samples will be collected from patients who 
consent to the procedure and sample acquisition.  An aqueous humor sample will be 
collected prior to or immediately following the patient’s study eye treatment visits as 
indicated in Appendix 1.  The aqueous humor sample collection consists of an anterior 
chamber paracentesis ( removing 0.05 to 0.1mL of fluid from the anterior chamber of the 
eye).
The anterior chamber paracentesis will be performed by a qualified physician b y placing 
a drop of topi[INVESTIGATOR_178740], passing a [ADDRESS_667370] be injected into 
the eye pr ior to study treatment .
Appendix 20
Central Laboratory  Sample Collection and Shi ppi[INVESTIGATOR_007] (cont.)
Ranibizumab Port Delivery System —Genentech, Inc.
183/Protocol GX28228 , Version 8EYE FLUID SAMPLE COLLECTION FR OM IMPLA NT TREA TMENT ARMS
Vitreous or aqueous humor sample collection must be performed at the start of 
explantation for all patients undergoing an explantation procedure.  The choice between 
vitreous collection or aqueous humor collection is per investigator’s discretion .  
The aqueous humor sample collection consists of an anterior chamber paracentesis 
(removing 0.050.1mL of fluid from the anterior chamber of the eye).
The vitreous humor sample collection consists of a vitreous tap (removing 
0.05 0.1mL of undiluted vitreous from the central vitreal cavity ).
The vitreous humor sample collection will be performed by a qualified physician using
standard 23-gauge or [ADDRESS_667371] are under development.  
In addition, the explan ted Implants may undergo physical inspec tion and/or functional 
testing.
Refer to the Study Manual for detailed sample collection, storage, and shippi[INVESTIGATOR_3930].  All necessary transfer tubes, Vacutainers , labels, shippi[INVESTIGATOR_19263], 
andforms will be provided by [CONTACT_2237].
Ranibizumab Port Delivery System —Genentech, Inc.
184/P rotocol GX28228 , Version 8Appendix 21
Ranibizumab Port Delivery  System:  Device Clinical
Investigation Plan
Ranibizumab Port Delivery  System —Genentech,  Inc. 
185/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
  TABLE OF CONTENTS 
1. GENERAL  ................................................................................................. 195 
2. IDENTIFICATION AND DESCRIPTION OF THE 
INVESTIGATIONAL DEVI CE .................................................................... 196 
2.1 SUMMARY DESCRIPTION OF THE 
INVESTIGATIONAL DEVICE AND ITS 
INTENDED PURPOSE ........................................................ 197 
2.1.1 Implant  ................................................................................. 197 
2.1.2 Initial Fill Needle  .................................................................. 199 
2.1.3 Insertion Tool  ....................................................................... 200 
2.1.4 Refill Needle  ........................................................................ 201 
2.1.5 Explant Tool  ......................................................................... 202 
2.2 DETAILS CONCERNING THE MANUFACTURER OF THE INVESTIGATIONAL 
DEVICE  ............................................................................... 203 
2.3 NAME [CONTACT_514957]/TYPE TO PERMIT FULL IDENTIFICATION ........................................ [ADDRESS_667372] WITH TISSUES OR 
BODY FLUIDS ..................................................................... 204 
2.7.1 Implant  ................................................................................. 205 
2.7.2 Initial Fill Needle  .................................................................. 205 
2.7.3 Insertion Tool  ....................................................................... 206 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
186/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 2.7.4 Refill Needle  ........................................................................ 206 
2.7.5 Explant Tool  ......................................................................... 207 
2.8 SUMMARY OF THE NECESSARY TRAINING 
AND EXPERIENCE NEEDED TO USE THE INVESTIGATIONAL DEVICE SYSTEM  ............................... 208 
2.9 DESCRIPTION OF THE SPECIFIC MEDICAL OR SURGICAL PROCEDURES INVOLVED IN 
THE USE OF THE INVESTIGATIONAL DEVICE  ................ 208 
3. JUSTIFICATION FOR THE DESIGN OF THE CLINICAL 
INVESTIGATION ...................................................................................... 209 
3.1 EVALUATION OF THE RESULTS OF THE RELEVANT PRECLINICAL 
TESTING/ASSESSMENT CARRIED OUT TO 
JUSTIFY THE USE OF THE INVESTIGATIONAL 
DEVICE IN HUMAN SUBJECTS  ......................................... 212 
3.2 EVALUATION OF CLINICAL DATA THAT ARE RELEVANT TO THE PROPOSED CLINICAL INVESTIGATION ................................................................. 213 
4. RISKS AND BENEFITS OF THE INVESTIGATIONAL DEVICE AND CLINICAL INVESTI GATION  ............................................................. 213 
4.1 ANTICIPATED CLINICAL BENEFITS ................................. 213 
4.2 ANTICIPATED ADVERSE DEVICE EFFECTS  ................... 214 
4.3 RESIDUAL RISKS ASSOCIATED WITH THE INVESTIGATIONAL DEVICE, AS IDENTIFIED IN THE RISK ANALYSIS REPORT  ..................................... 214 
4.4 RISKS ASSOCIATED WITH PARTICIPATION IN THE CLINICAL INVESTIGATION ........................................ 214 
4.5 POSSIBLE INTERACTIONS WITH CONCOMITANT MEDICAL TREATMENTS  ........................ 215 
4.6 STEPS THAT WILL BE TAKEN TO CONTROL OR MITIGATE THE RISKS  ................................................. 215 
4.7 RISK- TO-BENEFIT RATIONALE  ........................................ 216 
5. OBJECTIVES AND HYPOTHESES OF THE CLINICA L 
INVESTIGATION ...................................................................................... 216 
5.1 DEVICE OBJECTIVES ........................................................ 216 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
187/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 5.2 HYPOTHESES, IMPLANT FUNCTIONALITY TO 
BE ACCEPTED OR REJECTED BY [CONTACT_514927] ................................................................. 216 
5.3 CLAIMS AND INTENDED PERFORMANCE OF THE IMPLANT THAT ARE TO BE VERIFIED ..................... 217 
5.4 RISKS AND ANTICIPATED ADVERSE DEVICE 
EFFECTS THAT ARE TO BE ASSESSED  .......................... 218 
6. DESIGN OF THE CLINICAL INVESTIGATION ........................................ 218 
6.1 GENERAL  ........................................................................... 218 
6.1.1 Type of Clinical Investigation and Rationale  ........................ 218 
6.1.2 Measures to Minimize or Avoid Bias  .................................... 219 
6.1.3 Device Endpoints, with Rationale for Their Selection and Measurement  ................................................ 219 
6.1.4 Methods and Timing for Assessing, Recording, and Analyzing Variables  ...................................................... 220 
6.1.5 Equipment to be Used for Assessing the Clinical Investigation Variables and Arrangements for Monitoring Maintenance and Calibration ............................. 220 
6.1.6 Procedures for the Replacement of Subjects  ...................... 220 
6.2 INVESTIGATIONAL DEVICE(S) AND 
COMPARATOR(S)  .............................................................. 220 
6.2.1 Description of the Exposure to the Investigational 
Device(s) or Comparator(s), If Used .................................... 220 
Patients in the ITV Injection Treatment (Control) Arm  ............................... 220 
6.2.2 Justification of the Choice of Comparator(s)  ........................ [ADDRESS_667373] Withdrawal or Discontinuation  ................................................................ 221 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
188/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 6.3.[ADDRESS_667374]'s 
Participation  ......................................................................... [ADDRESS_667375] this Number (i.e., Enrolment Period)  ........................................................ 222 
6.4 PROCEDURES  ................................................................... 222 
6.4.1 Description of All the Clinical- investigation-
related Procedures that Subjects Undergo During 
the Clinical Investigation ...................................................... 222 
6.4.2 Description of Those Activities Performed by [INVESTIGATOR_391931] (Excluding Monitoring)  ................ 223 
6.4.3 Any Known or Foreseeable Factors That May 
Compromise the Outcome of the Clinical 
Investigation or the Interpretation of Results  ....................... 223 
6.4.4 Monitoring Plan  .................................................................... 223 
7. STATISTICAL CONSIDER ATIONS  .......................................................... 223 
7.1 STATISTICAL DESIGN, METHOD AND ANALYTICAL PROCEDURES  ............................................ 223 
7.2 SAMPLE SIZE ..................................................................... 224 
7.3 THE LEVEL OF SIGNIFICANCE AND THE 
POWER OF THE DEVICE CLINICAL INVESTIGATION ................................................................. 224 
7.4 EXPECTED DROP- OUT RATES  ........................................ 225 
7.5 PASS/FAIL CRITERIA TO BE APPLIED TO THE 
RESULTS OF THE DEVICE CLINICAL 
INVESTIGATION ................................................................. 225 
7.6 FLEXIBLE INTERIM ANALYSIS  .......................................... 226 
7.7 CRITERIA FOR THE TERMINATION OF THE CLINICAL INVESTIGATION ................................................ 226 
7.8 SUBGROUPS  ...................................................................... 226 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
189/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 7.9 PROCEDURES THAT TAKE INTO ACCOUNT 
ALL DAT A ............................................................................ 226 
7.10 MISSING, UNUSED OR SPURIOUS DATA; EXCLUSION OF PARTICULAR INFORMATION ................ 226 
7.11 NUMBER OF SUBJECTS TO BE INCLUDED 
FOR EACH CENTER  .......................................................... 226 
8. DATA MANAGEMENT  .............................................................................. 226 
8.1 DATA REVIEW  .................................................................... 226 
8.2 VERIFI CATION, VALIDATION AND SECURING 
OF ELECTRONIC CLINICAL DATA SYSTEMS .................. 227 
8.3 DATA RETENTION AND SPECIFIED 
RETENTION PERIOD  ......................................................... 227 
8.4 OTHER ASPECTS OF CLINICAL QUALITY ASSURANCE  ...................................................................... 227 
9. AMENDMENTS TO THE RP DS CIP ......................................................... 227 
10. DEVIATIONS FROM CLINICAL INVESTIGATION PLAN ......................... 227 
10.1 RECORDING, REPORTING AND ANALYZING RPDS CIP DEVIATIONS  ..................................................... 227 
10.2 CORRECTIVE AND PREVENTIVE ACTIONS .................... 228 
11. DEVICE ACCOUNTABILIT Y ..................................................................... 228 
12. STATEMENTS OF COMPLI ANCE  ........................................................... 228 
13. INFORMED CONSENT PROCESS  .......................................................... 229 
14. ADVERSE EVENTS, ADVERSE DEVICE EFFECTS A ND 
DEVICE DEFICIENCIES  ........................................................................... 229 
14.1 DEFINITIONS OF ADVERSE EVENTS AND 
ADVERSE DEVICE EFFECTS  ............................................ 229 
14.2 DEFINITION OF DEVICE DEFICIENCIES  .......................... 229 
14.3 DEFINITIONS OF SERIOUS ADVERSE 
EVENTS AND SERIOUS ADVERSE DEVICE EFFECTS AND, WHERE APPROPRIATE, 
UNANTICIPATED SERIOUS ADVERSE DEVICE 
EFFECTS  ............................................................................ 229 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
190/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 14.[ADDRESS_667376] DETAILS FOR 
REPORTING SERIOUS ADVERSE EVENTS 
AND SERIOUS ADVERSE DEVICE EFFECTS  .................. 231 
14.9 INFORMATION REGARDING THE SAFETY REVIEW COMMITTEE ........................................................ 231 
15. VULNERABLE POPULATIO N .................................................................. 231 
15.1 SPECI FIC INFORMED CONSENT PROCESS  ................... 231 
15.2 ETHICS COMMITTEE'S SPECIFIC 
RESPONSIBILITY ............................................................... [ADDRESS_667377] OF T ABLES  
Table 1  Material of Construction of Implant  ........................................... 205 
Table 2  Material of Construction of Initial Fill Needle  ............................. 205 
Table 3  Materials of Construction of Insertion Tool  ................................ 206 
Table 4  Materials of Construction of Refill Needle  ................................. 207 
Table 5  Materials of Construction of Explant Tool  ................................. 208 
Table 6  Operation States for the Implant  ............................................... 210 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
191/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
  
 LIST OF FIGURES  
Figure 1 Port Delivery Implant in the Eye ................................................ 197 
Figure 2 Implant  ...................................................................................... 198 
Figure 3 Initial Fill Needle  ........................................................................ 200 
Figure 4 Insertion Tool  ............................................................................ 201 
Figure 5 Refill Needle  .............................................................................. 202 
Figure 6 Explant Tool  .............................................................................. 203 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
192/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
Abbreviation  Definition  
ADE adverse device effect  
AE adverse event  
AMD  age-related macular degeneration 
BCVA  best corrected visual acuity  
BLQ below  the lower limit of quantification  
CIP Clinical Investigational  Plan 
DME  diabetic  macular  edema 
EC Ethics  Committee  
eCRF  electronic case report form 
ETDRS  Early Treatment Diabetic  Retinopathy St udy 
FSV4  Forsight  Vision4  
GCP  Good Clinical  Practice  
HA Health Authority  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation of 
Technical Requirements for Registration  of 
Pharmaceuticals  for Human Use 
ICF Informed Consent Form  
IFU instructions  for use  
IMC Internal  Monitoring Committee  
IMP investigational medicinal product  
IND Investigational New Drug (application)  
IRB Institutional  Review Board 
ISO International Organization for Standardization 
ITV intravitreal  
PK pharmacokinetic  
RCE  Release Control Element  
RPDS  Ranibizumab Port Delivery  System  
SAE serious  adverse event  
VEGF  vascular endothelial growth factor  
VA visual acuity  
Ranibizumab Port Delivery  System —Genentech,  Inc. 
193/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 GLOSSARY OF TERMS  
Assessment  A procedure  used to generate data required by [CONTACT_514928]  A group of newly enrolled patients treated at a specific  
dose and regimen (i.e. treatment group)  at the same  time 
Control drug  Any drug (an active drug or an inactive drug, such as a 
placebo) which is used as  a comparator to the drug being 
tested in the  trial 
Dose level  The dose of drug given to the patient (total daily or  
weekly etc.) 
Enrollment  Point/time of  patient entry into the study at which  informed 
consent must be obtained (i.e. prior to starting any of the 
procedures  described in the  protocol)  
Investigational drug  The drug whose properties are being tested in the 
study; this definition is consistent with U.S. Code of  
Federal Regulations 21 Section  312.3 and is  
synonymous  with “investiga tional new drug” or  
“investigational medicinal product.”  
Investigational treatment  All investigational drug(s) whose properties are being  
tested  in the study  as well as their associated treatment  
controls.  
This includes  any placebos, any active controls, as well  as 
approved drugs used outside of their indication/approved 
dosage or tested in a fixed  combination.  
Investigational treatment  generally  does not include 
protocol -specified concomitant background therapi[INVESTIGATOR_514837]  A unique identifier  on the label of each  
investigational/study drug package in studies that 
dispense medication using  an Interactive Response 
Technology system  
Protocol  A written account of all the procedures to be followed  in a 
trial, which describes  all the administrative,  documentation, 
analytical and clinical processes used in the trial. 
Part A single component  of a study which contains different  
objectives or  populations  within that single study.  
Common parts within a study are: a single dose part  and a 
multiple dose part, or  a part in patients with established 
disease and in those with newly -diagnosed disease.  
Period  A subdivision of a cross- over study  
Ranibizumab Port Delivery  System —Genentech,  Inc. 
194/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
  
Premature subject/patient  
withdrawal  Point/time when the patient  exits from the study prior to  the 
planned completion of  all study treatment  administration 
and/or assessments; at this time all study  treatment 
administration is discontinued and no further  assessments 
are planned, unless the patient  will be followed  for 
progression and/or  survival  
Randomization number  A unique identifier assigned to  each randomized 
patient, corresponding to a specific treatment arm  
assignment  
Study drug/ treatment  Any single drug or combination  of drugs administered to 
the patient as part of the required study procedures;  
includes  investigational drug (s), active  drug run-ins or  
background therapy  
Study/investigational  
treatment  discontinuation  Point/time when patient  permanently  stops taking 
study/investigational treatment for any reason; may or  
may not also be the point/time of premature patient  
withdrawal  
Subject Number  A number assigned to each patient who enrolls  into the 
study  
Variable A measured value or assessed response that  is 
determined in specific assessments and  used in data  
analysis  to evaluate the drug being tested  in the study  
Ranibizumab Port Delivery  System —Genentech , Inc. 
195/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 1. GENERAL  
The Ranibizumab Port Delivery  System  (RPDS)  Device  Clinical Investigational Plan (CIP)  
describes  the data that will be extracted from the Phase II study  (GX28228)  that is being  
conducted with the RPDS  in order  to assess  its safety  and performance. This CIP also 
focuses  on the endpoints  and analyses  that will demonstrate that the RPDS works  as 
intended. The purpose of the CIP is to comply  with the International Organization for 
Standardization (ISO) [ADDRESS_667378] "Clinical investigation of medical  devices  for 
human subjects", to assess the Implant safety  and performance. The CIP will also be 
used  to support  obtaining a Conformité Européenne (CE; European Conformity)  
certificate,  which  is necessary  for regulatory  approval  in the European Economic  Area. 
This CIP is intended to complement the Phase II pi[INVESTIGATOR_108516], which  will collect the 
clinical  information needed to fulfill the Essential  Requirements  of the European Medical  
Device  Directive. Data are collected as part of the Phase II protocol. This CIP is 
specifically  designed to investigate the functionality  of the Implant while the ancillary  
devices’  functionality  will mainly  be demonstrated as part of engineering/  design  
verification testing and human  factor  engineering studies.  
Age-related macular degeneration (AMD) is a chronic  disorder  of the macula and is the 
most  common cause of irreversible vision loss in older  Americans  and Europeans.  AMD  
is categorized into two subtypes, dry and wet, based on clinical  examination, ocular  
imaging, and pathologic  findings. Dry AMD  represents  approximately  80% to 90% of 
AMD  cases.  In approximately  10% of dry AMD  cases,  a conversion to wet, or 
neovascular, AMD  occurs  over time. Although wet AMD  is comparatively  rare, prior to 
the development of anti-vascular endothelial growth  factor  (anti-VEGF) therapy, it 
accounted for the majority  of severe vision loss from AMD.  Central  vision loss is painless  
and emerges  gradually  or suddenly  (Bressler 1995; Kle in et al. 1997). 
Ranibizumab, a recombinant, humanized monoclonal  antibody  fragment (Fab), which  
binds  to all known isoforms  of VEGF-A, was first registered for use in neovascular  wet 
AMD  in the [LOCATION_002]  on 30 June 2006 and in the European Union on 22 January  
2007 and has a well-established efficacy  and safety  profile. 
Ranibizumab is approved for the treatment  of wet AMD,  macular edema secondary  to 
retinal  vein occlusion, diabetic  macular  edema (DME), and diabetic  retinopathy  in DME.  
In the European Union, ranibizumab is also approved for the treatment of choroidal  
neovascularization due to pathological  myopia. The primary treatment modality  is 
injection of ranibizumab into the vitreous  humor of the patient’s  eye. 
Ranibizumab Port Delivery  System —Genentech , Inc. 
196/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 Ranibizumab is injected directly  into the vitreous  humor of the eye. Intravitreal  (ITV)  
injections  of ranibizumab have shown  efficacy  in treating these  ocular diseases, however,  
a drug delivery  system  that could reduce the burden of reg ular, often monthly, injections  
while maintaining satisfactory  clinical  outcomes  is desired. Ranibizumab has been  
studied extensively  to date and treatment  with ITV injection has been demonstrated to be 
effective in preventing vision loss associated with VEGF -related retinal disorders. For 
many  patients  with VEGF-driven ocular diseases,  long-term  managment involving  
frequent, repeated ranibizumab ITV injections  and monitoring visits  is required.  
Frequent clinic  visits can place a significant burden on the p atients  and their caregivers  
as well as treating physicians  and the healthcare  system.  
Administration of ranibizumab through an intra- ocular  implant  with a drug reservoir  and a  
controlled release element may enable sustained delivery  over extended periods  of time,  
to substantially  reduce the number of ITV injections  while achieving similar  efficacy  to 
monthly  injections. This decrease in treatment burden could reduce the risk from ITV 
injection- related adverse events  (AE), increase treatment compliance, and reduce the 
burden to patients, their caregivers, and the healthcare system  while maintaining  
optimum  visual  outcomes. 
2. IDENTIFICATION AND DESCRIPTION OF THE 
INVESTIGATIONAL DEVI CE 
The RPDS  is a novel, investigational  intraocular  drug delivery  system  designed to be 
used specifically  with ranibizumab. The system  consists  of an intraocular  Implant along  
with four ancillary  devices. 
The Implant is a refillable  drug reservoir. It is filled with ranibizumab before it is inserted  
into the eye through the pars plana.  The Implant is secured within the sclera, with an 
injection port that remains  visible through the conjunctiva following insertion.  Once  filled 
with ranibizumab,  the Implant is designed to provide sustained release of ranibizumab  for 
the treatment of patients  with neovascular  wet AMD.  The Implant can be refilled with 
ranibizumab in situ via an injection through the conjunctiva and Implant septum. 
The RPDS consists  of five components: 
• Implant 
• Insertion Tool 
• Initial  Fill Needle 
• Refill  Needle 
• Explant Tool 
Ranibizumab Port Delivery  System —Genentech , Inc. 
197/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
  
Each of these components  is a novel,  investigational device, specifically  designed as part 
of the RPDS.  
Figure [ADDRESS_667379] is provided by [CONTACT_33641], 
ranibizumab. 
The Implant is intended  for surgical  placement  through the pars plana of the eye (see  
Figure 1 ). The distal  end of the Implant extends  into the vitreous  humor with the proximal  
end accessible through the conjunctiva.  When in place, an injection port is visible 
through the conjunctiva,  and ranibizumab is refilled into the Implant through a septum that 
is in contact [CONTACT_514929], thus not requiring repeat penetration of the sclera  or 
choroid. The Implant is designed to contain approximately  20 µL of ranibizumab solution 
when filled. 
The rate of ranibizumab release from the Implant into the vitreous  is controlled by 
[CONTACT_514930], concentration gradient -driven  molecular diffusion through the porous  distal  end 
of the Implant. This porous  barrier, known as the Release Control  Element (RCE),  allows  

Ranibizumab Port Delivery  System —Genentech , Inc. 
198/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 molecules  to diffuse at a rate dependent on the diffusivity  of the molecule and the 
concentration gradient across the RCE.  
The Implant is filled with ranibizumab solution  with a custom  Initial  Fill Needle prior to 
insertion.  After placement of the Implant, subsequent  injections  are performed with a 
custom  Refill  Needle that allows  for the exchange of the contents  of the Implant (residual  
ranibizumab, vitreal  components)  with the new ranibizumab solution.  
The Implant is presented  below  in Figure 2 . No material  or design changes  are expected 
after the clinical  batch release of the Phase II Implant. 
Figure 2 Implant  
 
 
The Implant is a refillable  reservoir  designed for intravitreal insertion through the pars 
plana. The Implant consists  of four primary  components  (Figure 2 ): 
• Extrascleral  flange  
• Septum  
• Body  
• RCE  
 

Ranibizumab Port Delivery  System —Genentech , Inc. 
199/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
 Once  inserted in the eye, the body  and the release control  element of the Implant extend  
into the vitreous  cavity,  while the flange anchors  the Implant within the sclera. 
The extrascleral  flange provides secure anchoring  of the Implant within the  sclera and is 
encased in silicone.  
The septum is a self -sealing interface through which ranibizumab is injected into the 
Implant both prior to insertion and during subsequent refills in situ. 
The body of the Implant contains the drug reservoir, which holds  approximately 20 µL of 
drug. The Implant  arrives with an empty  reservoir. The reservoir is filled with ranibizumab 
by [CONTACT_514931]. 
The RCE  controls  the rate of ranibizumab diffusion from the drug reservoir  into the 
vitreous. 
The Implant is packaged in a sterile blister.  
2.1.2 Initial Fill  Needle  
The Initial  Fill Needle is a needle designed to fill the Implant with ranibizumab  prior to 
Implant insertion.  The Initial  Fill Needle consists  of five primary components  (Figure 3 ): 
• Needle (33-gauge)  
• Soft stop 
• External  hub 
• Luer hub 
• Blue cap 
 
The needle contains a specialized external hub. This hub will be used to guide the 
syringe along the needle guide channel of the Insertion Tool so that the needle tip will be 
properly aligned with the Implant septum for Implant filling.  
The soft stop surrounds the needle at the junction of the needle and the external hub. The soft stop provides a seal with the septum during Implant filling.  
The Initial Fill Needle is packaged in a sterile pouch. 
  
Ranibizumab Port Delivery  System —Genentech , Inc. 
200/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
  
Figure 3 Initial Fill Needle  
 
  
2.1.3 Insertion Tool  
The Insertion  Tool is a handheld ophthalmic  instrument designed to facilitate  handling of 
the Implant during the initial filling and insertion procedures . The Insertion  Tool consists  
of four primary components  (Figure 4 ): 
• Insertion Tool tips 
• Finger  grips  
• Stainless  steel  shafts  
• Needle guide channel  
 
The Insertion Tool arrives preloaded with the Implant in a sterile  plastic  tray packaged in 
a sterile pouch.   

Ranibizumab Port Delivery  System —Genentech , Inc. 
201/Protocol  GX28228, Version 8 Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
  
Figure 4 Insertion Tool  
 
  
2.1.4 Refill Needle 
The Refill  Needle is designed to simultaneously  exchange the contents  of the Implant 
reservoir  with new ranibizumab in situ. The Refill  Needle consists  of five primary  
components  (Figure 5 ): 
• Vented needle (34-gauge) 
• Soft stop 
• Fluid collection reservoir  
• Luer hub 
• Clear cap 
 
The vented needle and fluid collection reservoir  enable exchange of ranibizumab  
between the Implant and the refill syringe. As fresh  drug solution is injected into the 
Implant through the needle,  fluid remaining in the Implant flows  through openings  in the 
vented needle and is collected into the fluid collection reservoir. 
The soft stop provides  a non-traumati c contact [CONTACT_514932].  
The Refill  Needle is packaged in a sterile blister.  

Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
202/Protocol  GX28228, Version 8   
Figure 5 Refill Needle 
 
  
2.1.5 Explant Tool  
The Explant Tool consists  of a set of forceps  with contoured tips. The contoured tips are 
designed to grasp underneath the Implant flange and securely  pull the Implant for 
explantation (Figure 6 ). 
The Explant Tool is packaged in a sterile blister . 

Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
203/Protocol  GX28228, Version 8  Figure 6 Explant  Tool  
 
 
 
2.2 DETAILS CONCERNING THE MANUFACTURER OF T HE 
INVESTIGATIONAL DEVI CE 
The Sponsor (Genentech) is the manufacturer for the investigational device.   The 
Contract Manufacturing Organizations involved in the manufacture of the RPDS dev ices 
are a) ) or b)  
).  
2.3 NAME [CONTACT_514957]/TYPE TO PERM IT FULL 
IDENTIFICATION  
Each RPDS device package is labeled with the name [CONTACT_514958].  
• Implant/Insertion Tool 
• Initial  Fill Needle 
• Refill  Needle 
• Explant Tool 
 
2.[ADDRESS_667380] (IMP; ranibizumab)  and RPDS  required for 
completion of this study  (including  all the components  of the RPDS)  will be provided by 
[CONTACT_1034].  In order  to ensure traceability,  each RPDS device will be identified by a 
batch  number.  

Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
204/Protocol  GX28228, Version 8  2.5 INTENDED PURPOSE OF THE INVESTIGATIONAL DEVICE IN 
THE PROPOSED CLINICAL INVESTIGATION 
The following are the intended use of the RPDS  devices : 
• Implant: The Implant is intended to be inserted through the pars plana of the eye to 
deliver  ranibizumab in a controlled manner  into the vitreous  humor. The physician 
will initially  fill the reservoir  with the drug and refill it in accordance with the 
instructions  for use. The RPDS  is contraindicated for use with medications  other 
than ranibizumab.  
• Insertion Tool:  The Insertion  Tool is designed to a) hold the Implant during  
sterilization and insertion,  b) assist  with filling of the Implant before insertion,  and c) 
enable insertion of the Implant through a pars plana sclerectomy.  
• Initial  Fill Needle:  The Initial Fill Needle is a 33-gauge Luer-Lock  needle  designed to 
perform  the initial  fill of the Implant while the Implant is held in the Insertion  Tool. 
• Refill  Needles:  The Refill  Needle is a Luer-Lock  needle designed to simultaneously  
exchange (in situ) any remaining old drug product  in the Implant  reservoir  with new 
drug product. 
• Expla nt Tool: The Explant Tool is designed to enable the removal of the Implant 
from the posterior  segment of the eye after resection of the conjunctiva and removal 
of any scar tissue.  
 
For addition
al RPDS  details  (e.g., fill, insertion, refill, and explantation of the Implant),  
consult the RPDS  instructions  for use (IFU) document and RPDS Investigator’s  Brochure 
(IB) Section 3. 
2.[ADDRESS_667381] contact[CONTACT_514933], manufacturing 
processes, and sterilization process resulted in biocompatible devices.  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
205/Protocol  GX28228, Version 8  2.7.1 Implant  
Table 1 Material of Construction of Implant  
Component  of Implant  Raw Material  and/or Trade  
Name, Vendor Patient/ User  contact  
[CONTACT_514934],   Patient:  eye contact  
(conjunctiva, vitreous,  sclera)  
User: N/A  
Distal/Proximal  
Body  PSU,  Patient: vitreous  
User: N/A  
Septum  Silicone,   Patient:  eye contact (vitreous)  
User: N/A  
Adhesive bond Epoxy,  
 Patient: vitreous  
User: N/A  
Release Control  
Element (RCE)  Titanium,   Patient: vitreous  
User: N/A  
N/A = not applicable; PSU = polysulfone.   
2.7.[ADDRESS_667382] with the patient’s eye.  Future material change information on the Initial 
Fill Needle may be provided to the clinical investigators according to the Sponsor’s 
internal procedure. 
Table 2 Material of Construction of Initial Fill Needle 
Component  of Initial Fill  
Needle  Raw Material  and/or Trade  
Name, Vendor Patient/ User  contact  
[CONTACT_514935],   
 
 Patient: N/A 
User: N/A  
 Prim er 
(Manufacturing Material)  Silicone  Primer,  
 Patient: N/A 
User: N/A  
 Silicone  Silicone,   
 Patient: N/A 
User: N/A  
Cannula, 33 -1/2G Long, Sterile  
Needle  Surgical Stainless Steel  
 Patient: indirect cont act 
through the drug 
User: N/A  

Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
206/Protocol  GX28228, Version 8  Component  of Initial Fill  
Needle  Raw Material  and/or Trade  
Name, Vendor Patient/ User  contact  
[CONTACT_514936],  
 Patient: indirect contact  
[CONTACT_514937]: N/A  
Hydrocarbon Solvent  
(Manufacturing Material)  DCM  
 Patient: indirect contact  
[CONTACT_514937]: N/A  
Cap Polypropylene;  
 Patient: N/A  
User: surgical  gloves  
DCM  = dichloromethane;  N/A = not applicable; UV = ultraviolet.   
2.7.3 Insertion Tool  
The Insertion Tool consists of polyether  ether ketone (PEEK) plastic grippers holding the 
Implant. The grippers are attached with screws to a reverse-action forceps. 
If the Implant is repositioned during the insertion, the grippers listed in  Table [ADDRESS_667383] with the conjunctiva.  Future material change information on the Insertion Tool 
may be provided to the clinical investigators according to the Sponsor’s internal 
procedure.  
Table 3 Materials of Construction of Insertion Tool  
Component  of Insertion Tool  Raw Material  and/or Trade  
Name, Vendor Patient/ User  contact  
[CONTACT_514938],  
PEEK  Patient: conjunctiva 
User: N/A  
Tweezers  Stainless  steel,  Patient:  N/A 
User: surgical  gloves  
Screws  Stainless  steel,  
 Patient: N/A  
User: surgical  gloves  
N/A = not applicable; PEEK = polyether ether ketone.   
2.7.[ADDRESS_667384] (direct contact [CONTACT_514939]) with the patient’s eye.  Future material 
change information on the Refill Needle may be provided to the clinical investigators 
according to the Sponsor’s internal procedure.  

Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
207/Protocol  GX28228, Version 8  Table 4 Materials of Construction of Refill Needle 
Component  of Refill Needle  Raw Material  and/or Trade  
Name, Vendor Patient/ U ser contact  
[CONTACT_514940],  
 silicone,  
 Patient: eye contact  
(conjunctiva)  Indirect contact  
(drug contact)  
User: N/A  
Assembly  Adhesive  Patient: Indirect  contact  (drug 
contact)  
User: N/A  
Body  Polycarbonate,  
 Patient: Indirect  contact (drug 
contact)  
User: gloves  
Outer  cannula Polyimide,  Patient: eye contact  
(conjunctiva)  and indirect  
contact (drug contact)  
User: N/A  
Inner  cannula  Stainless steel  Patient: eye contact  
(conjunctiva)  and indirect  
contact (drug contact)  
User: N/A  
Bushing  Stainless steel  Patient: indirect (drug contact)  
User: N/A  
Needle Cap   
 Patient: N/A  
User: surgical  gloves  
LSR = liquid silicone  rubber; N/A = not applicable; UV = ultraviolet.   
2.7.[ADDRESS_667385] with the patient’s  eye.  Future material 
change information on the Explant Tool may be provided to the clinical investigators 
according to the Sponsor’s internal procedure.  

Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
208/Protocol  GX28228, Version 8  Table 5 Materials of Construction of Explant Tool  
Component  of Explant  Tool Raw Material  and/or Trade  
Name, Vendor Patient/ User  contact  
[CONTACT_514941],  Patient:  eye contact  
(conjunctiva)  
User: N/A  
Body  Acrylonitrile butadiene styrene 
polymer ,  Patient: N/A  
User: surgical  gloves  
N/A = not applicable.   
2.8 SUMMARY OF THE NECESSARY TRAINING  AND EXPERIENCE 
NEEDED TO  USE THE INVESTIGATIONAL DEVICE SYSTEM  
The RPDS  is intended for use by [CONTACT_514942], scrub nurses, other  
hospi[INVESTIGATOR_307]/clinic  staff, and patients. Study  investigators  will be qualified ophthalmologists  
trained in the management of retinal  diseases  and ocular surgery,  and will be certified by 
a Sponsor-selected vendor  to perform  initial  Implant fill, insertion,  refill,  and explantation.  
The surgical  procedures  involved in the use of the RPDS  are detailed in the RPDS  IFU. 
Scrub nurses  will assist  the surgeon in selected preparation tasks. Other hospi[INVESTIGATOR_514838],  such  as receipt or storage  
of the product.  Patients  will retain the Implant for an extended period of time.  
2.[ADDRESS_667386]  to minimize  the risk of 
ocular infection.  The Implant is filled with approximately  20 µL of ranibizumab  
immediately  prior to insertion of the Implant into the patient’s  study  eye. 
In addition to standard  p re-operative instructions  used in practice,  patients  will be 
instructed to apply  topi[INVESTIGATOR_514839] 4 times  
within 24 hours  prior to the procedure.  

Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
209/Protocol  GX28228, Version 8  At each refill,  a volume of approximately  100 µL of ranibizumab will be injected in situ into 
the Implant through the septum  to exchange the remaining contents  of the Implant with 
newly  introduced ranibizumab.   During the refill procedure,  the contents  of the Implant 
will be collected in the fluid collection reservoir  of the Refill  Needle. The volume of newly  
introduced ranibizumab remaining in the Implant after the refill procedure will be 
approximately  20 µL 
The Implant has undergone design verification  confirming Implant performance through  
the expected use life, including 93 punctures  of the Implant septum  for Implant refills.  
For detailed instructions  on the Implant initial  fill, insertion,  refill,  and e xplantation  
procedures, refer to the RPDS  IFU. 
3. JUSTIFICATION FOR TH E DESIGN OF THE CLINICAL  
INVESTIGATION 
The Phase II study  is being  conducted to determine the dose of ranibizumab that is both 
efficacious  for patients  and allows  for a dosing schedule that is less frequent  than 
monthly  ITV injections.  While the design and sample size of this clinical  study  is aiming  
at the determination of an appropriate dosing regimen for the drug ranibizumab delivered  
through the Implant, this study  will also appropriately inform  the safety  and performance  
of the Implant in human subjects.  
This RPDS  CIP will document whether  the Implant and ancillary  devices  “work as 
intended.”  
The data extraction and analysis  will allow  documenting the following aspects:  
• Establish that there is no evidence of Implant clogging in more  than 10% of patients  
in the Implant arms  at Month 9 
• Demonstrate that the AE profile observed when using the Implant is clinically  
acceptable  as compared with ranibizumab dosed using conventional ITV injection.  In 
other words, any complications  associated with Implant insertion, refill,  or 
explantation, or associated with the long term presence of the Implant within the 
posterior  chamber  of the eye, are manageable and acceptable in an overall  benefit-
risk assess ment versus  ITV dosing.  
 
This will include a characterization of the “Prespecified RPDS -associated AEs”, i.e., 
those adverse device effects  (ADEs) that have been pre-specified as being most  relevant 
for the risk assessment of the Implant and the procedures  of Implant insertion,  refill,  and 
explantation.  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
210/Protocol  GX28228, Version 8  For each AE (including “Prespecified  RPDS-associated AEs”) observed during the clinical  
study,  the case report form (CRF)  will collect  a separate assessment of investigator 
causality  for each “study  intervention”  element (i.e., investigator  causality  for “drug”, 
investigator  causality  for “procedures”, and investigator  causality  for Implant or ancillary  
devices). Investigators  will be trained on the requirement  to assess each  AE for potential  
causal association to “drug”, “procedure”, Implant or ancillary  devices  – so that they may  
determine whether there is a causal  association with one, more  than one, or none of the 
“Study  intervention”  elements.  
• Particular focus  will be paid to evaluate the safety  of the RPDS,  as measured by 
“Prespecified RPDS -associated AE” (see protocol  Section 6.5.1)  
 
The RPDS  CIP will evaluate whether  the Implant  is failing to operate as intended.  As a  
passive diffusion device, the Implant can only operate in four different states  as shown  in 
Table [ADDRESS_667387] State in Human Study 
Failure to Operate State 1:  
RCE  is clogged and no drug  
diffuses from reservoir  High detectability  
Will be apparent as deterioration in visual function and the 
development of further  disease activity in a patient who had 
responded to ITV ranibizumab prior to the Implant  insertion.  
The Implant  will be assessed for possible clogging if the 
Implant  is explanted.  For a full description of the assessments 
refer to CIP section 5.3 
Failure to Operate State 2:  
RCE rapi[INVESTIGATOR_514840] “failure to operate state  2” will be based upon 
bench testing with the Implant,  as this is anticipated to be a 
very rare event with clinically implanted devices.  
It would be difficult to reliably observe a typi[INVESTIGATOR_514841] a clinical study due to the potential high 
variability of the PK measurement.  
Clinically, the patient would be expected  to require frequent  
refill. From previous  high dose ITV studies, no safety signals  
have been identified that would be indicative of high  ITV drug 
levels.  
Therefore,  this failure  mode is best evaluated as  part of bench 
testing  after explantation.  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
211/Protocol  GX28228, Version [ADDRESS_667388] State in Human Study  
Failure to Operate State 3:  
RCE elutes  too slowly  Low detectability  in humans  
This will be based upon bench testing with the Implant. A 
target release rate of 4 µg/day and a vitreous concentration no 
lower than 12 µg/mL is currently established in the 
specifications.  
Implant Operational States Ability  to Detect State in Human Study 
Successful Operation:  
Drug diffuses across  RCE in a 
manner consistent with Fick’s  
Law of Diffusion as  
demonstrated  in bench and 
animal studies.  No direct detectability  in humans of Implant functionality  
can be shown  
Implant functionality is demonstrated best in bench studies.  It 
cannot be demonstrated in humans because there is no ethi cal 
method for directly measuring the flow of drug into the vitreous  
and serum pharmacokinetics is  seen as  too variable a 
measurement.  
CIP = Clinical Investigational Plan; ITV = intravitreal;  PK = pharmacokinetic; RCE = release 
control element   
This RPDS  CIP is not designed to determine a therapeutic  dosing regimen for 
ranibizumab. It will determine whether the Implant meets  an acceptable rate of failure  to 
Operate State 1. 
The Implant is a passive  diffusion  device,  so it cannot act outside of its native p hysics.  It 
must  diffuse  the drug in accordance with Fick’s Law.  Bench studies, in models  of the 
ocular environment, are the most  effective ways  to document the rate of drug diffusion  
from the Implant. As a result, it is deemed unnecessary  to directly  measure  the flow of 
ranibizumab from the Implant in humans. In addition, there is no appropriate method to 
directly  measure the flow of ranibizumab from the Implant in humans. No direct  
monitoring of drug levels  in the reservoir or vitreous  would be ethical  in humans  as there  
is no benefit  to an individual  patient that would balance the risk of these repeated  
invasive  collections  of vitreous.  There is no method for monitoring the drug levels  in the 
Implant reservoir. 
Additionally, measurement of serum  ranibizumab cannot provide quantitative data for the 
Implant diffusion. Serum  ranibizumab concentration- time data are remote from the site of 
drug release (Implant vitreous   serum) and therefore are not a direct quantitative  
measurement of the drug release rate from the Implant. In addition, serum  
pharmacokinetics  have high intersubject  variability  when administered by [CONTACT_514943];  
similar  variability  is expected by [CONTACT_514944]. This may also confound the use of 
serum  pharmacokinetics  as a quantitative reflection of drug release from the Implant. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
212/Protocol  GX28228, Version 8  This high variability  was observed in the serum  pharmacokinetic  (PK) levels  following  
refills  in the Phase I human trial. Therefore, PK data will be collected in all patients  in the 
Phase II study, but no clear  conclusion on the Implant diffusion rate can be prespecified 
before results  become available.  
It can be concluded that human studies  will not provide better  quantitative information  
about the diffusion rate of ranibizumab from the Implant than bench studies  will. 
Adequate data have been generated in bench studies  to demonstrate that the Implant  will 
reliably  diffuse ranibizumab in a controlled manner into the vitreous  humor.  
3.1 EVALUATION OF THE RESULTS OF THE RELEVAN T 
PRECLINICAL TESTING/ASSESSMENT CARRIED OUT TO 
JUSTIFY  THE USE OF THE INVESTIGATIONAL DEVICE IN 
HUMAN SUBJECTS  
The RPDS  is a drug delivery  system  intended to release therapeutic  levels  of 
ranibizumab into the vitreous  humor over an extended period of time. The RPDS  
includes  three primary components: t he drug (ranibizumab), the port delivery  system  
permanent implant, and the ancillary  devices. 
A comprehensive non clinical  testing strategy  was developed to support the clinical  
development (Phase II and Phase III) and registration of the Implant. The strategy 
included the assessment  of the in vitro and in vivo functionality  and biocompatibility  of a 
prototype implant, Phase  II Implant, and the ancillary  devices. 
In vitro and in vivo bi ocompatibility  studies  were  chosen based on direct and indirect  
interaction of the Implant and ancillary  devices  with ocular tissues  and long- term ocular  
implantation, and are consistent with ISO [ZIP_CODE] (Biological  evaluation of medical  
devices), ISO [ZIP_CODE]-5 (Ophthalmic  implants -intraocular  lenses  part 5: biocompatibility);  
and ANSI Z80.7 (Testing for intraocular  lens devices). Biocompatibility  testing is 
conducted with the finished Implant, and extracts  from the Implant and ancillary  devices. 
The nonclinical testing results  are summarized  in the RPDS  IB Section 4. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
213/Protocol  GX28228, Version 8  3.2 EVALUATION OF  CLINICAL DATA THAT ARE RELEVANT TO  
THE PROPOSED CLINICAL INVESTIGATION  
The Implant has been investigated in a prospective, Phase I, open-label  study  in patients  
with wet AMD,  conducted by [CONTACT_178758]4 at a single  site in Latvia. The study  investigated the 
safety, tolerability, and duration of ranibizumab exposure delivered with the Implant. 
This Phase I Implant was composed of biocompatible materials  (polymethyl  
methacrylate, silicone, 316L stainless  steel).  
For details  of the design of the Phase  I study  as well as the results, refer to protocol  
Section 1.3 and to the RPDS  IB Section 5. 
4. RISKS AND BENEFITS OF THE INVESTIGATIONAL DEVICE 
AND CLINICAL INVESTI GATION  
The general  approach to identifying, planning, and execution of the risk management  
activities  of the Phase II RPDS  is in accordance with ISO [ZIP_CODE]:2007/2012: Medical  
devices  – application of risk management to medical  devices.  
Risk management plans  have been created to cover  the following: 
• Implant, Insertion Tool, Initial Fill Needle,  Refill  Needle, and Explant Tool 
• Labeling  
• Packaging manufacturing of the combination product (assembly  operations)  
• Shippi[INVESTIGATOR_353183] (e.g., product shippi[INVESTIGATOR_007], handling and storage)  
• Clinical trial surveillance (e.g., product monitoring and complaints) 
• Components  not off-the-shelf (e.g., molding assembly  components)  
 
The results  of risk/benefit  assessment from the overall  risk analysis  are described in the 
RPDS  IB Section 6. 
4.1 ANTICIPATED CLINICAL  BENEFITS 
As a result of the chronic, progressive nature of wet AMD,  frequent ranibizumab ITV 
injections  continue for extended periods for many  patients. Pi[INVESTIGATOR_514842]  (FV2598g and FVF2587g)  demonstrated significant and well-
maintained visual  acuity  (VA) outcomes  with monthly  ITV injections  for [ADDRESS_667389] been several  studies  
evaluating a PRN treatment regimen, with different re-treatment  criteria also showing 
early  response after start of treatment ( Busbee et al 2013; CAT T Research  Group 2011). 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
214/Protocol  GX28228, Version 8  In clinical  practice,  frequent  office monitoring visits  are required and regular  injections  are 
necessary  to maintain optimal  vision gains.  Sustained release of ranibizumab from the 
Implant is an alternate dosing method that may result in a less frequent  need of 
retreatment than dosing with ITV injections.  This decrease in treatment burden could  
possibly  reduce the risk of ITV injection-related AEs, increase  compliance,  and reduce  
the burden to patients, their caregivers, and the healthcare system,  while  maintaining  
optimum  visual  outcomes. 
4.2 ANTICIPATED ADVERSE DEVICE EFFECTS  
The safety  of the RPDS,  as assessed  using the following “Prespecified  RPDS -associated 
AEs” include, but is not limited  to an evaluation of: 
• Vitreous  hemorrhage associated with a >30-letter decrease in best corrected  visual  
acuity  (BCVA) on the Early Treatment Diabetic  Retinopathy  Study  (ETDRS) chart  
compared with the last assessment of BCVA prior to the onset  of vitreous  
hemorrhage  lasting >1 month 
• Reduced VA ( >30-letter  loss from previous  scheduled visit) 
• Traumatic  cataract  
• Endophthalmitis  
• Damage to sclera  
• Retinal detachment  
• Interference of the Implant with visual  field 
 
Refer to pr
otocol  Section  6.5.1 and to the RPDS  IB Section 6 for additional  details.  
4.3 RESIDUAL  RISKS ASSOCIATED WITH THE INVESTIGATIONAL 
DEVICE, AS IDENTIFIED IN THE RISK ANALYSIS RE PORT  
The details  of the residual risks identified in the different  risk analysis  (e.g., failure mode  
and effects  analysis) are described in the RPDS  IB Section 6. 
4.4 RISKS ASSOCIATED WITH PARTICIPATION IN THE CLINICAL  
INVESTIGATION 
The benefit and risks associated with participation in this study  are outlined in the 
Informed Consent Form  (ICF) and will be explained to the patient  by [CONTACT_093].  
Ranibizumab has a well characterized safety  profile, with clearly  identified and potential  
risks associated with its use, which  is described in the RPDS  IB. The safety  and 
tolerability  of ranibizumab exposure delivered through the Implant were  investigated  in a 
Phase I prospective, open- label study  in a wet AMD  patient population by [CONTACT_178758]4 at a 
single site in Latvia. The surgical  procedure associated with Implant insertion could  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
215/Protocol  GX28228, Version 8  potentially  lead to ocular AEs. These  include,  but are not limited to: ocular  tissues  
inflammation or infection,  conjunctival erosion, damage  to the sclera, endophthalmitis,  
hypotony, suprachoroidal  hemorrhage, and retinal detachment. The RPDS  IFU 
describes  all of the procedures  necessary  for successful  insertion,  refilling,  and 
explantation of the Implant. It is imperative that specific  surgical  procedures  are adhered  
to in order  to minimize  the risk of ocular  AEs related to the procedure.  
4.[ADDRESS_667390] treatments  administered for other conditions with certain exceptions  as detailed  
in the protocol  Section 4.5.2.  
4.6 STEPS THAT WILL BE TAKEN TO CONTROL OR M ITIGATE  
THE RISKS 
Patients  not considered suited for receiving the RPDS  in this clinical  investigation are 
excluded as outlined under  exclusion criteria (see the pro tocol  Section 4.1.2).  
Study  investigators  will be qualified ophthalmologists, trained in the management of 
retinal  diseases  and ocular  surgery, and will be certified by a Sponsor -selected vendor  to 
perform  initial  Implant fill, insertion, refill, and explantation.  The surgical  procedures  
involved in the use of the RPDS  are also detailed in the RPDS  IFU document. 
Patients  must  adhere  to  the instructions  for prohibited therapy  (see Section 4.5) and dose 
interruptions/study  treatment or study  discontinuation criteria (protocol  Table 6). 
Prior to Implant insertion  or explantation, patients  will be required to verify  that they have  
self-administered their antimicrobial eye drops  to the study  eye 4 times  within the 
previous  24 hours . As per investigator’s  discretion, patients  may also be required to 
have self-administered antimicrobial  eye drops  to the study  eye [ADDRESS_667391]  be performed 
in the surgery  room while  the refill procedure is permitted in the physician office setting. 
The results  of risk/benefit  assessment from the overall  risk analysis  are described in the 
RPDS  IB Section 6. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
216/Protocol  GX28228, Version 8  4.7 RISK- TO-BENEFIT RATIONALE  
The Phase I study  provided preliminary  evidence of a positive benefit− risk profile for the 
use of RPDS  in patients  with wet AMD  and supports  the evaluation of RPDS  in a Phase II 
study.  It is expected that in the Phase  II study  the drug efficacy  of at least  one Implant 
treatment arm will be similar  to the control  ITV monthly  injection treatment  arm. 
Further  details  are included in the protocol  Section 1.4. 
5. OBJECTIVES AND HYPOTHESES OF THE CLINICA L 
INVESTIGATION 
The objectives  of the Phase  II study  are described in the protocol section 2. This RPDS  
CIP provides  an overview of the device objectives  and focuses  on the parameters  used  
for the assessment of RPDS functionality  and safety. 
5.1 DEVICE OBJECTIVES 
• To evaluate the functionality  of the Implant by [CONTACT_514945] 10% of patients  in the Implant arms  at Month 9 
• To explore the serum  ranibizumab concentration  data with a PK model  in an attempt  
to infer the concentration −time pattern in the vitreous  humor and, if possible,  derive  
information on the rate of ranibizumab release from the Implant 
• To evaluate the safety  of the RPDS,  as measured by “Prespecified  
RPDS -associated AEs” (see protocol  Section 6.5.1)  
 
5.2 HYPOTHESES, IMPLANT FUNCTIONALITY TO BE ACCEPTED  
OR REJECTED BY [CONTACT_514946]  
10% of Implant arm patients  at Month 9. In order  to evaluate whether  the Implant  
clogging rate exceeds  10% within the first 9 months, the proportion of clogged Implants  
will be estimated and the 90% confidence interval  will be calculated.  All clogging data 
from patients  in the Implant  arms  will be pooled for this analysis.  
In the study,  the Impl ant will be judged as “failed” if it is determined that the RCE  is 
clogged and can no longer  deliver  the ranibizumab into the ocular  space (see  Table 6  
“Failure to Operate State 1” and description below).  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
217/Protocol  GX28228, Version 8  5.3 CLAIMS AND INTENDED PERFORMANCE OF THE IMP LANT  
THAT ARE TO BE VERIF IED 
Intended performance of the Implant is demonstrated by [CONTACT_514947] a manner consistent with Fick’s Law of Diffusion as 
demonstrated in bench and animal  studies.  Implant functionality  is demonstrated best in 
bench studies  since  there  is no direct  detectability  in humans  of Implant functionality  that 
can be shown.  No ethical  method exists  for directly  measuring the flow of drug into the 
vitreous. Additionally  serum  pharmacokinetics  is seen as too variable a measurement. 
The clinical  performance of the Implant will be demonstrated  by [CONTACT_514948]. 
The Implant will be assessed for possible clogging if the Implant is explanted.  The 
following assessments  will be performed: 
• Serum pharmacokinetics  of ranibizumab will be used to judge whether  Implant  
clogging may have occurred.  Aqueous  and vitreous  humor PK samples  will also be 
collected at explantation and may be used to further assess  possible Implant  
clogging. For each individual patient,  possible Implant clogging will be documented  
if at least  one of the following conditions  is met: 
– For 40-mg/mL or 100-mg/mL dose groups: At Implant insertion and prior to the 
first refill:  serum  ranibizumab  concentrations  are below  the lower limit of 
quantification (BLQ)  or below  the baseline serum  ranibizumab concentration 
value at all time-points  prior to refills,  that is, on Day 1 (within 60 min of 
insertion – only if possible to collect),  Day 2, Day 7, Day 14, and all monthly  
time points  after insertion and prior to the first refill or to the last study  visit for 
the patient, if no refill occurs  
– For the 10-mg/mL dose group: At Implant insertion and prior to the first refill: 
serum ranibizumab  concentrations are below the lower limit of quantification 
(BLQ) value at all time-points prior to refills,  that is, on Day 1 (within 60 min of 
insertion – only if possible to collect), Day 2,  Day 7, Day 14, and all monthly 
timepoints after insertion and prior to the first  refill or to the last study visit for 
the patient, if no refill occurs  
OR 
– After  the first refill:  serum  ranibizumab concentrations  are BLQ or below  the 
last pre-refill  serum  ranibizumab concentration value at all time-points  post 
refills,  that is, on Day 7, and all monthly  time points  prior to the next refill for 
two consecutive refills,  or to the last study  visit for the patient, if no further refill 
occurs  
 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
218/Protocol  GX28228, Version 8  The Implants  meeting  PK criteria for possible clogging will then undergo further 
diagnostics  if explanted to confirm  whether treatment failure was due to clogging.  The 
“implant complete clogging”  failure statistics  will be summarized across all patients  based 
on the first 9 months  of Implant insertion.  
5.4 RISKS AND ANTICIPATED ADVERSE DEVICE EFFECTS THAT  
ARE TO BE ASSESSED  
At the end of the study, the incidence of “Prespecified RPDS- associated AEs” will be 
compared between subjects  receiving ranibizumab from the Implant and the control  
subjects  receiving ranibizumab as ITV injections:  
• Vitreous hemorrhage associated with a > 30-letter decrease in BCVA on the ETDRS  
chart compared with the last assessment of BCVA prior to the onset of vitreous  
hemorrhage  lasting >1 month  
• Reduced VA (> 30-letter  loss from previous  scheduled visit) 
• Traumatic  catarac t 
• Endophthalmitis  
• Damage to sclera  
• Retinal  detachment 
• Interference of the Implant with visual  field 
 
In addition, ocular AEs and serious  adverse events  (SAEs) attributed by [CONTACT_514949]: 1) the Implant insertion procedure,  2) the Implant refill procedure, 3) Implant  
explantation procedure, and 4) the Implant and other RPDS  components, will be 
reported. 
Please also refer to  the protocol  Section 6.5.1. 
6. DESIGN OF THE CLINICAL INVESTIGATION 
6.1 GENERAL  
6.1.1 Type  of Clinical Investigation and Rationale 
Study  GX282 28 is a Phase II, multicenter, randomized, active treatment (monthly  ITV 
injection) −controlled study  to evaluate ranibizumab delivered through the Implant using  
three ranibizumab formulation arms  (10 mg/mL, 40 mg/mL, and 100 mg/mL)  compared  
with the contro l arm (0.5-mg monthly  ITV injections  of 10-mg/mL  formulation)  in patients  
with subfoveal  neovascular  (wet) AMD.  
For details  of the rationale for the design, refer to the Phase II protocol  Section 3.4. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
219/Protocol  GX28228, Version 8  6.1.2 Measures to Minimize or Avoid Bias 
Patients  will be ran domized through an interactive voice/Web response system  to one of 
four treatment arms.  
Study  patients  and all study  site personnel  will be masked to the Implant treatment arms’  
ranibizumab formulation assignment (10 mg/mL  vs. 40 mg/mL  vs. 100 mg/mL)  until the 
study  conclusion. 
The Sponsor’s  personnel directly  involved in the study  conduct (except the Internal  
Monitoring Committee [IMC] members)  will be masked to the Implant treatment arms’  
ranibizumab formulation assignment (10 mg/mL  vs. 40 mg/mL  vs. 100 m g/mL) until the 
time of primary analyses. The IMC will closely  monitor patient safety  throughout the 
study  (see protocol  Section 3.1.4). The IMC roles and responsibilities  will be outlined  in 
the IMC charter. 
Clinical pharmacology  and PK scientists  may be unmasked early  for the purposes  of 
interpreting emerging safety  and efficacy  data; those unmasked staff will not be part of 
the study  team  or have any interactions  with sites or investigators.  
In addition, the VA examiner  will only conduct refraction  and VA assessments and will be 
masked to patient study  eye assignment  and patient treatment assignment. The VA  
examiner  will have no access  to patient  VA scores  from previous  visits  but will be only 
aware of the patient’s  refraction data from previous  visits.  The VA examiner may perform  
no other direct  patient-care  tasks.  Patients  will be asked not to discuss  their study       
eye assignment (right versus  left) with the VA examiner. 
Patients  and study  site p ersonnel  will not be masked with regard to patient  assignment to 
the ITV arm or an Implant arm because of the difficulties  of maintaining masking  following 
the surgical  procedure,  the additional  safety  visits applicable only to the Implant arms,  
and Implant visualization  upon ophthalmic  examination.  
6.1.3 Device Endpoints, with Rationale for Their  Selection and 
Measurement  
The Implant endpoint is the Implant status  at the end of trial, which  will be reported as 
either clogged or not clogged. The rationale for selecting  Implant clogging as an 
endpoint is described in Section 3 of this RPDS  CIP. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
220/Protocol  GX28228, Version 8  6.1.4 Methods and Timing for Assessing,  Recording,  and Analyzing 
Variables  
Details  of the assessments  to be performed during the study  are provided in Appendix  1 
of the Phase  II protocol. The Implant clogging rate at Month 9 will be determined 
(see Section 5.3). 
6.1.5 Equipment to be Used for Assessing the Clinical Investigation 
Variables and Arrangements for Monitoring Maintenance and  
Calibration  
Not applicable. 
6.1.6 Procedures for the Replacement of Subjects 
Patients  who discontinue from the study  will not be replaced.  
6.2 INVESTIGATIONAL  DEVICE(S) AND COMPAR ATOR(S)  
6.2.1 Description of the Exposure to the Investigational Device(s) or  
Comparator(s), If Used 
Patients in  the Implant  Treatment  Arms 
Patients  will have the Implant (prefilled with approximately  20 µL of either the 10-mg/mL  
[approximately  0.2 mg dose], 40-mg/mL  [approximately  0.8 mg dose], or 100-mg/mL  
formulation [approximately  2 mg dose] of ranibizumab)  surgically  inserted in the s tudy 
eye at the Day 1 visit. For further details  regarding exposure, refer to protocol  
Section [IP_ADDRESS]. 
Patients in the ITV Injection Treatment (Control) Arm  
Patients  will receive their first ITV injection of 50 µL of the 10-mg/mL  ranibizumab (0.5 mg 
dose) formulation at the Day 1 visit. For further details  regarding exposure, refer to 
protocol  Section [IP_ADDRESS].  
6.2.2 Justification of the Choice of Comparator(s)  
Refer to details  in protocol  Section 3.4.4. 
6.2.[ADDRESS_667392] of Any Other Medical Device or Medication to be Used 
During the Clinical Investigation 
No medical  devices  other  than the RPDS  or medication for the treatment of neovascular  
AMD  in the study  eye will be used during the clinical  investigation.  
6.2.4 Number of Investigational Devices to be Used  
One Implant  per study  eye will be used during the clinical  investigation in patients  
randomized to the RPDS  treatment arms.  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
221/Protocol  GX28228, Version [ADDRESS_667393] t he right to voluntarily  withdraw from the study  at any time for any reason.  
In addition, the investigator  has the right to withdraw  a patient  from the study  at any time.  
For details, refer to protocol  Section 4.7.1.  
Discontinued patients  will not be allowed to re-enter the study. 
6.3.4 Point of Enrollment  
The study  will include pre-screening (if applicable),  “run-in” (if applicable),  screening, and 
randomization visits  followed by a treatment period. Subjects  will be enrolled into the 
study  at the office of their vitreo-retinal  specialist.  Patients  randomized to the Implant  
treatment arms  will have  the Implant (pre-filled with ranibizumab)  surgically  inserted in the 
study  eye at their Day 1 visit. 
For additional details  regarding description of study,  refer to pro tocol  Section 3.1. 
6.3.5 Total Expected Duration of the Clinical Investigation  
Approximately 220 patients will be randomized within an approximate 24-month period 
of time. It is expected that the duration of the clinical investigation (length of study plus  
enroll ment period) will be approximately [ADDRESS_667394]'s Participation  
Patients in the ITV injection arm will be evaluated monthly and will receive monthly 
study treatments (Day 1, Month 1 through Month X  visit, see protocol  Appendix  2) until 
the Sponsor decides, based on the primary analysis results, to either terminate the 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
222/Protocol  GX28228, Version 8  study and discontinue study treatment, or offer patients entry into the RPDS 
Extension Study.  Their participation (excluding screening period) in the study will last approximately 13
−38 months dependent on the date of their randomization to the study.   
The patients  in the Implant arms  will continue to be evaluated monthly  for the Implant  
refill (see protocol  Appendix  1)until the Sponsor decides, based on the primary analysis 
results, to either terminate the study and discontinue study treatment, or offer patients 
entry into the RPDS Extension Study .  The Implant arms  patients’  study  participation  
(excluding screening period)  is expected to last approximately  13 to 38 months  
dependent on the date of their randomization to the study. 
6.3.7 Number of Subjects Required to be Included in the Clinical  
Investigation 
Approximately 220 patients up to 60  sites in the [LOCATION_002]  will be randomized in a 
3:3:3:2 ratio to four treatment arms:  approximately 60 patients  will receive the Implant 
filled with 10-mg/mL ranibizumab formulation, 60 patients  will receive the Implant filled 
with 40-mg/mL  ranibizumab formulation, 60 patients will receive  the Implant filled  with 
100-mg/mL  ranibizumab formulation, and 40 patients will receive  monthly  ITV injections 
of 10-mg/mL ranibizumab formulation (50 µL for the 0.5-mg  dose).  
6.3.[ADDRESS_667395] this Number (i.e., Enrolment  
Period)  
The enrolment period is expected to be approximately  [ADDRESS_667396]- trial access to treatment, refer to protocol  Section 4.4.2. 
6.4.1 Description of All the Clinical -investigation- related Procedures 
that Subjects Undergo During the Clinical  Investigation  
Medical  history  and demographic  information will be collected. 
Medical  history  includes  clinically  significant  diseases, surgeries,  smoking history, and 
use of alcohol.  
All medications  other than protocol -specified procedural  medications  used  by [CONTACT_514950] 7 days  prior to the randomization visit until the study  completion will be recorded  
on the electronic case  report  form (eCRF)  concomitant medication log. 
Demographic  data will include age, sex, and self-reported race/ethnicity.  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
223/Protocol  GX28228, Version 8  The Implant insertion and explantation procedures  will be captured on video for 
Investigators’  training purposes  unless  the study  center has policies in place that prohibit  
these procedures  being captured by [CONTACT_98991]. The Implant refill procedure video capture is 
optional.  
For a complete list of study  assessments, refer to protocol  Section 4.6. 
Please see the schedule  of assessments  provided in protocol  Appendix  1 and Appendix  
2 for the s chedule of assessments  to be performed at each study  visit. 
6.4.2 Description of Those Activities Performed by  [CONTACT_514951] (Excluding Monitoring)  
Genentech and/or  its designee will perform  study  management, oversight of data 
management, statistical  programming, project management, monitoring, vendor  
management, and data management (quality  checking of the data). 
For additional details  regarding administrative structure, refer to protocol  Section 9.4. 
6.4.3 Any Known or Foreseeable Factors That May  Compromis e the  
Outcome of the Clinical Investigation or the Interpretation of  
Results 
Not applicable. 
6.4.4 Monitoring Plan 
Study  monitors  will perform  ongoing source data verification to confirm  that critical  
protocol  data (i.e., source data) entered into the eCRFs  by [CONTACT_514952], complete,  and verifiable from source documents. Refer to protocol  Section 7.4 
for additional details  regarding source data documentation.  
7. STATISTICAL CONSIDER ATIONS 
7.1 STATISTICAL DESIGN, METHOD AND ANALYTICA L 
PROCEDURES  
One objective in the clinical  study  is to demonstrate that there is no evidence that the 
Implant clogging rate exceeds  10% of patients  in the Implant arms  at Month 9. 
Implant clogging data from all patients that receive the Implant will be pooled together  for 
this analysis. If there are 22 or fewer clogged Implants, among 165 evaluable Implants,  
within 9 months  since insertion,  we can declare that there is no evidence for the initial  
Implant clogging rate exceeding 10%. This acceptance criterion will be adjusted based  
on the actual  number  of evaluable Implants  at end of study.  The proportion of Implants  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
224/Protocol  GX28228, Version 8  that clog within 9 months  and its 90% confidence interval  will be estimated based on the 
binomial  distribution.  
In addition, the safety  data from three Implant arms  will be pooled and compared with 
monthly  ITV injection arm. The summary  statistics (frequency  and percentage)  will be 
provided by [CONTACT_514953]. The safety  assessment will review the 
following:  
• AEs 
• SAEs 
• “Prespecified RPDS -associated AEs” (see protocol Section 6.5.1) 
 
7.[ADDRESS_667397] refill (TTFR) 
for each of the RPDS treatment arms (10 mg/mL, 40 mg/mL, and 100 mg/mL) enrolling 
[ADDRESS_667398] ratio for comparing the 100-mg/mL arm to the 10-mg/mL arm was estimated to be 0.[ADDRESS_667399] 125 events from all 
three Implant groups is expected at the primary analysis time (approximately 85 events 
in the 10 -mg/mL group and a higher dose group).  With [ADDRESS_667400] 
approximately 80% power to detect a  hazard ratio
=0.[ADDRESS_667401] at a one- sided sig nificance level of 15%.  No multiplicity adjustment 
is planned for this Phase II study. 
Forty patients in the ITV arm will be sufficient to compare each device arm versus the 
ITV arm in change in BCVA from baseline through Month 9 (assuming an estimated SD=10 letters, a two-sided 80% CI will extend approximately 2.62 l etters from the 
observed mean). 
7.[ADDRESS_667402] will be performed.  80% statistical  power  was used in above sample size section. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
225/Protocol  GX28228, Version 8  7.4 EXPECTED DROP- OUT RATES  
Less  than 8% dropout rate is expected based on the previous  clinical  trials for 
ranibizumab. Thus, an 8% dropout rate is assumed in the above s ample size section for 
Implant clogging data analysis.  
7.5 PASS/FAIL  CRITERIA TO BE APPLIED TO THE RESULTS OF 
THE DEVICE CLINICAL INVESTIGATION  
The RPDS clinical investigation will be considered to successfully  demonstrate Implant  
functionality  if the following objective is met: 
• Establish that there is no evidence that the initial  Implant clogging rate within 9  
months  exceed 10% 
 
The RPDS clinical investigation will be considered to successfully  demonstrate RPDS  
safety  if the following objective is met: 
• Demonstrate that the AE profile observed when ranibizumab is administered using  
the Implant is clinically  acceptable as compared with ranibizumab dosed using  
conventional  ITV injection.  In other words, any complications  associated with 
Implant insertion,  refill,  or explantation, or associated with the long term presence of 
the Implant within the posterior  chamber  of the eye, are manageable and are  
acceptable in an overall  benefit-risk assessment versus  ITV dosing. 
 This will include a characterization of the “Pres pecified RPDS -associated AEs”, that is,
 
those ADEs that have been pre-specified as being most  relevant for the risk assessment  
of the Implant and the procedures  of insertion, refill, and explantation.  
For each AE (inc luding “Prespecified  RPDS-associated AEs”) observed during the clinical  
study,  the CRF will collect a separate assessment  of investigator causality  for each 
“study  intervention”  element, that is, investigator causality  for “study  drug”  (i.e., 
ranibizumab [for both Implant arms  and ITV dosing arm]),  investigator causality  for 
“procedures”  (for both Implant arms  and ITV dosing arm), and investigator  causality  for 
each of the RPDS  components  (for Implant  arms  only – the Implant, the Initial  Fill 
Needle, the Insertion Tool,  the Refill  Needle, and the Explant Tool). Investigators  will be 
trained on the requirement to assess  each AE for potential  causal  association to “drug”,  
“procedure”  and each of the “RPDS” device components  −so that they  may 
determine whether there  is a causal association with one, more  than one, or none of the 
“Study  intervention”  elements.  
If these objectives are not met, further design changes  will be mandated. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
226/Protocol  GX28228, Version [ADDRESS_667403] an optional interim analysis and the 
timing of the analysis will be documented in the Sponsor’s trial master file prior to the conduct of the interim analysis.  The interim analysis will be performed by [CONTACT_436252]’s unmasked study team and will be interpreted by [CONTACT_514954].  Access to treatment assignment information will follow the Sponsor’s standard procedures.  The details of the timing and scope of the 
interim analysis, if any, will be specified in the IMC  Agreement. 
7.7 CRITERIA FOR THE TERMINATION OF THE CLIN ICAL  
INVESTIGATION 
The criteria for stoppi[INVESTIGATOR_514843] a treatment  arm will be outlined in the IMC charter.  
7.8 SUBGROUPS  
Subgroup analysis  will be performed  if necessary. The subgroup variables  should be 
pre-defined in the detailed statistical  analysis  plan before the clinical  database lock. 
7.9 PROCEDURES THAT  TAKE INTO  ACCOUNT ALL DATA  
All Implant clogging data up to Month 9 visit will be included for analysis.  
7.10 MISSING, UNUSED OR SPURIOUS DATA; EXCLUSION OF  
PARTICULAR INFORMATI ON 
Missing  data will not be imputed for Implant clogging assessment; however, all Implant  
data up to Month [ADDRESS_667404] visit will still be 
used for data analysis.  
7.11 NUMBER OF SUBJECTS TO BE INCLUDED FOR EACH 
CENTER  
It is expected that each site will enroll  approximately of 3-5 patients.  
8. DATA MANAGEMENT  
8.1 DATA REVIEW  
The Sponsor will be responsible for the data management of this study, including quality  
checking of the data. For additional  details, refer to protocol  Section 7.1. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
227/Protocol  GX28228, Version [ADDRESS_667405] (IRB)/Ethics  
Committee (EC) and to regulatory  authorities  in accordance with local regulatory  
requirements. 
Approval  must  be obtained from the IRB/EC and regulatory  authorities  (according to local 
requirements)  before implementation of any changes, except for changes  necessary  to 
eliminate an immediate hazard to patients  or changes  that involve  logistical  or 
administrative aspects  only (e.g., change in Medical  Monitor or contact [CONTACT_3031]). 
10. DEVIATIONS FROM CLINICAL INVESTIGATION PLAN  
Investigators  must  follow  instructions  and procedures  as described in the Phase II 
protocol. No deviations  from the RPDS  CIP or protocol  are allowed except when  
necessary  to protect the safety, rights, or welfare  of patients.  
10.[ADDRESS_667406]  on patient  safety  and 
data integrity  to the Sponsor and to the IRB/EC in accordance with established IRB/EC  
policies and procedures.  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
228/Protocol  GX28228, Version 8  10.2 CORRECTIVE AND PREVENTIVE ACTIONS 
The Sponsor has the right to close  a site at any time.  Reasons  for closing a site may 
include, but are not limited to, the following: 
• Exces sively  slow recruitment  
• Poor protocol  adherence 
• Inaccurate or incomplete  data recording 
• Non-compliance with the International  Conference on Harmonisation of Technical  
Requirements  for Registration of Pharmaceuticals  for Human  Use (ICH)  guideline  for 
Good C linical Practice (GCP)  
 
The Sponsor may also implement additional  training for Investigators  when warranted. 
11. DEVICE ACCOUNTABILIT Y 
All IMP (ranibizumab)  and RPDS  required for completion of this study  (including all the 
components  of the RPDS)  will be provided by [CONTACT_1034]. For additional  details  
regarding IMP and RPDS  accountability, refer to protocol  Section [IP_ADDRESS].2.  
12. STATEMENTS OF COMPLI ANCE  
This study  will be conducted in full conformance with the ICH E6 guideline for GCP  and 
the principles of the Declaration of Helsinki,  or the laws and regulations  of the country  in 
which  the research is conducted,  whichever  affords  the greater  protection  to the 
individual. It will also follow  ISO [ADDRESS_667407] an. 
The study  will comply  with the requirements of the ICH E2A guideline (Clinical Safety  
Data Management: Definitions  and Standards  for Expedited Reporting). Studies  
conducted in the [LOCATION_002]  or under  a U.S. Investigational New Drug  (IND)  
Application will comply  with U.S. Food and Drug  Administration regulations and 
applicable local,  state, and federal  laws.  
This protocol,  the ICFs, any information to be given to the patient,  and relevant  
supporting information must  be submitted to the IRB/EC by [CONTACT_45822] [INVESTIGATOR_162412]/EC  before the study  is initiated. In addition, any 
patient recruitment  materials  must  be approved by [CONTACT_1201]/EC.  
The Principal  Investigator  [INVESTIGATOR_514844]/EC annually  or more  frequently  in accordance with the requirements,  
policies,  and procedures  established by [CONTACT_1201]/EC.  Investigators  are also responsible  
for promptly  informing the IRB/EC of any protocol  amendments. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
229/Protocol  GX28228, Version [ADDRESS_667408]  
comply  with requirements  for reporting SAEs to the local Health Authority  (HA) and 
IRB/EC.  Investigators  may receive written IND safety  reports  or other safety -related  
communications  from the Sponsor. Investigators  are responsible for ensuring that such  
reports  are reviewed and processed in accordance with HA requirements  and the policies  
and procedures  established by [CONTACT_11577]/EC,  and archived in the site’s  study  file. 
The statement for patient’s  insurance due to injury  in the RPDS  Phase II clinical  trial is 
available in the RPDS  informed consent sample template. 
13. INFORMED CONSENT PRO CESS  
The Sponsor’s  sample ICF will be provided to each site. For additional  details,  refer to 
protocol  Section 8.2. 
14. ADVERSE EVENTS, ADVERSE DEVICE EFFECTS AND DEVICE 
DEFICIENCIES  
14.[ADDRESS_667409] to its identity, quality,  durability, reliability,  
safety  or performance. 
14.3 DEFINITIONS OF SERIOUS ADVERSE EVENTS AND SERIOUS  
ADVERSE DEVICE EFFECTS AND, WHERE APPROPRIATE,  
UNANTICIPATED SERIOUS ADVERSE DEVICE EFF ECTS  
Refer to protocol  Section  5.2.2. 
A serious  ADE is an ADE that has resulted in any of the consequences  characteristic  of 
an SAE. 
14.4 REPORTING OF ADVERSE EVENTS AND DEVICE 
DEFICIENCIES  
The investigator  is responsible for ensuring that all AEs are recorded on the Adverse  
Event eCRF  and reported to the Sponsor in accordance with instructions  provided. The 
investigator  is also responsible for reporting all complaints  associated with any of the 
components  of the RPDS.  
For additional  details, refer to protocol  Section 5.3.1. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
230/Protocol  GX28228, Version 8  Certain events  require immediate report ing to allow  the Sponsor to take appropriate  
measures  to address  potential new risks in a clinical  trial. For details, refer to protocol  
Section 5.4. 
14.5 PROCESS FOR REPORTING ADVERSE EVENTS  
After  informed consent has been obtained but prior to initiation of study drug (Day  1), 
only SAEs related to a protocol -mandated intervention will be reported (see protocol  
Section 5.4.2 for instructions  for reporting SAEs). 
After  initiation of study  drug, all AEs, regardless  of relationship to study  drug, Implant, or 
ancillary devices, or study  procedures, will be reported until the patient’s  study  
completion or early  termination from the study. All SAEs, (including serious  adverse  
reactions  and serious  adverse device  effects)  will be collected and reported to the 
Sponsor in compliance with GCP  guidelines.  
Investigators  will seek  information on AEs at each patient contact. All AEs,  whether  
reported by [CONTACT_514955], will be recorded in the patient’s  
medical  record and on the Adverse Event eCRF.  
The investigator  is responsible for ensuring that all AEs are recorded on the Adverse  
Event eCRF  and reported to the Sponsor in accordance with instructions  provided. For 
each AE recorded on the Adverse Event eCRF,  the investigator  will make  an assessment 
of seriousness, severity, and causality.  
14.[ADDRESS_667410]  report all medical  device complaints  associated with any of the 
components  of the RPDS to the Sponsor. 
For additional  details, refer to protocol  Section 5.4.4. 
14.7 FORESEEABLE ADVERSE EVENTS AND ANTICIPAT ED 
ADVERSE DEVICE EFFECTS  
The following are “Prespecified RPDS- associated AEs”: 
• Vitreous  hemorrhage associated with a > 30-letter decrease in BCVA on the ETDRS  
chart compared with the last assessment of BCVA prior to the onset of vitreous  
hemorrhage  lasting >1 month 
• Reduced VA ( >30-letter  loss from previous  scheduled visit) 
• Traumatic  cataract  
• Endophthalmitis  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
231/Protocol  GX28228, Version 8  • Damage to sclera 
• Retinal  detachment  
• Interference of the Implant with visual  field 
 
In addition, ocular AEs and SAEs attributed by [CONTACT_43073]: 1) the Implant  
insertion procedure,  2) the Implant refill procedure,  3) Implant explantation procedure,  
and 4) the Implant and other RPDS  components, will be reported  
14.[ADDRESS_667411] Information for Sponsor’s  Medical  Responsible is provided in 
protocol  Section 5.4.1. 
14.9 INFORMATION REGARDING THE SAFETY REVIEW  
COMMITTEE  
Ongoing review  of study  data (including adverse events  of special  interest, SAEs,  
adverse device effects  [ADEs],  and laboratory  abnormalities)  will be performed by [CONTACT_514956].  The IMC roles  and responsibilities  will be outlined in the IMC charter. 
15. VULNERABLE POPULATIO N 
15.1 SPECIFIC INFORMED CONSENT PROCESS  
This clinical  investigation  will only enroll  patients  who are able and willing  to provide  
signed informed consent. 
15.2 ETHICS COMMITTEE'S SPECIFIC RESPONSIBILI TY 
This protocol,  the ICFs, any information to be given to the patient,  and relevant  
supporting information must  be submitted to the IRB/EC by [CONTACT_45822] [INVESTIGATOR_162412]/EC  before the study  is initiated. In addition, any 
patient recruitment  materials  must  be approved by [CONTACT_1201]/EC.  
The Principal  Investigator  [INVESTIGATOR_514844]/EC annually  or more frequently  in accordance with the requirements,  
policies,  and procedures  established by [CONTACT_1201]/EC.  Investigators  are also responsible  
for promptly  informing the IRB/EC of any protocol  amendments. 
In addition to the requirements  for reporting all AEs to the Sponsor, investigators  must  
comply  with requirements  for reporting SAEs to the local HA and IRB/EC.  Investigators  
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
232/Protocol  GX28228, Version 8  may receive  written IND safety  reports  or other safety -related communications  from the 
Sponsor. Investigators  are responsible for ensuring that such  reports  are reviewed and 
processed in accordance with HA requirements  and the policies  and procedures  
established by [CONTACT_11577]/EC,  and archived in the site’s  study  file. 
15.3 MEDICAL  CARE PROVIDED FOR SUBJECTS AFTER THE 
CLINICAL  INVESTIGATION HAS BEEN COMPLETED 
Currently, the Sponsor doesn’t plan to provide ranibizumab via RPDS  or via ITV 
injections  or to provide other study  interventions  to patients  after the conclusion of the 
study  or following early  patient withdrawal.  The Sponsor will evaluate the 
appropriateness  of continuing to provide ranibizumab treatment to RPDS  treatment arms  
patients  after evaluating RPDS  efficacy, safety, and PK data gathered in the study. The 
Sponsor may offer study  patients  entry  to a separate RPDS Extension Study  to continue 
to provide ranibizumab to RPDS  treatment arms  patients  via Implant  in an open-label  
manner.  
For additional information, please refer to the ICF. 
16. SUSPENSION OR PREMATURE TERMINATION OF T HE 
CLINICAL  INVESTIGATION 
The Sponsor has the right to terminate this study  or close  a site at any time. For details,  
refer to protocol  Section  4.7.4. 
16.[ADDRESS_667412] FOLLOW -UP 
For details  refer to protocol  Section [IP_ADDRESS].  
17. PUBLICATION POLICY  
For details  regarding the publication policy, refer to protocol  Section 9.5 and the [COMPANY_002]  
Global  Policy  on Sharing of Clinical Trials  Data. 
Appendix  21  
Ranibizumab Port Delivery System:  Device Clinical  
Investigation Plan (cont.) 
Ranibizumab Port Delivery  System —Genentech,  Inc. 
233/Protocol  GX28228, Version 8  18. BIBLIOGRAPHY  
Bressler  NM. Submacular  surgery.  Are randomized trials  necessary? Arch 
Ophthalmol.  1995 Dec;113(12):1557- 60. 
Busbee BG, Ho AC, Brown  DM, et al. Twelve -month efficacy  and safety  of 
0.5 mg or 2.0 mg ranibizumab in patients  with subfoveal  neovascular  age-
related macular  degeneration.  Ophthalmology;  2013 May;120(5):1046- 56. 
CATT  Research Group et al. Ranibizumab and bevacizumab for age-related  
macular  degeneration (CATT  study).  N Engl J Med;  2011 May 
19;364(20):1897- 908. 
ISO [ZIP_CODE]:2011 Clinical  investigation of medical  devices  for human subjects  - 
Good  Clinical Practice.  
Klein  R, Klein  BE, Jensen SC, et al. The five-year incidence and progression of 
age-related  maculopathy:  the Beaver  Dam  Eye Study.  Ophthalmology.  1997  
Jan;104(1):7- 21. 